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Background: Atrial fibrillation (AF) can be treated using a maze procedure during planned cardiac surgery,
but the effect on clinical patient outcomes, and the cost-effectiveness compared with surgery alone, are
uncertain.
Objectives: To determine whether or not the maze procedure is safe, improves clinical and patient
outcomes and is cost-effective for the NHS in patients with AF.
Design: Multicentre, Phase III, pragmatic, double-blind, parallel-arm randomised controlled trial. Patients
were randomised on a 1 : 1 basis using random permuted blocks, stratified for surgeon and planned
procedure.
Setting: Eleven acute NHS specialist cardiac surgical centres.
Participants: Patients aged ≥ 18 years, scheduled for elective or in-house urgent cardiac surgery, with a
documented history (> 3 months) of AF.
Interventions: Routine cardiac surgery with or without an adjunct maze procedure administered by an AF
ablation device.
Main outcome measures: The primary outcomes were return to sinus rhythm (SR) at 12 months and
quality-adjusted life-years (QALYs) over 2 years after randomisation. Secondary outcomes included return
to SR at 2 years, overall and stroke-free survival, drug use, quality of life (QoL), cost-effectiveness and
safety.
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Results: Between 25 February 2009 and 6 March 2014, 352 patients were randomised to the control
(n = 176) or experimental (n = 176) arms. The odds ratio (OR) for return to SR at 12 months was 2.06
[95% confidence interval (CI) 1.20 to 3.54; p = 0.0091]. The mean difference (95% CI) in QALYs at 2 years
between the two trial arms (maze/control) was –0.025 (95% CI 0.129 to 0.078; p = 0.6319). The OR for
SR at 2 years was 3.24 (95% CI 1.76 to 5.96). The number of patients requiring anticoagulant drug use
was significantly lower in the maze arm from 6 months after the procedure. There were no significant
differences between the two arms in operative or overall survival, stroke-free survival, need for cardioversion
or permanent pacemaker implants, New York Heart Association Functional Classification (for heart failure),
EuroQol-5 Dimensions, three-level version score and Short Form questionnaire-36 items score at any time
point. Sixty per cent of patients in each trial arm had a serious adverse event (p = 1.000); most events were
mild, but 71 patients (42.5%) in the maze arm and 84 patients (45.5%) in the control arm had moderately
severe events; 31 patients (18.6%) in the maze arm and 38 patients (20.5%) in the control arm had severe
events. The mean additional cost of the maze procedure was £3533 (95% CI £1321 to £5746); the mean
difference in QALYs was –0.022 (95% CI –0.1231 to 0.0791). The maze procedure was not cost-effective
at £30,000 per QALY over 2 years in any analysis. In a small substudy, the active left atrial ejection fraction
was smaller than that of the control patients (mean difference of –8.03, 95% CI –12.43 to –3.62), but
within the predefined clinically equivalent range.
Limitations: Low recruitment, early release of trial summaries and intermittent resource-use collection may
have introduced bias and imprecise estimates.
Conclusions: Ablation can be practised safely in routine NHS cardiac surgical settings and increases return
to SR rates, but not survival or QoL up to 2 years after surgery. Lower anticoagulant drug use and recovery
of left atrial function support anticoagulant drug withdrawal provided that good atrial function is
confirmed.
Further work: Continued follow-up and long-term clinical effectiveness and cost-effectiveness analysis.
Comparison of ablation methods.
Trial registration: Current Controlled Trials ISRCTN82731440.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 22, No. 19. See the NIHR Journals Library website
for further project information.
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Plain English summary
I rregular heartbeat is common, and the most common type is atrial fibrillation (AF). The heart has fourchambers: two ventricles that propel blood from the heart and two atria that receive blood. In AF, the
chambers of the heart lose their pumping action and the heart becomes less efficient. Blood can settle in
the atria and form clots. These can detach and cause strokes, so AF patients are given blood-thinning
drugs to reduce this risk. These drugs can increase the risk of bleeding. The maze procedure is an
operation designed to stop AF and make the heart beat regularly again.
Many patients who need major heart surgery also have AF. The Amaze trial was designed to find out
whether or not adding a maze procedure to heart operations is useful in making the heartbeat regular
again, if it improves long-term survival and quality of life (QoL) and whether or not any benefits are worth
the extra costs.
Between 25 February 2009 and 6 March 2014, 352 patients in 11 hospitals were recruited and randomly
put into one of two treatment groups: (1) maze and planned heart surgery or (2) planned surgery alone.
The results showed that patients in the maze group were more likely to have a normal, regular heartbeat
afterwards; however, there were no differences in survival or QoL at 2 years. In addition, many maze
patients who recovered a regular heartbeat did well in terms of the heart’s pumping action, suggesting
that longer follow-up may show better QoL and survival in these patients.
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Scientific summary
Background
Atrial fibrillation (AF) is characterised by an irregular heartbeat resulting from abnormal electrical signals in
the atria. Prevalence is 1–2% of the population in high-income countries, and this increases with age and
comorbidities such as obesity, diabetes and hypertension. The UK prevalence is 7.2% in patients aged
≥ 65 years and 10.3% in patients aged ≥ 75 years. With the advancing age of the population and the
increasing prevalence of obesity, this is likely to increase.
Atrial fibrillation causes palpitations, chest pain, dizziness and breathlessness, and imposes a heavy burden
on both patient health-related quality of life (HRQoL) and NHS resources. Inefficient heart pumping as a
result of AF increases the risk of blood clot formation, which can lead to stroke; anticoagulant medication
reduces the risk of stroke, but confers an increased risk of bleeding. AF may also exacerbate existing heart
failure or cause heart failure; treatment of AF and its consequences is expensive for the NHS.
The maze procedure, developed in the 1980s, involves multiple cutting and sewing of the atria and
pulmonary veins to prevent AF. Despite success in restoring sinus rhythm (SR), the technical challenges
required for this procedure mean that it is reserved for severely symptomatic patients. Less demanding
methods of achieving the electrical block, using a range of energy sources (heat, cold, radiofrequency or
microwave) to ablate atrial tissue, have been developed. Although technically easier, quicker and safer,
these methods are a new and costly technology.
There is evidence that AF ablation increases rates of freedom from AF, atrial flutter and atrial tachycardia
and decreases antiarrhythmic medication use 3 months after surgery. However, effects on cardiovascular
mortality, adverse events (AEs), HRQoL and long-term outcomes are uncertain. Results of cost-effectiveness
analyses are mixed and limited by the lack of evidence on HRQoL and other key outcomes in the medium
term (1–5 years), which means that long-term economic models are not robust.
The Amaze trial aimed to evaluate the clinical and HRQoL benefits, as well as the cost-effectiveness for
the NHS, of this technology. The HESTER (Has Electrical Sinus Translated into Effective Remodelling?)
observational substudy explored atrial contractile function in maze patients who were in SR at least 1 year
after the procedure, compared with cardiac surgery patients who were in SR both before and at 1 year
after the procedure.
Objectives
The primary objective was to compare the maze procedure as an adjunct to routine cardiac surgery with
routine cardiac surgery alone in terms of:
l return to stable SR at 12 months
l quality-adjusted survival over 2 years.
The key secondary objective was to assess cost-effectiveness over 2 years from a NHS perspective.
The other secondary objective was to compare the two trial arms for return to stable SR at 2 years, overall
survival, thromboembolic neurological complications (e.g. stroke), stroke-free survival, anticoagulant and
antiarrhythmic drug use and HRQoL.
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Prespecified subgroup analysis explored differences in treatment effects between patients with paroxysmal
AF and non-paroxysmal AF, surgical centres (as a random effect), cardiac surgical procedures and
surgeons. Within the maze arm, the analysis explored differences between ablation devices and lesion sets
treated.
The HESTER substudy objective was to assess whether or not patients in SR at least 1 year after an adjunct
maze procedure had equivalent active left atrial ejection fraction (ALAEF) to control patients who had
undergone cardiac surgery and were in SR both before and after surgery.
Methods
Amaze was a Phase III, pragmatic, multicentre, double-blind, parallel-arm randomised controlled trial to
compare clinical, patient and cost outcomes for patients with pre-existing AF who underwent routine
cardiac surgery either with or without an adjunct device-based ablation procedure.
Setting
Eleven acute NHS specialist cardiac surgical centres, co-ordinated by the Papworth Trials Unit
Collaboration. Participating surgeons had at least 2 years’ experience in the use of ablation devices.
Patient recruitment
Consecutive cardiac surgery patients with a history of AF were screened for eligibility. Trial inclusion criteria
were as follows: patients aged ≥ 18 years, scheduled for elective or in-house urgent cardiac surgery
(coronary, valve, combined coronary and valve or any other cardiac surgery requiring cardiopulmonary
bypass), with a documented history (> 3 months) of AF (chronic, persistent or paroxysmal). Exclusion
criteria included patients who had had previous cardiac operations, emergency or salvage operations
surgery without cardiopulmonary bypass and patients who were unlikely to be available for the 2-year
follow-up or who were unable to consent.
Randomisation
On the day of surgery, in the anaesthetic room, eligible patients were randomised (1 : 1) to either
planned cardiac surgery (control arm) or planned cardiac surgery with additional device-based AF ablation
(experimental arm). The allocation sequence was computer generated using permuted blocks (sizes 6
and 8), stratified by surgeon and planned procedure.
Blinding
Although theatre staff could not be blinded to treatment allocation, patients, researchers collecting
HRQoL outcomes and cardiologists assessing the 4-day electrocardiography (ECG) results were unaware
of treatment allocation.
Treatment arms
In this pragmatic trial, cardiac surgery and postoperative management in the control arm was completed in
accordance with standardised hospital protocols.
For patients randomised to maze, the surgeon also administered ablation. The lesion set was at the
discretion of the treating surgeon. Any AF ablation device routinely used within the NHS was permitted,
including bipolar and unipolar radiofrequency, ‘cut-and-sew’, cautery, cryotherapy, ultrasound, laser and
microwave energy. Postoperative management, subsequent follow-up and data collection were identical to
the control arm.
Outcomes
Return to SR at 12 months after surgery and quality-adjusted survival over 2 years were joint primary
outcomes. Return to SR was defined as absence of any AF on 4-day continuous ECG recordings,
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analysed centrally at Papworth Hospital, by cardiologists unaware of patient identity or treatment arm.
Quality-adjusted survival over 2 years was estimated using serial utility measurements from the UK
population valuation of the EuroQol-5 Dimensions, three-level version (EQ-5D-3L), administered at
randomisation and discharge, and at 6 weeks and 6, 12 and 24 months after the procedure.
Quality-adjusted life-years (QALYs) over 2 years were estimated using the area under the curve method.
Secondary outcomes were return to SR at 2 years after surgery, overall survival, stroke-free survival,
incidence of hospital admission for haemorrhage, anticoagulant and antiarrhythmic drug usage, HRQoL
[measured by the EQ-5D-3L, the Short Form questionnaire-36 items (SF-36) and the New York Heart
Association (NYHA)], resource use and trial-based cost-effectiveness of the adjunct maze procedure up
to 2 years after randomisation.
Sample size
The maze procedure was considered effective if there was a significant effect for either return to SR at
12 months or QALYs over 2 years. The planned recruitment target of 200 patients per arm was based on
detecting a target difference of 15% in the return to SR rate (45% for maze and 30% for control) or
1 additional month of quality-adjusted life (0.083 QALYs, standard deviation 0.3), with approximately 80%
power, a two-sided significance of 5% and up to 15% death/loss to follow-up.
Owing to slower than expected accrual, recruitment was terminated in September 2014, when 352 patients
had been randomised.
Statistical analysis
The primary analysis used intention to treat, with multiple imputation for missing primary outcomes.
For AEs, patients were included in the arm corresponding to the intervention received (maze procedure
completed vs. no maze procedure).
Return to SR rates were analysed using binary logistic regression, including surgeon (random effect),
baseline heart rhythm and planned surgical procedure (fixed effects). For QALYs > 2 years, linear regression
was fitted to utilities post treatment, including surgeon (random effect), baseline utility and treatment arm
(fixed effects). For surviving patients with missing EuroQoL measurements, multiple imputation was used,
and a confidence interval (CI) for the QALY difference was estimated using non-parametric bootstrapping.
No discounting of QALY estimates was applied for the primary outcome. For both primary outcomes,
subgroup effects were investigated by including interaction terms.
Overall survival and stroke-free survival were analysed using Kaplan–Meier and Cox regression methods.
SF-36 scores were analysed using linear regression, including time point, treatment arm, time-by-
treatment-arm interaction and baseline SF-36 scores (all fixed effects), with random intercepts for patients.
Drug use was tabulated and analysed using logistic regression, including drug category, time period using
drug, baseline drug usage and treatment arm.
Economic analysis
NHS resource use covered the primary admission (operation, time in intensive care, cardiac and acute care
wards, transfers to rehabilitation centres or other hospitals), follow-up (including readmissions, diagnostic
tests and health-care visits) and drugs (antiarrhythmic, anticoagulant, antiplatelet and cardiac drugs).
Resource use was costed using national estimates of unit prices [Department of Health and Social Care
(DHSC). NHS Reference Costs 2014–15. London: DHSC; 2015], literature (e.g. 24-hour blood pressure
monitoring and chest radiography) or information from Papworth Hospital (e.g. theatre cost and cost of
device). The ablation device was costed at £3000 per patient for high-intensity focused ultrasound, and
at £1250 per patient for all other methods. Both costs and QALYs were discounted at 3.5% in year 2 for
the cost-effectiveness analysis [National Institute for Health and Care Excellence. Guide to the Methods
of Technology Appraisal 2013: Process and Methods. URL: www.nice.org.uk/process/pmg9/chapter/
the-reference-case#discounting (accessed 10 January 2018)].
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Costs and QALYs were analysed using seemingly unrelated regression, including age, sex, baseline
EQ-5D-3L score, baseline AF and, for QALYs only, specific procedure; regression coefficients were used to
estimate incremental cost-effectiveness ratios (ICERs). Probabilistic sensitivity analysis used bootstrapping.
Cost-effectiveness planes, the cost-effectiveness acceptability curve and incremental net monetary benefit
were estimated. Deterministic sensitivity analysis explored the impact of using Short Form questionnaire-6
Dimensions QALYs, complete-case analysis, truncating costs and QALYs at discharge, excluding outliers
and alternative imputation strategies.
The ‘Has Electrical Sinus Translated into Effective Remodelling?’ substudy
To assess whether or not contractile function after maze procedure was equivalent to that for non-AF
patients, 22 maze procedure patients who were in SR at least 1 year postoperatively, were matched
(1 : 1) to non-trial control patients who were in SR before, and at least 1 year after, routine cardiac surgery.
Matching criteria were time since procedure, age, sex, procedure, preoperative left ventricular ejection
fraction and logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE).
Eligible patients underwent ECG to confirm SR, transthoracic two- and three-dimensional echocardiography
and cardiac magnetic resonance imaging (MRI). The primary outcome was ALAEF; left atrial volumes and an
ECG marker of left ventricular function (E/A ratio) were secondary end points.
Sample size
The minimum clinically important difference in ALAEF was set at 18.2%. Equivalence was concluded if the
two-sided 95% CI of the estimated treatment effect (maze–control) was entirely in the interval (95% CI
–18.2% to 18.2%). Twenty-two matched pairs provided 80% power to demonstrate equivalence.
Statistical analyses
For the primary end point, the linear regression model, including treatment, matching variables (fixed effects)
and matched pairs (random effect), was fitted.
Results
Between 25 February 2009 and 6 March 2014, 1013 patients were screened in 11 UK specialist cardiac
surgery centres and 352 patients were randomised to the control (n = 176) or experimental (n = 176) arms.
Thirty surgeons participated in the trial. The SR status of patients at 12 months was available for 141 maze
procedure and 145 control patients (80% and 82%, respectively); QALYs up to 2 years were available for
160 patients in each arm (91%).
Primary outcome results
Among complete cases in the maze procedure arm, 87 out of 141 patients (61.7%) were in SR compared
with 68 out of 145 (46.9%) control patients. The odds ratio (OR) (95% CI) for return to SR was 2.06 (1.20
to 3.54; p = 0.0091). Surgical results varied by surgeon in both groups, but the treatment effects did not.
Results were broadly consistent across subgroups.
In both trial arms, QALYs could be estimated for 160 patients. Unadjusted, undiscounted mean QALYs
(95% CI) over 2 years were 1.489 (1.416 to 1.558) for maze procedure patients and 1.485 (1.403 to
1.559) for control patients. The mean difference (95% CI) in QALYs at 2 years (maze–control) was –0.025
(–0.129 to 0.078; p = 0.6319). Results did not vary by surgeon or subgroup.
Secondary outcomes
In the maze procedure arm, 69 out of 118 (58.5%) completers were in SR compared with 47 out of 129
(36.4%) completers in the control arm. The adjusted OR for patients in SR at 2 years was 3.24 (95% CI
1.76 to 5.96). The number of patients requiring anticoagulant drug therapy was significantly lower in the
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maze arm from 6 months to 2 years post procedure. Slightly more maze procedure patients required
antiarrhythmic drugs throughout follow-up, but the difference was not statistically significant.
There were no significant differences between the arms for any of the following secondary outcomes at
any time point: operative or overall survival, stroke-free survival, need for cardioversion or permanent
pacemaker implants, NYHA score, EQ-5D-3L utility and SF-36 dimensions.
Safety
Sixty per cent of patients in each arm had a serious adverse event (p = 1.000); most events were mild,
but 71 (42.5%) maze procedure patients and 84 (45.5%) control patients had at least one moderately
severe event, and 31 (18.6%) maze procedure patients and 38 (20.5%) control patients had a severe event.
Twenty-three events in 17 (10.2%) patients were possibly related to treatment in the maze procedure arm
compared with 28 events in 19 (10.3%) patients in the control arm; one patient (0.5%) in the control
group was admitted to hospital for investigation of atrial flutter, classed as ‘definitely related’ to treatment.
Cost-effectiveness
The mean additional cost of the maze procedure was £3533 (95% CI £1321 to £5746), which was
statistically significant, but the mean difference in QALYs was not statistically significant (–0.022, 95% CI
–0.1231 to 0.0791). None of the analyses suggested that the maze procedure was cost-effective at
£30,000 per QALY over 2 years. The smallest ICER was £83,625 per QALY for the complete-case analysis.
The ‘Has Electrical Sinus Translated into Effective Remodelling?’ substudy
Between 24 July 2013 and 8 July 2015, 22 eligible patients were recruited for each cohort and underwent
echocardiography and MRI. The mean difference (95% CI) in ALAEF between maze procedure and control
patients was –8.03 (–12.43 to –3.62). The 95% CI was contained entirely in the interval (–18.2 to 18.2),
so that the predefined criterion for equivalence was met. However, the mean ALAEF was significantly
lower in maze procedure patients than in control patients (p = 0.0015).
Mean E/A ratio was significantly higher and mean left atrial ejection fraction (four-chamber view and MRI)
was significantly lower for maze procedure patients than for control patients. There were no significant
differences in the other end points.
Conclusions
Implications for future health care
The Amaze trial demonstrated that ablation can be practised safely in a routine NHS cardiac surgical
setting and that it increases the proportion of patients who return to SR up to 2 years after surgery.
Clinical effects did not translate into improved survival or QALYs, and the addition of the maze procedure
was not cost-effective over 2 years.
The reduction in anticoagulant drug use and results of the substudy provide support for anticoagulant
drug withdrawal, but varying rates of left atrial functional recovery after the maze procedure mean that
atrial function should be measured before considering withdrawal of anticoagulant drugs.
Implications for further research
The clinical results are promising, and continued follow-up of clinical events, HRQoL and long-term clinical
effectiveness and cost-effectiveness analysis is warranted.
Subgroup analyses had low power to provide robust recommendations on specific methods. Further
comparison of ablation methods would inform best practice.
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Chapter 1 Background
The health problem
Atrial fibrillation (AF) is the most common disturbance of heart rhythm. It is characterised by an irregular
heartbeat caused by low-amplitude, supraventricular oscillations.1
The normal rhythm of the heart is sinus rhythm (SR). The stimulus to beat is triggered by the sinoatrial
node. This results in atrial contraction while the stimulus is conducted to the atrioventricular node,
which relays it to the ventricles, initiating ventricular contraction. AF is a condition whereby the atria
beat unevenly because of abnormal electrical signals. As a result, there is no SR, the ventricles respond to
the disordered atrial electrical activity in a haphazard fashion, the pulse becomes irregular and the entire
heartbeat is abnormal.
Atrial fibrillation has a prevalence of 1–2% of the population in high-income countries.2,3 In the UK, the
prevalence of AF is 7.2% in patients aged ≥ 65 years and 10.3% in patients aged ≥ 75 years.4 Prevalence
is associated with age and comorbidities, such as obesity, diabetes and hypertension. With the advancing
age of the population and the increasing prevalence of obesity, this proportion is likely to increase.5
Consequences of atrial fibrillation
Atrial fibrillation can cause palpitations, chest pain, dizziness and breathlessness, and imposes a heavy burden
on both patients and clinicians, as it has a considerable impact on quality of life (QoL) and NHS resources.6
When the atria fibrillate, they lose their pumping action, and this has two very important sequelae.
There is blood stagnation in the atria, which can lead to clot formation. Blood clots can then exit the heart
(thromboembolism), leading to stroke and other complications. There is an associated four- to fivefold
increased risk of thromboembolic stroke in AF, and if AF is left untreated, around 1 in 25 patients will have
a stroke.7 The NHS devotes 5% of its budget to preventing and treating strokes, and 15% of strokes can
be attributed to AF.4 Drugs and other treatments can control AF, but not without complications. Routine
anticoagulant drug treatment reduces the risk of stroke in AF patients by two-thirds, but this incurs an
increased risk of bleeding and needs careful monitoring. The substantial burden of monitoring anticoagulant
therapy usually falls on general practice, anticoagulant clinics and haematology laboratories.
When the atria do not pump, the heart is less efficient. The presence of AF exacerbates heart failure that
arises from other heart conditions, and can itself cause heart failure, especially if the fibrillating atria dilate
and this results in leakage of the mitral and tricuspid valves.
Treatment of AF and its consequences (antiarrhythmic and anticoagulant drugs, hospital monitoring and
stroke treatment) is expensive for the NHS. Implementation of the 2006 National Institute for Health and
Care Excellence (NICE) guidelines,6 on management of AF, was estimated to cost £21.86M per year.3
Types of atrial fibrillation
Atrial fibrillation is classified into three distinct subgroups. In the Expert Consensus Statement on Catheter
and Surgical Ablation of Atrial Fibrillation,8 paroxysmal AF is defined as recurrent AF (more than two
episodes) that terminates spontaneously within 4 days, persistent AF is defined as AF that continues
beyond 4 days and chronic or longstanding AF is persistent AF beyond 1 year.8 These patterns of AF have
slightly different electrophysiological mechanisms.
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Diagnosis of atrial fibrillation
Atrial fibrillation is confirmed by electrocardiography (ECG) when the patient presents with symptoms of
palpitations, as is the case with paroxysmal AF; however, both paroxysmal and more longstanding AF can
be asymptomatic and, when that is the case, can be missed on the electrocardiogram, unless the AF
coincides with the time at which ECG is carried out. This is especially important in assessing treatments
aimed at correcting AF, as many historical series reported only the recurrence of symptomatic AF and have
used only intermittent ECG for follow-up.9 In the majority of published studies, success in the ‘resumption
of SR’ was based on a single ECG recording at 12 months, which is not necessarily representative. More
recently, there has been recognition of the importance of more robust AF documentation and Holter
monitoring records have been reported in some AF trials.10–12 Better evaluation of any residual AF after
treatment, by continuous ECG monitoring over several days, documents the percentage of time for which
a patient is in AF, and this is called the ‘AF burden’.
A number of studies (cited in Calkins et al.8) suggest not only that AF increases the risk of a poor outcome
from prospective cardiac surgery, but is also that AF an independent risk factor for early and late morbidity
and mortality. This leads to the (unproven) hypothesis that efforts to eliminate pre-existing AF during
cardiac surgery may improve survival and reduce adverse cardiac events after surgery.
Current treatment
Until the 1980s, AF was treated using antiarrhythmic drugs and direct current cardioversion. When that
failed, AF was managed with rate control medication and anticoagulant drugs to reduce the risk of stroke.
There has been a substantial development in our understanding of the pathophysiology of AF, and two
very important findings have been the roles of the pulmonary veins and macro-re-entry circuits.
We now know that the majority of electrical trigger points that initiate AF lie within the pulmonary
veins and not in the atria themselves.13 Moreover, the maintenance of AF depends on the presence of
macro-re-entry circuits, in which delayed conduction of the electrical signal means that the signal arrives
at the originating point when that point is no longer refractory. These circuits are quite large (several
centimetres). As a result of this knowledge, the maze procedure was developed in the 1980s by Cox and
Boineau.14 The procedure prescribed a number of surgical cuts aimed at achieving two objectives: electrical
isolation of the pulmonary veins from the atria, thus dealing with the site of most AF trigger points, and
further cuts in the atria to disrupt macro-re-entry circuits, thereby preventing the maintenance of the AF
rhythm. The maze procedure therefore involves multiple cutting and sewing of the atria and pulmonary
veins. Several studies have reported freedom from AF ranging from 75% to 90% after the Cox maze
procedure (see Huffman et al.’s9 systematic review and associated references), and one reported a 15-year
success rate in restoring SR as high as 94%.15 This traditional cut-and-sew technique, despite being
available since 1987, has failed to achieve widespread use, as it is technically demanding and adds
substantially to the operative burden of a heart operation. It is currently in very limited use by a few
surgeons in a few centres and tends to be reserved for otherwise fit patients with severely symptomatic
AF, who are prepared to take the risk of such a major intervention to relieve their symptoms.
Alternatives to the cut-and-sew maze procedure have been produced. A number of devices have been
developed to achieve the electrical block needed, using energy sources to ablate atrial tissue. These have
made a technically difficult and time-consuming operation easier, quicker and safer for cardiac surgeons
to perform. Ablation devices use an energy source (heat, cold, radiofrequency or microwave) to replicate
the lesion set produced by the cut-and-sew maze procedure.16 As a rule, the procedure is safe and well
tolerated and adds little to the length and burden of the operation, but these devices are a new and costly
technology, which is currently being heavily marketed to treat AF.17
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There has been no direct comparison between the traditional Cox maze procedure and the ablation maze
procedure,9 presumably because of the problems of incorporating such technically demanding surgery into
an adequately powered randomised controlled design. However, a propensity analysis that matched
patients who underwent the ablation maze procedure with those undergoing the Cox maze procedure
showed no differences in freedom from AF at 3, 6 and 12 months afterwards.18
Patients who have AF before surgery are generally older and have an increased procedural risk and other
comorbidities, so that treating AF at the time of cardiac surgery may be advantageous to the patient.
When the Amaze trial was planned, the only evidence supporting this came from five small randomised
controlled trials (RCTs) of the ablation maze procedure as an adjunct to surgery.11,19–22 These trials found
that SR was restored in 44–94% of treated patients compared with 5–33% of control patients. The trials
were small and follow-up was short. Success was mostly defined on the basis of single ECG recordings.
No trial looked at patient-centred outcomes or cost-effectiveness. Despite this lack of robust evidence, the
number of patients with AF undergoing open heart surgery and being offered concomitant ablation maze
procedures, or ‘adjunct maze procedures’, was increasing. Although there were instances of its use as a
standalone procedure, the widest use of the ablation maze procedure in the NHS was in patients already
having cardiac surgery for other problems.23 This trial was designed in response to the National Institute for
Health Research (NIHR) Health Technology Assessment (HTA) programme call to evaluate ablation devices
that were being rapidly assimilated into NHS practice without formal assessment.
Patient benefit
It is essential to recognise that the primary justification of the ablation procedure is to treat symptomatic
AF.24 When the Amaze trial was in the planning stage, no effectiveness studies had investigated the
QoL benefit and cost-effectiveness of maze procedures. Since the original grant application, four small
randomised trials have reported on health-related quality of life (HRQoL) after the maze procedure.12,25–27
No difference was reported in the overall QoL scores. However, patients in the studies by Gillinov et al.12
and Van Breugel et al.27 were not blinded to the treatment they received, which could have influenced the
reporting of QoL outcomes. Cherniavsky et al.25 reported improvement in the Short Form questionnaire-36
items (SF-36) score; however, the trial overall reported that the adjunct maze procedure arm did no better
than coronary artery bypass graft operation (CABG) alone.
Recent evidence
A Cochrane collaboration review9 assessed the effects of adjunct AF surgery.9 Using a comprehensive
systematic review methodology, the authors identified 22 published trials (1899 participants) comparing
cardiac surgery with and without adjunct AF surgery, with five additional ongoing studies and three
studies not classified at the time of reporting.10–12,19,20,22,25–40 All included studies were rated as being
at a high risk of bias in at least one domain assessed. The Cochrane review9 found that AF surgery,
regardless of technique, doubles the rate of freedom from AF, atrial flutter and atrial tachycardia [51.0%
vs. 24.1%; relative risk (RR) 2.04, 95% confidence interval (CI) 1.63 to 2.55], with more patients not
taking antiarrhythmic medication 3 months after cardiac surgery. There was little evidence of a difference
between patients with AF who were treated and those who were not treated in either 30-day mortality
(2.3% vs. 3.1%; RR 1.25, 95% CI 0.71 to 2.20) or all-cause mortality (7.0% vs. 6.6%; RR 1.14, 95% CI
0.81 to 1.59). However, patients who were treated for AF were more likely to be fitted with a permanent
pacemaker (6.0% vs. 4.1%; RR 1.69, 95% CI 1.12 to 2.54). The review authors concluded that there
remained uncertainty about the effects on cardiovascular mortality, adverse events (AEs), HRQoL and
long-term outcomes.9
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In summary, there is little rigorous evidence that attempting to restore SR by treating AF with an ablation
device during cardiac surgery is of benefit to the patient. Nevertheless, these devices are being incorporated
into routine practice nationally and internationally. The Amaze trial provided a timely evaluation of this
technology with the objective of assessing the clinical and HRQoL benefits for patients, as well as
cost-effectiveness for the NHS.
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Chapter 2 Amaze trial methods
Objectives
Primary objectives
The primary objectives were to compare patients undergoing the maze procedure as an adjunct to routine
cardiac surgery with patients undergoing routine cardiac surgery alone, in terms of:
l return to stable SR at 12 months
l quality-adjusted survival over 24 months after randomisation.
Secondary objectives
The main secondary objective was to assess the cost-effectiveness of the adjunct maze procedure, relative
to cardiac surgery alone, from a NHS perspective.
Other secondary objectives were to compare the following outcomes between the two arms:
l return to stable SR at 24 months after surgery
l overall survival
l thromboembolic neurological complications (e.g. stroke)
l stroke-free survival
l anticoagulant and antiarrhythmic drug use up to 24 months post randomisation
l HRQoL up to 24 months post randomisation, as measured by the EuroQol-5 Dimensions, three-level
version (EQ-5D-3L), the SF-36 and the New York Heart Association (NYHA)
l resource use and costs.
Exploratory analyses
Prespecified subgroup analysis was planned to explore differences in treatment effects between:
l patients with paroxysmal AF and non-paroxysmal AF (i.e. persistent, chronic or longstanding AF)
l individual centres (as a random effect)
l cardiac surgical procedures
l surgeons.
Within the maze treatment arm, analysis was planned to explore differences between:
l different ablation devices
l different lesion sets treated.
Design
Overview
The Amaze trial was a Phase III, pragmatic, multicentre, double-blind, parallel-arm RCT to compare clinical,
patient-based and cost outcomes for patients with pre-existing AF who undergo routine cardiac surgery
either with or without an adjunct device-based ablation procedure.
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5
Eligible patients were randomised (in a 1 : 1 ratio) to receive either:
l planned routine cardiac surgery with no additional procedure
l planned routine cardiac surgery with an additional device-based AF ablation procedure.
The study was reviewed and approved by the Essex 1 Research Ethics Committee (reference number
08/H0301/98) and was registered as International Standard Randomised Controlled Trial Number 82731440
(ISRCTN82731440). The trial protocol can be accessed at www.papworthhospital.nhs.uk/research/data/
uploads/ptuc/protocol-v4-may-20151.pdf (accessed 2 March 2018)41 and the HESTER (Has Electrical Sinus
Translated into Effective Remodelling?) substudy protocol can be accessed at www.papworthhospital.nhs.uk/
research/data/uploads/ptuc/hester-study-protocol-3.pdf (accessed 2 March 2018).42
As much as possible, the design and reporting of this trial adhered to the guidelines of the Consolidated
Standards of Reporting Trials (CONSORT) statement43 and incorporated recommendations of the Expert
Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation.24
Patient and public involvement
Mr Brian Elliott was an independent member and lay representative on the Trial Steering Committee (TSC),
providing input on all aspects of the trial design, conduct and recruitment strategies. Professor Paul Kinnersley
has a background in primary care and public health and provided further independent advice on the conduct
and progress of the trial through membership of the TSC.
Setting and investigators
Eleven acute NHS specialist cardiac surgical centres (Papworth Hospital, Cambridgeshire; Royal Brompton
Hospital, London; Brighton and Sussex University Hospitals, Brighton; University Hospitals Coventry and
Warwickshire NHS Trust, Coventry; Glenfield Hospital, Leicester; Wythenshawe Hospital, Manchester;
Northern General Hospital, Sheffield; Guy’s and St Thomas’ Hospital, London; Derriford Hospital, Plymouth;
Freeman Hospital, Newcastle upon Tyne; and Blackpool Victoria Hospital, Blackpool) participated in the
study, which was co-ordinated by the Papworth Trials Unit Collaboration. For surgeons to participate, they
were required to be experienced in the use of ablation devices for at least 2 years. During the trial design
period, participating surgeons met to agree the permissible procedures, ablation methods and lesion sets
to be treated.
Participants
Consecutive cardiac surgical patients undergoing major cardiac surgery (e.g. coronary, valve or combined
operations), with a history of paroxysmal, persistent or chronic AF beginning > 3 months before the date
of the operation, were screened for eligibility.
l Paroxysmal AF was defined as recurrent AF (two or more episodes) that terminated spontaneously
within 4 days.24
l Non-paroxysmal but persistent AF was defined as AF that continued for > 4 days.
l Chronic or longstanding AF was defined as AF that was persistent for > 1 year.
The Amaze trial inclusion criteria included patients who:
l were aged > 18 years
l were scheduled to undergo elective or in-house urgent cardiac surgery (coronary surgery, valve surgery,
combined coronary and valve surgery or any other cardiac surgery requiring cardiopulmonary bypass)
l had a history of documented AF (chronic, persistent or paroxysmal) beginning > 3 months before entry
into the study
l were willing to provide written informed consent to participate.
AMAZE TRIAL METHODS
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Exclusion criteria included patients who:
l had had previous cardiac operations
l had had emergency or salvage cardiac operations
l had had surgery without cardiopulmonary bypass
l were unlikely to be available for follow-up over a 2-year period
l were unable to provide consent.
Recruitment
The procedure for informing and obtaining consent from patients was devised to accommodate local
variations in the patient pathway, but was otherwise identical for all centres. At most centres, potential
participants were initially given a simple summary of the study by the local investigator at the initial surgical
clinic when treatment options were discussed. Before the next attendance, the trial co-ordinator or a
research nurse contacted the patients by telephone to assess interest in the trial, and posted the full
patient information sheet to the homes of those who expressed an interest. Written consent was taken at
the pre-admission clinic, at approximately 2 weeks prior to surgery, by the trial co-ordinator or research
nurse. HRQoL questionnaires were administered by the research nurse, after consent, at this pre-admission
clinic. Thereafter, patients were registered for the trial and provided with a 4-day ECG recording device
and instructions on its use, to take home to monitor their heart rate for 4 days. On admission for surgery,
the patient returned the 4-day ECG recorder.
Randomisation
Eligible patients who satisfied the inclusion criteria and provided written consent were randomised (in a
1 : 1 ratio) to receive either their planned cardiac surgery with no additional procedure or their routine
cardiac surgery with an adjunct maze procedure.
The allocation sequence was generated by permuted block randomisation (using block sizes of 6 and 8),
and randomisation was stratified by surgeon and planned cardiac procedure (CABG, aortic valve, mitral
valve or combined procedure). On the day of surgery, when the patient was in the anaesthetic room, the
local centre contacted the Papworth Trials Unit Collaboration by telephone. Patient details, surgeon and
planned cardiac procedure were registered with the Papworth Trials Unit Collaboration, whose staff were
not otherwise involved with the trial. Once registration was complete, the allocation was released to the
surgical team, which was also responsible for completing the surgical clinical report form (CRF). The
treatment allocation was not made available to any other staff who were directly or indirectly involved in
the trial.
Blinding
Although theatre staff could not be blinded to the treatment allocation, the trial was double-blind to the
extent that neither the patients themselves, nor any researchers collecting HRQoL outcomes nor the
cardiologists assessing the 4-day ECG results were aware of the trial arm to which the patient had been
allocated.
Patients’ medical notes were labelled to indicate that they were Amaze trial participants. Routine reports
provided details of their elective surgery and the fact that they were randomised within the Amaze trial.
The surgical CRF describing the research intervention (maze procedure or no maze procedure) was placed
in a sealed envelope labelled ‘The Amaze Trial’ and kept in the patient’s notes. Clinicians were able to
access this information in the event of a serious adverse event (SAE) considered to be related to surgery.
At discharge, the data management staff retrieved the sealed envelope and uploaded the procedure
details onto a secure database, before resealing the envelope and returning it to the notes. Cardiologists
who analysed electrocardiograms for the primary outcome and researchers recording HRQoL outcomes did
not have notes, including the procedural information, available at the time of outcome assessment.
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Interventions
Control arm
The Amaze trial was planned as a pragmatic trial, following standard treatment and care as closely as
possible in order to assess outcomes in a real-world context. Patients randomised to the control arm
received preoperative management, elective or in-house urgent cardiac surgery and postoperative
management in accordance with standardised hospital protocols.
Experimental arm
Patients randomised to the experimental arm received preoperative management and elective or in-house
urgent cardiac surgery, as described in standardised hospital protocols. During the operation, the conduct
of the adjunct maze procedure and the choice of lesion set was at the surgeon’s discretion. At the time of
trial design, there was no evidence for the superiority of one ablation device or one energy source over
another. Therefore, any AF ablation device that was routinely used within the NHS by the investigators was
permitted. This allowed surgeons to use the devices with which they were most familiar and comfortable,
and which were in routine use at their institution. These included bipolar and unipolar radiofrequency,
‘cut-and-sew’, cautery, cryotherapy, ultrasound, laser and microwave energy. Postoperative management,
subsequent follow-up and data collection were identical to the control arm.
Standardisation between centres
In order to minimise potential confounding by other components of a patient’s care, the following aspects
of the trial were standardised across participating hospitals.
Management of patients before, during and after surgery
Management was undertaken in accordance with the local site’s normal practice, irrespective of
randomisation. The only exceptions were processes required to maintain the blinding of the patient,
cardiologist and QoL interviewer (see Blinding).
Conducting and reporting on the adjunct maze procedure and defining the prescribed
lesion set
The full lesion set considered is illustrated in Figure 1, although the specific lesion set treated was left to
the participating surgeon’s discretion. Details of the ablation procedure and all lesions treated were
documented. Published guidelines for reporting data and outcomes for surgical treatment of AF were
followed.8,15
Postoperative drug use
l Amiodarone: unless contraindicated, 200 mg three times per day was prescribed, reducing over a
period of 3 weeks to 200 mg per day for 6 weeks. The drug was stopped if stable SR was established
at 6 weeks. Further prescription after this period was based on individual clinical judgement.
l Warfarin: prescribed until the patient was in stable SR. Thereafter, centres adopted normal practice.
l Beta-blockers: prescribed at the individual clinician’s discretion.
l Other drugs: prescribed at the individual clinician’s discretion; cardiac drugs with antiarrhythmic,
antihypertensive and anticoagulant actions, including aspirin and warfarin, were documented.
Indications for cardioversion, timing and number of attempts
The protocol did not require cardioversion to be carried out at discharge, but if it was performed for
clinical reasons, the details were recorded. For patients in AF at the first follow-up appointment,
cardioversion was attempted within 3 months of surgery. If cardioversion was unsuccessful, then it was
attempted again at 6 months after surgery.
AMAZE TRIAL METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
Outcome measures
Primary outcomes
Return to sinus rhythm at 12 months
Sinus rhythm at 12 months after surgery was determined by the absence of any AF on outputs from
continuous monitoring by 4-day ECG recorders. All 4-day continuous ECG recordings were analysed centrally
at Papworth Hospital. Participating hospitals forwarded the anonymised secure digital cards from the ECG
recorders to Papworth Hospital. Analyses using the proprietary automated software package, together with
manual checking of the recording in its entirety, were completed by cardiologists who were not aware of the
patient’s identity or allocated treatment arm. Total time spent in SR and in AF (AF burden) during the 4-day
recording was calculated. Episodes of atrial flutter were noted and included in the AF burden.
Quality-adjusted survival over 2 years
The EQ-5D-3L was administered at randomisation, on discharge and at 6 weeks and 6, 12 and 24 months
after the procedure (Table 1).44 Although the current version of the EuroQol-5 Dimensions has five levels
for each item, when the Amaze trial was designed, the three-level version was recommended for the
cost-effectiveness analysis.45 EQ-5D-3L responses were converted into utility scores reflecting values from
a representative sample of the UK population.46 Clinical effectiveness was measured by quality-adjusted
life-years (QALYs) over 2 years using the area under the curve method (see Statistical analyses).47
Left side Right side
1.   Around RPV
2.   Around LPV
3.   Connecting RPV to LPV
4.   Connecting RPV to mitral annulus
5.   Left atrial appendage
6.   Left atrial appendage to LPV
Note that some lesions were not treated in 
some patients
1.   SVC to IVC
2.   SVC–IVC to tricuspid annulus
3.   Trans-septal SVC–IVC to RPV
4.   Right atrial appendage
5.   Right atrial appendage to RA body
6.   Right atrial appendage to tricuspid
      annulus
7.   Coronary sinus ostium
Tricuspid
annulus
Right 
coronary 
artery
IVCCircumflex
Coronary sinus
Mitral
annulus
Left atrial
appendage
Right atrial
appendage
SVC
FIGURE 1 Complete modified Cox maze procedure III lesion set. IVC, inferior vena cava; LPV, left pulmonary vein;
RA, right atrium; RPV, right pulmonary vein; SVC, superior vena cava.
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Secondary outcomes
Sinus rhythm was determined by the absence of any AF on 4-day ECG recorders at 24 months after
surgery. Other secondary outcomes were overall survival from the date of randomisation to date of death
(all patients were registered with the Office for National Statistics’ tracking system to allow long-term
follow-up of survival); stroke-free survival, defined as the time between randomisation and the date of
stroke or death (whichever occurred first); incidence of hospital admission for (anticoagulant-related)
haemorrhage, anticoagulant and antiarrhythmic drug usage up to 24 months after randomisation; HRQoL
measured by the EQ-5D-3L, the SF-36 and the NYHA for breathlessness (completed at baseline, on
discharge and at 6 weeks and 6, 12 and 24 months post surgery after randomisation); and resource use
and trial-based cost-effectiveness of the adjunct maze procedure up to 24 months after randomisation.
Health-related quality of life
Health-related quality-of-life interviews were conducted by clinical research co-ordinators/research nurses
in face-to-face interviews at hospital research clinics. Six-month questionnaires were administered by
telephone, as patients did not have clinical appointments. The questionnaires administered are summarised
in Table 1. The SF-36 consists of eight dimensions, which are the weighted sums of the questionnaire item
responses. Each dimension ranges from 0 to 100, with a higher score representing better health or fewer
limitations for that domain. Standardised physical and mental health scores were calculated, which, for a
general UK population, are expected to be approximately normally distributed with a mean of 50 and a
standard deviation (SD) of 10.48 For missing items, we used the methods recommended in the manual.49
Briefly, if at least half the items were available for any scale, the mean of the recorded items was imputed
for the missing items. If more than half the items for a scale were missing, then the scale was recorded as
missing.
Sample size
The dual primary outcomes were a clinical end point (return to SR at 12 months) and an outcome of
importance to patients and service providers (quality-adjusted survival over 2 years). The maze procedure
was considered effective if there was a significant effect for return to SR or if the mean difference in
QALYs between the groups did not include zero. No adjustments were made to the sample size to
TABLE 1 Health-related quality-of-life questionnaires administered
Type Questionnaire Description
Generic EQ-5D-3L l Five dimensions (morbidity, self-care, usual activities, pain/discomfort and anxiety/
depression), each having three levels (no problems, moderate problems, severe problems)
l One derived utility measure (EQ-5D-3L) measured on a scale from –0.591, through
0 (representing death), to 1 (representing full health)
l One overall health scale from 0 to 100 (not analysed)
Generic SF-36 l Eight dimensions (physical functioning, role limited because of physical problems, pain,
energy/vitality, social functioning, mental health, role limited because of emotional
problems and general health). Dimension scores range from 0 (minimum function) to
100 (maximum function)
l One derived utility measure (SF-6D) ranging from 0 (death) to 1 (full health)
Specific NYHA Breathlessness was classified on a four-point scale:
l Class I – no limitation during ordinary physical activity
l Class II – ordinary physical activity slightly limited. Comfortable at rest, but ordinary
physical activity results in fatigue, palpitation or dyspnoea
l Class III – marked limitation of physical activity. Comfortable at rest, but less than ordinary
activity causes fatigue, palpitation or dyspnoea
l Class IV – unable to carry on any physical activity without discomfort; symptoms of
cardiac insufficiency at rest
SF-6D, Short Form questionnaire-6 Dimensions.
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accommodate the multiple testing of these two outcomes, which is inherent in this approach, as the
focus for the QALY end point was on estimation of the treatment effect, rather than hypothesis testing.
However, to guard against overinterpretation of hypothesis tests, we recommend that p-values between
0.025 and 0.05 are considered to have borderline significance.
Return to sinus rhythm at 12 months
Prior to the trial, published RCTs of ablation as an addition to cardiac surgery reported rates of return to
SR at 12 months ranging from 44% to 87% in the maze procedure arms, and from 5% to 33% in the
control arms.19,22 We took a conservative estimate of the difference between the arms (45% vs. 30%) as
the target effect. In order that a realistic recruitment target was achieved, 80% power was used in the
calculation. Combining this with a two-sided significance of 5%, an estimated sample size of 176 in each
arm (total of 352) would be sufficient to detect this effect. With planned recruitment of 400 patients, this
allowed for approximately 15% death/loss to follow-up at 12 months.
Quality-adjusted survival over 2 years
The emphasis in cost-effectiveness studies is on estimation, rather than hypothesis testing, so that formal
sample size calculations were considered less important. However, we provided a power calculation based
on the effectiveness measure ‘QALYs at 2 years post randomisation’. We could find no studies reporting
comparative QALYs in similar patients undergoing ablation and cardiac surgery. From previous studies of
patients undergoing angiography for suspected ischaemic heart disease and patients with refractory
angina, the SD of QALYs over 12 and 18 months was at most 0.3.50,51 Over 2 years, the minimum clinically
important improvement was considered to be 1 extra month of quality-adjusted life or 0.083 QALYs.
With a sample of 200 patients per arm (total of 400), we would have exactly 79% power to detect a
difference of 0.083 QALYs (at a two-sided significance of 5%).
If the accepted threshold for cost-effectiveness was in the range £20,000–30,000 per QALY and we could
demonstrate a significant increase in QALYs of 0.083, then the procedure would be cost-effective for an
incremental cost of, at most, £2500.
Failure to reach target recruitment
Based on audit data, our target recruitment of 400 patients was expected to be achieved in 18 months
at six centres. Owing to the slower than expected accrual, recruitment terminated in September 2014,
when 352 patients had been randomised, with approximately 70% power to identify the target treatment
effects.
Analysis populations
Intention-to-treat population
The primary analysis used the intention-to-treat (ITT) population, defined as all randomised patients,
regardless of eligibility, withdrawal, compliance with the protocol, loss to follow-up or actual treatment
received. No patients withdrew consent for their data to be used, despite withdrawing from trial follow-up.
Multiple imputation was used for missing primary outcomes.
Quality-of-life population
For each instrument (the SF-36 and the EQ-5D-3L), all patients who returned a completed baseline
questionnaire, regardless of subsequent questionnaire return, were included in the analysis. In addition,
imputation (based on planned procedure and centre) of missing baseline EQ-5D-3L scores was completed
for two patients.
Safety population
All patients were included in the safety population if they underwent a surgical procedure. Patients were
included in the arm corresponding to the intervention received (maze procedure completed vs. no maze
procedure).
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Statistical analyses
All statistical analyses and reporting complied with CONSORT guidelines where possible.52
Formal analyses were conducted using a two-sided 5% level of significance, with no adjustment for
multiple testing. All analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).
The statistical analysis plan is provided in Appendix 1.
In descriptive summaries, the number of non-missing items and the mean (SD) or median (upper and lower
quartiles) were summarised for continuous variables, and the number and proportion by treatment arm
were summarised for each level of categorical variables.
Return to sinus rhythm
The odds of being in SR for maze procedure patients was compared with the odds for control patients,
and estimated using a binary logistic regression model, including surgeon (normal random effects on the
logistic scale), baseline heart rhythm and planned surgical procedure (fixed effects). The odds ratio (OR) for
return to SR was reported with the 95% CI and p-value from this model. Validity of logistic regression
models was assessed by examining the following statistics and graphical summaries:
l Pearson residuals/deviance (half-normal plots)
l leverage values
l Cook’s distance
l cross-validation probabilities (the probability of a particular observation, conditional on the
remaining observations)
l L-statistics (the influence of an observation on the difference in deviance as a result of fitting the
treatment effect).
The percentage of time in AF across the 4 days of monitoring at baseline and at 12 months was
summarised by treatment arm.
Quality-adjusted survival
For the primary outcome, QALYs over 2 years were estimated from serial measurements of the EQ-5D-3L
for each patient. The UK social tariff for the EQ-5D-3L, completed at baseline and on discharge, and at
6 weeks and 6, 12 and 24 months post surgery, as estimated by Dolan et al.,46 was applied to calculate
utility values. Using actual rather than nominal times of assessment, and assuming a linear change in
values between time points, patient-specific utility curves up to 24 months post randomisation were
calculated. A value of zero was assigned at the date of death for patients who died. QALYs were
calculated as the area under the utility curve to 24 months or date of death, whichever occurred first.
In order to adjust for differences in baseline utilities, a linear regression was fitted to the utilities post
treatment, with baseline utility and treatment arm as explanatory variables. For patients who did not
complete all EQ-5D-3L questionnaires or those who were censored, multiple imputation was used to
estimate mean QALYs (see Missing data). Model fit was assessed by examining standardised residuals
and association with the predicted values, as well as identifying influential observations by referring to
leverage statistics. A CI for the true difference in QALYs was estimated using a non-parametric bootstrap
resampling approach.53
Note that, for the primary outcome analysis, no discounting of the QALYs estimates was applied. However,
when costs and benefits were estimated for the health economics analysis, both were discounted at 3.5%
for the second year.
Missing data
Proportions of, and reasons for, missing data were investigated.
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For the clinical primary end point (return to SR at 12 months), if a patient withdrew consent or was lost to
follow-up within 12 months, the missing outcome (AF or SR at 12 months) was multiply imputed as a
function of the baseline heart rhythm, surgeon, surgical procedure and treatment arm.54 Rubin’s rules
were used to combine imputed data sets.55
For the patient-based primary end point (QALYs), whereby a patient died before the end of follow-up,
the utility value of 0 was imputed for all subsequent assessments. If the response was missing, and the
patient was alive, the missing value was imputed using the method of multiple imputation.54 A number of
sensitivity analyses related to missing data were completed; further details are provided in Appendix 1.
In response to a reviewer’s request, we also provided a supportive analysis using complete cases, but with
predictors of missingness included in the model.
Subgroup analysis
Prespecified subgroups are listed above (see Exploratory analysis).
For the SR end point, a logistic regression model was fitted to heart rhythm at 12 months, including
baseline heart rhythm, surgeon, surgical procedure, treatment arm and subgroup variable of interest and
its interaction term with the treatment arm. Within-subgroup treatment effects and the interaction effect
between subgroup and treatment arm were estimated with 95% CIs and p-values.
For the QALYs end point, a linear regression model was fitted to the area under the utility curve,
with baseline EQ-5D-3L score, surgeon, surgical procedure, treatment arm, subgroup variable and the
subgroup-by-treatment interaction variable.
Because analysis revealed an increasing OR for the maze procedure arm relative to the control arm as the
trial progressed, we explored changes in baseline characteristics, surgery and cointerventions throughout
the trial in an attempt to explain this finding.
Secondary end point analysis
Return to stable SR at 24 months was analysed in a similar way to return to SR at 12 months, using a
binary logistic regression model, including baseline heart rhythm, surgeon, surgical procedure and
treatment arm.
Overall survival was summarised using Kaplan–Meier methods for the time between randomisation and
death. Patients who were alive at the end of the study, or who withdrew before the end of follow-up,
were censored at the date they were last seen. Similarly, stroke-free survival, defined as the time
between randomisation and the date of stroke or death, whichever occurred first, was summarised
using Kaplan–Meier methods. Patients who were alive and stroke free at the end of the study, or who
withdrew without having suffered a stroke before the end of follow-up, were censored at the date they
were last seen. Cox regression models were used to estimate hazard ratios (HRs) for maze procedure
patients relative to control patients.
Patients who had a stroke within 12 months of surgery, and the overall proportion of stroke events,
were calculated by treatment arm, using the total number of patients participating in the trial as the
denominator. The relationship between stroke and treatment arm was tested by Fisher’s exact test, and
the difference in stroke rates was reported along with 95% CIs for differences in proportions.
Short Form questionnaire-36 items dimension scores and summarised mental component score (MCS)
and physical component score (PCS) were analysed using a linear regression model, including time point,
treatment arm, time-by-treatment-arm interaction and baseline SF-36 scores (all modelled as fixed effects),
and allowing random intercepts for patients.
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Drug use for each arm was tabulated by time point (at baseline, discharge, 6 weeks and 6, 12 and
24 months) and drug category. Logistic regression for the outcome of each patient (1 = have one or more
drugs during time period t, 0 = have no drugs during time period t) was fitted, including drug category,
time period of drug usage, baseline drug usage and treatment arm as independent variables. ORs were
estimated with 95% CIs and p-values.
The occurrence of atrial flutter and atrial tachycardia (organised atrial arrhythmia) and junctional rhythm
were summarised by arm. The relationship between the completeness of the lesion set and the
occurrences of organised atrial arrhythmia and junctional rhythm was tabulated.
Safety analysis
The number of AEs in each category and deaths from any cause were summarised by treatment arm,
corresponding to the treatment received. Events were summarised according to whether or not they met
the criteria of SAEs, severity and relationship to the procedure.
Economic analysis
Data collection and sources
NHS resource use was collected during primary admission and at the 6-week and 6-, 12- and 24-month
follow-ups. Research nurses/clinical trial co-ordinators extracted data about inpatient stay from individual
patient records and administered bespoke questionnaires about follow-up health service use either face to
face or by telephone/post (for those who missed an appointment). Hospital records were checked to
validate patient-reported hospital readmission.
Resources related to the primary admission (from randomisation to discharge) included theatre use (initial
operation and returns to theatre), intensive care (days) and cardiac and acute care wards (days). The total
length of stay was compared with the sum of recorded days in an intensive care unit (ICU) and ward, and
any double-counting that was identified was subtracted. For patients who were not discharged home,
subsequent admissions to rehabilitation centres or acute hospitals were added. Surgery-specific resource
use, including equipment and energy sources for the maze procedure, were retrieved from patient notes.
The resource use recorded during follow-up was divided into three categories: hospital readmissions
(length of stay in hospitals or rehabilitation centres), 16 types of test [e.g. cardiac related, magnetic
resonance imaging (MRI) and radiographic] and 12 types of health-care visit [e.g. accident and emergency
(A&E), outpatient, primary and community health services]. In all resource-use calculations, a value of
zero was assigned to any unused resource item, including all resource items after death.
Medication use was limited to antiarrhythmic, anticoagulant and antiplatelet drugs and seven classes of
cardiac drugs (beta-blockers, diuretics, calcium channel blockers, nitrates, angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers and statins). The daily dose of each drug type was based on
patient record review for inpatient stay and patient reports after discharge. As specific drug names were
not recorded for cardiac drugs, the chief investigator (SN) identified the most likely drugs to be prescribed,
and the daily dose was taken to be the most common reported daily dose in the CRFs for that category of
drugs. For example, bisoprolol and atenolol were the assumed drugs when beta-blocker was indicated,
with the dose equalling that reported by 90% of respondents.
The total amount of each drug used per patient was estimated by taking a mid-value of daily dose at
consecutive follow-up time points, multiplied by duration between follow-up time points, and costed using
the NHS Prescription Services Electronic Drug Tariff56 and the British National Formulary (2016).57 Missing
drug use at each time point was replaced, depending on the nature of missingness, as follows: patients
who died were assigned zero medication use from date of death; if a patient indicated use of a drug at
only one follow-up, the duration was taken to be the mid-point between this and the next follow-up
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(except for drugs recorded only at baseline, which were excluded, as the trial focused on drugs post
randomisation). For patients who either had completely missing drug data at a follow-up time point or were
lost to follow-up, costs were multiply imputed using chained equations with predictive mean matching,
stratified by treatment arm (see Missing data).
Unit costs were multiplied by the frequency of resource use to provide total resource cost for each item.
National estimates of unit prices were sourced58,59 to increase generalisability. For resources for which
national prices were not available, estimates were sourced either from the literature (e.g. 24-hour blood
pressure monitoring and chest radiography) or from Papworth Hospital (e.g. theatre cost and cost of
device). The hospital and community health services pay and price index58 was applied to adjust for
inflation when necessary (see Appendix 2, Table 23). The ablation device was costed at £3000 per patient
for high-intensity focused ultrasound, and £1250 per patient for all other methods. All resource costs, from
the date of operation (randomisation) up to 2 years post randomisation, were summed, with year 2 costs
discounted at 3.5%.45
Health-related quality of life, assessed using the EQ-5D-3L and SF-36 questionnaires, was an important
outcome, and is described in Secondary end point analysis. SF-36 health state responses were converted to
the Short Form questionnaire-6 Dimensions (SF-6D) utility scale using values from the UK population.47
QALYs, as described in Statistical analyses on page 12, were discounted at 3.5% in year 2 for the cost-
effectiveness analysis.45
Missing data
Missing baseline variables that were required for the imputation model, for example missing baseline
EQ-5D-3L assessments, were replaced by the mean value for each trial arm.60 Logistic regression identified
variables that were related to missingness.
Missing resource use and utility data were imputed jointly using chained equations with predictive mean
matching. The imputation models included age, sex, paroxysmal AF and baseline EQ-5D-3L score, and
were stratified by trial arm. A total of 60 imputed data sets were created to attain a stable imputation.
The distribution of imputed values was checked for comparability with observed data [e.g. counts of
general practitioner (GP) visits, matched observations].
For 28 resource-use variables (tests and health-care visits), multiple imputation at each data collection point
was not possible, as a result of the small numbers of events, and, therefore, the annual average for each
resource-use variable was imputed for each arm. To assess the sensitivity of results to this assumption, an
alternative imputation model was fitted, in which each test and health-care visit was multiplied by the
corresponding unit cost. All tests and (separately) all health-care visits were grouped for each trial data
collection point using total cost, and multiple imputation was applied to these categories of resource-use
cost.
Incremental cost-effectiveness analysis and sensitivity analyses
Differences in estimated costs and QALYs between trial arms were explored using two-sample t-tests with
equal variances. Linear regression analysis was used to adjust for differences in age, sex, baseline EQ-5D-3L
score, AF at baseline and, for QALYs only, the primary surgery [isolated mitral valve replacement or repair
(MVR), isolated CABG, isolated aortic valve replacement or repair (AVR), CABG and MVR, CABG and
AVR and all others]. The incremental cost-effectiveness ratio (ICER) was calculated using adjusted mean
estimates of costs and QALYs from ‘seemingly unrelated regression’, to allow for correlation between costs
and effects at the patient level, and for skewness of data.
One thousand bootstraps were generated for each sample for the probabilistic sensitivity analysis. Costs for
the resource-use components were sampled from gamma distributions and applied to the bootstrapped
samples, and the total costs and QALYs for each sample were estimated using seemingly unrelated regression.
The probability that the maze procedure was cost-effective was considered at varying willingness-to-pay (WTP)
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threshold values, using cost-effectiveness planes, the cost-effectiveness acceptability curve and incremental net
monetary benefit (INMB).
Deterministic and probabilistic sensitivity analyses were used to explore the robustness of cost-effectiveness
results that adopted different methodological approaches or assumptions. These analyses included the use
of SF-6D QALYs, clinical effectiveness as measured by conversion of AF to SR, complete case analysis,
examining costs and QALYs only up to discharge, examining the impact of outliers, excluding maze device
cost, limiting the patient group to those randomised from April 2001 (to match the time-based post hoc
statistical analysis) and an alternative imputation technique. The probability distribution of unit costs could
not be resampled when the alternative imputation technique was used, as the imputation was for cost at
each follow-up point, rather than resource use.
AMAZE TRIAL METHODS
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Chapter 3 Trial results: clinical effectiveness and
health-related quality of life
Recruitment and compliance
Between 25 February 2009 and 6 March 2014, 1013 patients were screened for the Amaze trial in 11 UK
specialist cardiac surgery centres: (1) Papworth Hospital, Cambridgeshire (n = 546); (2) Glenfield Hospital,
Leicester (n = 186); (3) Derriford Hospital, Plymouth (n = 95); (4) Freeman Hospital, Newcastle (n = 72);
(5) Northern General Hospital, Sheffield (n = 49); (6) Blackpool Victoria Hospital, Blackpool (n = 27); (7) Royal
Brompton Hospital, London (n = 16); (8) Guy’s and St Thomas’ NHS Foundation Trust, London (n = 13);
(9) Wythenshawe Hospital, Manchester (n = 10); (10) University Hospitals Coventry and Warwickshire NHS
Trust, Coventry (n = 4); and (11) Brighton and Sussex University Hospitals, Brighton (n = 3). The flow of
Amaze trial patients from the initial screening to final follow-up is illustrated in Figure 2.
A total of 661 patients were excluded at screening, but screening logs were only completed for all patients
in the co-ordinating centre (Papworth Hospital). At Papworth Hospital, 366 out of 546 patients (67%)
were excluded between registration and randomisation (see Appendix 3, Table 32); 107 of these patients
declined to participate, mostly because of concerns about either the trial requirements or the planned
surgery they were about to undergo. Only one patient cited concerns about not knowing the treatment
arm until 2 years after the procedure (as a result of patient blinding), although 38 patients declined
without giving a reason. A further 115 patients were excluded by the consultant surgeon, with 49 (43%)
of these patients undergoing the maze procedure outside the trial (as a result of severe or symptomatic AF
or patient preference) and 11 patients opting for minimally invasive access or another procedure. The
reason for exclusion by the surgeon was not recorded for 23 cases. Other reasons were related to trial
exclusion criteria, such as patient participation in other clinical trials (n = 19), lack of time to recruit some
in-house urgent cases (n = 6), not having a well-documented history of AF (n = 5) and having previous
cardiac surgery (n = 3). Between screening and randomisation, eight patients died, and for a further four,
their conditions deteriorated to such an extent that trial participation was not considered appropriate.
A further 42 patients were excluded for various administrative reasons (see Appendix 3, Table 32).
After exclusions, 352 patients were randomised to either the planned cardiac procedure alone (n = 176) or
maze procedure in addition to the planned procedure (n = 176). Thirteen patients (3.7%) did not receive
their allocated treatment: 11 (6.3%) maze and two (1.1%) control patients. The maze procedure was not
completed for a number of patients, as a result of (1) operation complexity and concern about prolonged
cross-clamp time (n = 4); (2) an enlarged atrium or other technical difficulty (n = 3); (3) patient withdrawal
from surgery after randomisation was revealed (n = 1); and (4) unrecorded surgeon decision (n = 3).
Two control patients had the maze procedure as a result of perceived patient benefit by the consultant
post randomisation.
Complete blinding was maintained for 339 (96%) patients. Treatment allocation was revealed in the notes
of 13 patients (nine at Papworth Hospital, three at Derriford Hospital and one at Wythenshawe Hospital);
of these, 10 underwent the maze procedure and three were control patients. The unblinding was
attributable to initial protocol misunderstanding; after re-education of trial personnel, complete blinding
was achieved for subsequent patients. The cardiologist reviewing the ECG recording did not have access to
the patient’s medical notes. All patients and HRQoL assessors remained unaware of treatment allocation.
At 12 months, 150 maze procedure patients and 151 control patients (85% and 86%, respectively)
remained in the trial. The reasons recorded for loss to follow-up at 12 months were death in 33 cases,
patient withdrawal in 14 cases and loss to follow-up in four cases. Note that one maze procedure patient
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(out of 33) died just after 12 months, but the patient was too sick to complete follow-up. The clinical
primary end point (SR at 12 months post randomisation) was completed for 141 (80%) maze procedure
patients and 145 (82%) control patients, as 11 patients declined the 4-day ECG (eight maze procedure
patients and three control patients) and, for four patients, the recordings were not usable (one maze
procedure patient and three control patients). The frequency of missing outcomes and associated reasons
was similar for the two trial arms.
Allocation
Randomised
(n = 352)
Consent
(n = 360)
Screened
(n = 1013)
Follow-up
Reasons for exclusion 
(at Papworth Hospital only)
See Appendix 3, Table 32
Reasons for exclusion (n = 8)
• Declined 4-day ECG, n = 1
• Died, n = 1
• Withdrawn by consultant, n = 2
• Patient withdrew, n = 1
• Off-pump procedure, n = 1
• Withdrawn from surgery, n = 1
• Patient wanted maze 
   procedure, n = 1
Assigned to control (n = 176)
Received control (n = 174)
Received maze procedure (n = 2)
• Clinical decision, n = 2
12-month follow-up
• Completed, n = 151
• [Primary outcome (SR) available,
   n = 145]
• Death, n = 16
• Withdrawal, n = 6
• Lost to follow-up, n = 3
24-month follow-up
• Completed, n = 142
• [Primary outcome (QALY)
   available, n = 160]
• Death, n = 18
• Withdrawal, n = 13
• Lost to follow-up, n = 3
Assigned to maze procedure (n = 176)
Received maze procedure (n = 165)
Did not receive maze procedure (n = 11)
• Operation complexity and
   prolonged cross-clamp, n = 4
• Enlarged atrium, n = 2
• Clinical decision, n = 3
• Enlarged heart, PAPVD, risk, n = 1
• Withdrawn from surgery, n = 1
12-month follow-up
• Completed, n = 150
• [Primary outcome (SR) available,
   n = 141]
• Death, n = 17
• Withdrawal, n = 8
• Lost to follow-up, n = 1
24-month follow-up
• Completed, n = 136
• [Primary outcome (QALY)
   available, n = 160]
• Death, n = 24
• Withdrawal, n = 15
• Lost to follow-up, n = 1
Enrolment
FIGURE 2 Patient flow through the Amaze trial. PAPVD, partial anomalous pulmonary venous drainage.
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The patient-based primary end point (QALYs up to 24 months post randomisation) was completed for
160 patients in each arm (91%). We note that patients who died during follow-up were included in the
calculation of QALYs, contributing zero to the estimate from the date of death. Thirty-two patients were
excluded from this analysis, as a result of either patient withdrawal from the study (n = 28) or loss to
follow-up (n = 4).
Baseline characteristics
Patient characteristics at baseline are shown in Table 2. Almost 50% of cases were recruited in the
co-ordinating centre (Pathworth Hospital) by 13 surgeons, and over one-quarter were recruited in the
second highest recruiting centre (Glenfield Hospital) by four surgeons. The Amaze trial population had a
mean age of 71.9 years (SD 7.67 years), almost two-thirds (65.9%) were men and the mean risk of
TABLE 2 Baseline characteristics for patients randomised in the Amaze trial
Characteristic
Treatment arm
Total (n= 352)Maze procedure (n= 176) Control (n= 176)
Number of patients at each randomising centre, n (%)
Papworth Hospital 89 (50.6) 85 (48.3) 174 (49.4)
Glenfield Hospital 49 (27.8) 44 (25.0) 93 (26.4)
Derriford Hospital 16 (9.1) 16 (9.1) 32 (9.1)
Northern General Hospital, Sheffield 12 (6.8) 14 (8.0) 26 (7.4)
Freeman Hospital, Newcastle upon Tyne 3 (1.7) 5 (2.8) 8 (2.3)
Guy’s and St Thomas’ Hospital, London 1 (0.6) 5 (2.8) 6 (1.7)
Wythenshawe Hospital 4 (2.3) 1 (0.6) 5 (1.4)
Brighton and Sussex University Hospitals 1 (0.6) 1 (0.6) 2 (0.6)
University Hospitals Coventry and
Warwickshire NHS Trust
1 (0.6) 1 (0.6) 2 (0.6)
Royal Brompton Hospital – 2 (1.1) 2 (0.6)
Blackpool Victoria Hospital – 2 (1.1) 2 (0.6)
Patient age (years)
Mean (SD) 72.3 (7.53) 71.4 (7.81) 71.9 (7.67)
Range 50.0–86.0 48.0–89.0 48.0–89.0
Patient sex, n (%)
Male 112 (63.6) 120 (68.2) 232 (65.9)
Female 64 (36.4) 56 (31.8) 120 (34.1)
Body mass index (kg/m2)
Mean (SD) 28.1 (5.27) 27.6 (4.62) 27.9 (4.96)
Range 17.4–46.0 17.9–42.8 17.4–46.0
Logistic EuroSCORE61 (%)a
Mean score (SD) 6.94 (5.489) 6.64 (4.869) 6.79 (5.184)
Range 0.88–30.41 1.40–23.85 0.88–30.41
EuroSCORE, European System for Cardiac Operative Risk Evaluation.
a EuroSCORE was not recorded for one control patient.
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in-hospital death as a result of the procedure [the 2003 logistic European System for Cardiac Operative
Risk Evaluation (EuroSCORE)61] was 6.79% (SD 5.18%). The characteristics of Amaze patients were broadly
similar to those of UK NHS cardiac surgery patients, but Amaze patients were slightly older and more likely
to be female, and had a slightly lower average EuroSCORE.62 On average, the two treatment arms had
similar characteristics.
Table 3 summarises symptoms at baseline. Heart failure symptoms, defined by the NYHA classification,
were common, with 40.3% of patients reporting mild symptoms or slight limitations during ordinary
activity, and 41.4% of patients reporting either marked or severe limitations, even during mild activity or
at rest. Symptoms of angina, as defined by the Canadian Cardiovascular Society’s grading scale for angina
pectoris, were less common, with 73.3% of patients being angina free at baseline and only a small
proportion (5.7%) reporting moderate or severe limitations as a result of angina.
Other markers of cardiac function were also similar between the two arms (Table 4). For example,
approximately two-thirds of patients (66.5%) had a left ventricular ejection fraction (LVEF) of > 50% at
baseline, and 2.6% of patients had suffered a recent myocardial infarction (MI). The frequency of other
risk factors for heart disease was similar between the two arms: 3.4% of patients were insulin-dependent
diabetics, 12.5% were non-insulin-dependent diabetics, 37.8% were treated for high cholesterol and
57.4% had hypertension. The frequency of comorbidities was similar in both treatment arms, with chronic
obstructive pulmonary disease (COPD) present in 9.7% of patients and pulmonary hypertension present in
15.1% of patients. In both treatment arms, 6.3% of patients had a history of cerebrovascular accidents
and 8.8% had previous transient ischaemic attacks, with 2.8% of these patients having neurological
dysfunction at baseline (see Appendix 3, Table 33).
TABLE 3 Symptoms of heart failure at baseline
Classification
Treatment arm, n (%)
Total number of patients
(n= 352), n (%)Maze procedure (n= 176) Control (n= 176)
CCS classification
Class 0 125 (71.0) 133 (75.6) 258 (73.3)
Class 1 13 (7.4) 17 (9.7) 30 (8.5)
Class 2 21 (11.9) 16 (9.1) 37 (10.5)
Class 3 10 (5.7) 8 (4.5) 18 (5.1)
Class 4 1 (0.6) 1 (0.6) 2 (0.6)
Missing/not known 6 (3.4) 1 (0.6) 7 (2.0)
NYHA classification at baseline
I 31 (17.6) 30 (17.0) 61 (17.3)
II 74 (42.0) 68 (38.6) 142 (40.3)
III 59 (33.5) 71 (40.3) 130 (36.9)
IV 10 (5.7) 6 (3.4) 16 (4.5)
Missing/not known 2 (1.1) 1 (0.6) 3 (0.9)
CCS, Canadian Cardiovascular Society’s grading scale for angina pectoris.
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Table 5 documents patients’ medical history associated with AF. For 26.1% of patients, AF was
paroxysmal; the 73.9% of patients who had non-paroxysmal AF included almost 60% of patients classed
as having chronic/longstanding AF and 13.9% classed as having persistent intermittent symptoms. Over
two-thirds (68.5%) of patients had AF for > 12 months. Only 4.3% of patients had been fitted with a
permanent pacemaker and 13.4% had previously undergone cardioversions; previous ablation had been
attempted in slightly more maze procedure patients (1.7%) than control patients (0.6%). Anticoagulant
and antiarrhythmic drugs were prescribed for 77.6% and 83.2% of patients, respectively.
Table 6 summarises the HRQoL for the EQ-5D-3L utility score and the SF-36 dimensions at baseline.
The mean EQ-5D-3L utility score was 0.75 (SD 0.22) at baseline, which compares well with the UK norms
of 0.78 (SD 0.26) for people aged 65–74 years and 0.73 (SD 0.27) for people aged ≥ 75 years.63 Thus,
patients selected for cardiac surgery, who entered the Amaze trial, have comparable limitations to the
general population of the same age, as measured by this generic HRQoL scale. In contrast, the mean scores
for the SF-36 dimensions were very much lower than the published norms at baseline, particularly for the
physical dimensions (see Table 6).64 The mean standardised MCS at baseline was 50.19 (SD 10.32) for this
population, almost exactly the same as the mean score for the UK population, whereas the mean for the
standardised PCS was 30.59 (SD 13.36), which is significantly lower than the mean (SD) score for the UK
population.
Surgical results
Table 7 summarises the surgical procedures completed; the most common were isolated MVR (24.7%),
CABG (19.6%) and AVR (15.6%), followed by combined CABG with either AVR (10.5%) or MVR (7.7%).
All other procedures were combinations of CABG and/or multiple valve procedures, with the exception of
two patients for whom no procedure could be completed.
TABLE 4 Markers of cardiac function and cardiovascular risk factors at baseline
Marker
Treatment arm, n (%)
Total number of patients
(n= 352), n (%)Maze procedure (n= 176) Control (n= 176)
Left ventricular function
Poor (LVEF of < 30%) 4 (2.3) 8 (4.5) 12 (3.4)
Moderate (LVEF of 30–50%) 50 (28.4) 56 (31.8) 106 (30.1)
Good (LVEF of > 50%) 122 (69.3) 112 (63.6) 234 (66.5)
Recent MI 4 (2.3) 5 (2.8) 9 (2.6)
Previous PCI 16 (9.1) 14 (8.0) 30 (8.5)
Congestive cardiac failure 5 (2.8) 1 (0.6) 6 (1.7)
Diabetes
Insulin dependent 5 (2.8) 7 (4.0) 12 (3.4)
Non-insulin dependent 27 (15.3) 17 (9.7) 44 (12.5)
Hyperlipidaemia/hypercholesterolaemia 70 (39.8) 63 (35.8) 133 (37.8)
Systemic hypertension 103 (58.5) 99 (56.3) 202 (57.4)
LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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Descriptions of surgical indices are given in Table 8. As expected, the time spent in theatre was longer for
the maze procedure arm; the difference (maze procedure vs. control) in the mean length of time spent
in theatre was 13.8 minutes (95% CI –4.4 to 32.0 minutes; p = 0.1375). Similarly, there was a mean
difference in the time taken for cross-clamp of 5.1 minutes (95% CI –4.0 to 14.2 minutes; p = 0.2725) and
in the time taken for cardiopulmonary bypass of 18.9 minutes (95% CI 9.9 to 27.8 minutes; p < 0.0001).
Note that three patients’ surgical procedures were completed with a beating heart (with one patient
randomised to the maze procedure arm and two patients randomised to the control arm), so that the
time taken for both cross-clamp and cardiopulmonary bypass was zero minutes; on these occasions, the
maze procedure was not performed. One more maze procedure patient had zero minutes recorded for
cross-clamp, but 205 minutes recorded for the time taken for cardiopulmonary bypass.
TABLE 5 Atrial fibrillation-related clinical history at baseline
Marker of AF
Treatment arm, n (%)
Total (n= 352), n (%)Maze procedure (n= 176) Control (n= 176)
AF classification
Paroxysmal (intermittent) 44 (25.0) 48 (27.3) 92 (26.1)
Persistent (intermittent) 30 (17.0) 19 (10.8) 49 (13.9)
Chronic/longstanding (continuous) 102 (58.0) 109 (61.9) 211 (59.9)
AF-related medical history
0–3 months ago 4 (2.3) 2 (1.1) 6 (1.7)
3–6 months ago 25 (14.2) 25 (14.2) 50 (14.2)
6–12 months ago 31 (17.6) 23 (13.1) 54 (15.3)
> 12 months ago 115 (65.3) 126 (71.6) 241 (68.5)
Not known 1 (0.6) – 1 (0.3)
Permanent pacemaker 7 (4.0) 8 (4.5) 15 (4.3)
Time of pacemaker implant
0–3 months ago – 2 (1.1) 2 (0.6)
3–6 months ago 2 (1.1) – 2 (0.6)
6–12 months ago 2 (1.1) 2 (1.1) 4 (1.1)
> 12 months ago 3 (1.7) 4 (2.3) 7 (2.0)
Previous cardioversions
0–3 months ago 1 (0.6) 1 (0.6) 2 (0.6)
3–6 months ago 1 (0.6) – 1 (0.3)
6–12 months ago 5 (2.8) 3 (1.7) 8 (2.3)
> 12 months ago 17 (9.7) 19 (10.8) 36 (10.2)
Previous ablation 3 (1.7) 1 (0.6) 4 (1.1)
Arrhythmias other than AF/flutter 2 (1.1) 2 (1.1) 4 (1.1)
Any anticoagulant use at baseline 137 (77.8) 137 (77.3) 274 (77.6)
Any antiarrhythmic use at baseline 145 (82.4) 148 (84.1) 293 (83.2)
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The left atrial appendage was also significantly more likely to be excised in the maze procedure arm
(55.1%) than in the control arm (30.1%).
Table 9 provides details of the lesion sets completed. Eleven patients in the maze procedure arm did not
have the adjunct procedure at all. The most common ablation procedure was applied to the left and right
atria and the mitral annulus (43.8%), with 22.2% applied to the left atrium and mitral annulus and 18.2%
applied to the left atrium only. The mean number of lesions was 6.5 (SD 3.55) in the maze procedure arm,
with 47.7% of patients having 5–9 lesions and 23.3% of patients having ≥ 10 lesions. The most common
mode of delivery was bipolar radiofrequency ablation (81.8%), with unipolar radiofrequency ablation,
cryotherapy and ultrasound applied to smaller numbers of maze procedures; no procedures applied laser
or microwave energy.
TABLE 6 The mean scores for the EQ-5D-3L utility and SF-36 dimensions at baselinea
HRQoL measurement
Treatment arm, mean score (SD)
Total, mean score
(SD) (n= 352)
UK norm, mean
score (SD)Maze procedure (n= 176) Control (n= 176)
EQ-5D-3L utility score 0.74 (0.22) 0.75 (0.21) 0.75 (0.22) –
SF-36 dimensions
Bodily pain 72.00 (28.47) 72.26 (26.18) 72.13 (27.30) 81.49 (21.69)
General health 57.22 (19.11) 55.61 (20.76) 56.41 (19.94) 73.52 (19.90)
Physical function 47.18 (26.16) 48.40 (27.33) 47.79 (26.72) 88.40 (17.98)
Role emotional 71.10 (41.76) 65.90 (45.61) 68.49 (43.75) 82.93 (31.76)
Role physical 27.75 (37.20) 30.57 (40.84) 29.17 (39.04) 85.82 (29.93)
Social functioning 64.73 (29.19) 64.44 (31.81) 64.58 (30.49) 88.01 (19.58)
Vitality 43.67 (21.73) 44.71 (23.76) 44.19 (22.74) 61.13 (19.67)
Mental health 75.24 (15.44) 73.51 (18.21) 74.37 (16.88) 73.77 (17.24)
PCS 30.18 (13.17) 31.00 (13.56) 30.59 (13.36) 50 (10)
MCS 50.81 (9.92) 49.58 (10.69) 50.19 (10.32) 50 (10)
a Three maze procedure patients and two control patients had missing baseline QoL data.
TABLE 7 Cardiac procedure completed
Procedure
Treatment arm, n (%)
Total (n= 352), n (%)Maze procedure (n= 176) Control (n= 176)
Actual procedure category
MVR 39 (22.2) 48 (27.3) 87 (24.7)
CABG 35 (19.9) 34 (19.3) 69 (19.6)
AVR 32 (18.2) 23 (13.1) 55 (15.6)
CABG and AVR 16 (9.1) 21 (11.9) 37 (10.5)
CABG and MVR 14 (8.0) 13 (7.4) 27 (7.7)
All other procedures, including none 40 (22.7) 37 (21.0) 77 (21.9)
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TABLE 8 Summary of theatre times and excision of left atrial appendage
Procedure characteristic
Treatment arm
Total (n= 352)Maze procedure (n= 176) Control (n= 176)
Total length of time (minutes) taken for cross-clamp
Mean (SD) 82.2 (37.25) 77.2 (48.60) 79.7 (43.31)
Median (quartiles) 74.0 (57.5–102.0) 67.5 (51.0–92.0) 72.0 (53.0–99.0)
Range 0.0–245.0 0.0–530.0 0.0–530.0
Total length of time (minutes) taken for cardiopulmonary bypass
Mean (SD) 118.1 (43.39) 99.3 (41.81) 108.7 (43.59)
Median (quartiles) 110.5 (84.0–145.0) 93.0 (72.5–120.0) 100.5 (80.0–132.0)
Range 0.0–342.0 0.0–300.0 0.0–342.0
Total length of time (minutes) spent in theatre
Mean (SD) 261.2 (79.68) 247.5 (93.27) 254.4 (86.89)
Median (quartiles) 260.0 (210.0–300.0) 218.0 (195.0–277.5) 240.0 (198.0–291.5)
Range 75.0–582.0 100.0–775.0 75.0–775.0
Excised left atrial appendage, n (%)
Yes 97 (55.1) 53 (30.1) 150 (42.6)
No 79 (44.9) 123 (69.9) 202 (57.4)
TABLE 9 Details of number and location of lesion sets that were operated on
Lesion sets
Treatment arm
Total
(n= 352)
Maze procedure
(n= 176)
Control
(n= 176)
Number of lesions treated
Mean (SD) 6.5 (3.55) 0.1 (0.91) 3.3 (4.11)
Median (quartiles) 7.0 (4.0–9.0) 0.0 (0.0–0.0) 0.0 (0.0–7.0)
Range 0.0–14.0 0.0–11.0 0.0–14.0
Lesion number category, n (%)
0 11 (6.3) 174 (98.9) 225 (63.9)
1–4 40 (22.7) – 40 (22.7)
5–9 84 (47.7) 1 (0.6) 85 (24.1)
≥ 10 41 (23.3) 1 (0.6) 42 (11.9)
Lesion set treated, n (%)
I: minimal left atrial lesion set: pulmonary vein isolation either with or
without left atrial appendage line
32 (18.2) – 32 (9.1)
II: more extensive left atrial lesion set, excluding mitral annulus 4 (2.3) – 4 (1.1)
III: more extensive left atrial only lesion set, including mitral annulus 39 (22.2) 1 (0.6) 40 (11.4)
IV: minimal left atrial lesion set and right atrial lesion set 2 (1.1) – 2 (0.6)
V: more extensive left atrial lesion set excluding mitral annulus and
right atrial lesion set
11 (6.3) – 11 (3.1)
VI: more extensive left atrial lesion set including mitral annulus and
right atrial lesion set
77 (43.8) 1 (0.6) 78 (22.2)
No lesions 11 (6.3) 174 (98.9) 185 (52.6)
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At least one perioperative complication was recorded for 34 (19.3%) maze procedure patients and
38 (21.6%) control patients (see Appendix 3, Table 34). As expected, the most common complication
was bleeding (for 10.8% of maze procedure patients and 9.7% of control patients) and pleural effusion
(for 8% of maze procedure patients and 13.6% of control patients). There were no important differences
in the number of patients requiring transfusion of red blood cells, platelets, fresh-frozen plasma,
cryoprecipitate or human albumin (see Appendix 3, Table 35).
Intensive care unit and hospital stay did not vary by treatment arm. The median (quartiles) duration of
stay in an ICU was 1.1 days (0.9–2.9 days) in the maze procedure arm and 1.0 days (0.9–2.0 days) in the
control arm, whereas the median (quartiles) total length of hospital stay was 9 days (7–13 days) and 8 days
(6–12 days) for the maze procedure and control arms, respectively. Eleven maze procedure patients and
12 control patients returned to an ICU on one or more occasions, with those returning having a median
(quartiles) total length of stay of 4.6 days (1.3–6.5 days) and 2.5 days (1.5–10.4 days) in the maze
procedure and control arms, respectively.
Primary outcome results
Sinus rhythm at 12 months
Despite a history of AF, 30 patients (17.0%) in the maze arm and 32 patients (18.2%) in the control arm
did not have any arrhythmias recorded by the 4-day ECG at baseline. At 12 months, 286 (81.3%) patients
completed the 4-day ECG recording; of these patients, 266 (93.0%) were either in SR 100% of the time
or in AF 100% of the time. Patients were classified as being in AF if any AF was observed during the 4-day
ECG recording; this was decided before linking trial outcomes to either treatment arm. Among complete
cases in the maze procedure arm, 87 out of 141 patients (61.7%) were in SR compared with 68 out of
145 (46.9%) control patients. In the ITT analysis, using multiple imputation of missing data, the OR for
return to SR was 2.06 (95% CI 1.20 to 3.54; p = 0.0091); see Appendix 3, Table 36 for the full results.
Overall, results varied substantially by surgeon, with an associated intraclass correlation coefficient (ICC) of
0.089, suggesting that 8.9% of the total variation in return to SR rates over both treatment arms resulted
from surgeon effects. However, there were no differences in the treatment effect (maze procedure vs.
control) among surgeons (the ICC on the treatment coefficient was zero). Table 10 shows that the
difference between the treatment arms arises almost solely from an additional 19 patients in the maze
procedure arm changing from having AF to SR (61 vs. 42) and 21 fewer patients remaining in AF at
12 months (50 vs. 71).
Sensitivity analysis
An exploratory analysis of the ITT population highlighted four outlying patients in accordance with
cross-validation probabilities of having undue influence; a secondary analysis excluding these patients was
conducted, with little change in the results (OR 2.20, 95% CI 1.27 to 3.82). In the sensitivity analyses, the
OR changed to 2.00 (95% CI 1.21 to 3.32) if only complete cases were included, 1.70 (95% CI 1.07 to 2.69)
if patients who died or withdrew were assumed to have been in AF, 1.92 (95% CI 1.17 to 3.15) if patients
who died were assumed to have been in AF and 1.75 (95% CI 1.10 to 2.79) using the last observation
carried forward; all remained statistically significant. An additional analysis, including the variables that
were most associated with a missing status for 12-month SR (baseline SR, sex, diabetes, left ventricular
function, history of rheumatic fever, non-AF/atrial flutter arrhythmias and COPD), resulted in a treatment
effect estimate of 2.13 (95% CI 1.27 to 3.59). As the treatment effect was significant in all sensitivity
analyses, we were confident that it was robust. Finally, in order to assess the treatment effect in patients
for whom the surgery was completed as planned, the complier average causal effect for the difference
in 12-month SR rates between the groups (maze procedure vs. control) was calculated; this was 15.8%
(95% CI 3.9% to 27.6%) compared with 14.8% (95% CI 3.2% to 26.3%) for completers.
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Subgroup analysis
Figure 3 shows the results of the subgroup analysis (see also Appendix 3, Table 37); no interactions were
statistically significant. The odds on returning to SR were increased by the adjunct maze procedure for
both paroxysmal and non-paroxysmal AF groups. The maze patients had increased ORs on return to SR
irrespective of the planned procedure, although the small numbers of patients in each subgroup meant
that the ORs varied widely and were not significant in most cases.
Within the maze procedure arm, there was little evidence that return to SR was associated with the
number of lesions treated, although this may simply reflect the skill of the surgeon in identifying the areas
to be treated (Table 11). Moreover, there was no evidence of variation in return to SR between different
ablation techniques, although bipolar ablation was clearly the preferred technique for many surgeons.
In October 2013, the independent Data Monitoring and Ethics Committee (DMEC) concluded that the
results did not look promising and the TSC should consider stopping the trial on the basis of futility.
After full and serious consideration of the recommendations made by the DMEC, the TSC decided to
recommend continuation of recruitment and follow-up for the following reasons: there were no safety
concerns at that stage of the trial; > 80% of patients had already been recruited; review of accruing data
suggested that the results may be more promising; the trial results had the potential to have a high
impact, particularly if no treatment effect was found. However, the investigators decided that the final
arbiters should be the HTA programme board, which concluded that, as there were no safety concerns,
it would support the continuation of recruitment to the trial until the end of May 2014. This discussion
was relayed to the study teams at all sites via the steering group and circulation of the minutes, and they
remained supportive of the decision to continue.
As a result of these concerns, a post hoc exploratory analysis was undertaken to assess whether or not
there were changes in effects over time. The analysis found that the adjusted OR for return to SR at
12 months increased from 1.6 (95% CI 0.6 to 4.0) for the first 120 patients (considered by the DMEC) to
2.9 (95% CI 0.9 to 9.6) for the final 71 patients randomised in the final year of recruitment (2013).
TABLE 10 Summary of ECG rhythm changes between baseline and follow-up
Rhythm changes
Treatment arm, n (%)
Total (n= 352), n (%)Maze procedure (n= 176) Control (n= 176)
Change from baseline to 12 months in AF/SR
Either baseline or follow-up missing 39 (22.2) 33 (18.8) 72 (20.5)
SR at baseline, SR at 12 months 23 (13.1) 25 (14.2) 48 (13.6)
SR at baseline, AF at 12 months 3 (1.7) 5 (2.8) 8 (2.3)
AF at baseline, SR at 12 months 61 (34.7) 42 (23.9) 103 (29.3)
AF at baseline, AF at 12 months 50 (28.4) 71 (40.3) 121 (34.4)
Change from baseline to 24 months in AF/SR
Either baseline or follow-up missing 62 (35.2) 50 (28.4) 112 (31.8)
SR at baseline, SR at 24 months 18 (10.2) 23 (13.1) 41 (11.6)
SR at baseline, AF at 24 months 3 (1.7) 4 (2.3) 7 (2.0)
AF at baseline, SR at 24 months 47 (26.7) 23 (13.1) 70 (19.9)
AF at baseline, AF at 24 months 46 (26.1) 76 (43.2) 122 (34.7)
Note
SR is defined as an absence of any AF recorded during the 4-day monitoring period.
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Maze Control
AF categorisation
Paroxysmal AF
Non-paroxysmal AF
32/38
55/103
18/30
26/34
12/27
9/12
19/33
24/29
37/61
25/42
46/69
16/30
75/116
13/20
13/21
21/33
3/5
4/9
3/7
4/11
5/10
17/28
30/42
15/29
24/43
7/16
2/10
5/4
15/33
38/103
Surgical procedure
CABG
MVR
AVR
CABG + MVR
CABG + AVR
All other, including none
Lesion sets performed
Lesion sets I and II
Lesion sets IV and V
Lesion set III
Lesion set VI
No lesions
Lesion counts
0–4
5–9
10 or above
Energy source usage
Bipolar RF
Cryotherapy
Cautery
Cut and sew
Unipolar RF
Ultrasound
0.125 0.250 0.500 1 2 4 8 16
Control
OR (SR 12 months
maze vs. control) (95% CI)
2.29 (0.68 to 7.69)
2.04 (1.12 to 3.71)
1.63 (0.55 to 4.85)
3.37 (1.14 to 9.98)
1.51 (0.39 to 5.84)
7.16 (0.91 to 56.50)
1.81 (0.27 to 11.92)
1.44 (0.50 to 4.15)
Adjusted odds (95% CI) of SR at 12 months
Maze
FIGURE 3 Forest plot showing (adjusted) odds on return to SR at 12 months after randomisation (details of lesion sets are given in Table 9). RF, radiofrequency.
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Quality-adjusted life-years at 24 months
For this patient-centred primary outcome, QALYs could be estimated for 320 out of 352 patients (90.9%).
The unadjusted and undiscounted mean QALYs over 2 years were 1.489 (95% CI 1.416 to 1.558) for the
maze procedure arm and 1.485 (95% CI 1.403 to 1.559) for the control arm. In the primary complete-case,
ITT analysis, adjusting for baseline covariates, the mean difference between the two arms (maze procedure
vs. control) was –0.025 QALYs (95% CI –0.129 to 0.078 QALYs; p = 0.6319; see Appendix 3, Table 38).
This difference corresponds to approximately 9 fewer days of life in perfect health for a maze procedure
patient. A sensitivity analysis, which used different imputation methods for missing data and excluded any
patients with outlying results, showed that these results were robust to model assumptions. Results did not
vary substantially by surgeon; the average ICC across 40 multiple imputation samples was 0.001, indicating
that only 0.1% of the total variation in 24-month QALYs was attributable to surgeon differences.
Sensitivity analysis
In a range of sensitivity analyses reflecting different assumptions about the missing data mechanism, the
mean difference in QALYs changed only slightly, ranging from –0.029 (95% CI –0.135 to 0.078), for the
last observation carried forward, to –0.010 (95% CI –0.119 to 0.100), for the analysis that adjusted for
predictors of missingness (baseline EQ-5D-3L score, sex, diabetes and thoracic aorta surgery). Further
details are available on request.
Subgroup analysis
The differences in QALYs at 2 years between the maze procedure and control arms are plotted in Figure 4
for a range of subgroups (see also Appendix 3, Table 39). A number of subgroups had an estimated QALY
difference above our predefined minimum clinically important difference of 0.083, in favour of the maze
TABLE 11 Odds and 95% CI of return to SR at 12 months in patients randomised to the maze procedure arm by
subgroup (details of lesion sets are given in Table 9)
Subgroup Number in SR/number in subgroup Adjusted OR 95% CI
Lesion sets performed
Lesion sets I and II 19/33 2.236 0.838 to 5.962
Lesion set III 24/29 8.585 2.295 to 32.109
Lesion sets IV and V 4/11 1.198 0.282 to 5.095
Lesion set VI 37/61 2.803 1.214 to 6.472
Lesion counts
No lesions 3/7 1.412 0.279 to 7.142
0–4 lesions 25/42 2.337 0.903 to 6.050
5–9 lesions 46/69 3.009 1.320 to 6.861
≥ 10 lesions 16/30 2.312 0.813 to 6.577
Energy source usage
Bipolar RF ablation 75/116 2.991 1.372 to 6.521
Cryotherapy 13/20 2.561 0.731 to 8.971
Cautery 13/21 1.998 0.513 to 7.789
Cut and sew 21/33 3.029 1.065 to 8.609
Unipolar RF ablation 3/5 3.631 0.517 to 25.473
Ultrasound 4/9 1.242 0.210 to 7.352
RF, radiofrequency.
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0.0 0.5 1.0 1.5 2.0
2-year QALYs
Maze procedure arm
Control arm
– 0.08 (– 0.28 to 0.12)
– 0.00 (– 0.12 to 0.12)
0.01 (– 0.23 to 0.24)
– 0.10 (– 0.31 to 0.10)
0.18 (– 0.09 to 0.44)
0.18 (– 0.19 to 0.55)
– 0.24 (– 0.55 to 0.08)
– 0.08 (– 0.30 to 0.14)
1.51 (1.36 to 1.66)
1.38 (1.29 to 1.47)
1.40 (1.23 to 1.56)
1.53 (1.39 to 1.67)
1.27 (1.07 to 1.48)
1.35 (1.08 to 1.61)
1.30 (1.09 to 1.51)
1.53 (1.37 to 1.69)
1.43 (1.28 to 1.58)
1.37 (1.29 to 1.46)
1.40 (1.24 to 1.57)
1.43 (1.27 to 1.58)
1.45 (1.28 to 1.62)
1.52 (1.27 to 1.78)
1.07 (0.83 to 1.31)
1.45 (1.30 to 1.61)
AF categorisation
Paroxysmal AF
Non-paroxysmal AF
Lesion sets performed
Lesion sets I and II
Lesion set III
Lesion sets IV and V
Lesion set VI
No lesions
Lesion counts
0 – 4
5 – 9
≥ 10
Energy source usage
Bipolar RF ablation
Cryotherapy
Cautery
Cut and sew
Unipolar RF ablation
Ultrasound
 
1.52 (1.34 to 1.70)
1.44 (1.25 to 1.64)
1.45 (1.16 to 1.74)
1.31 (1.18 to 1.43)
1.31 (1.00 to 1.61)
 
1.49 (1.34 to 1.65)
1.38 (1.26 to 1.49)
1.29 (1.13 to 1.45)
 
1.40 (1.30 to 1.50)
1.42 (1.20 to 1.64)
1.20 (1.02 to 1.37)
1.35 (1.18 to 1.52)
1.43 (1.09 to 1.77)
1.42 (1.06 to 1.78)
Surgical procedure
CABG
MVR
AVR
CABG and MVR
CABG and AVR
All other, including none
QALY difference
(maze vs. control)ControlMaze procedure
QALY (95% CI) for each treatment arm
Subgroup
FIGURE 4 Forest plot showing the (adjusted) differences in QALYs at 2 years after randomisation for predefined subgroups (details of lesion sets are given in Table 9).
RF, radiofrequency.
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procedure arm (isolated AVR, CABG and MVR) or the control arm (isolated MVR, CABG and AVR), but no
differences were statistically significant and these values probably reflect the variation observed in small
subgroup analyses. Again, there were no apparent relationships between QALYs over 2 years and any of
the following: lesion sets, number of lesions treated or ablation method (Table 12).
Secondary outcomes
Sinus rhythm at 24 months after surgery
At 24 months after surgery, 247 (70.2%) patients completed a 4-day ECG recording. In the maze procedure
arm, 69 out of 118 (58.5%) completers were in SR compared with 47 out of 129 (36.4%) completers in the
control arm. Thus, although the proportion of patients in SR decreased in both arms, the decrease was
lower for the maze procedure arm. The baseline-adjusted OR for SR at 24 months was 3.24 (95% CI 1.76
to 5.96) in favour of the maze procedure arm (see Appendix 3, Table 40 for the full model results). Table 10
shows the number of people who had a change in SR between baseline and 24 months.
Survival and stroke-free survival
There were five (2.8%) postoperative deaths in the maze procedure arm and nine (5.1%) among the
control patients (Fisher’s exact test, p = 0.4144). This compares with the mean predicted in-hospital death
rate of 6.79% (logistic EuroSCORE,61 which is known to overestimate risk). Causes of death are listed in
Appendix 3, Table 41. Between discharge and the planned 24-month follow-up date, there were 19 deaths
in the maze procedure and nine in the control arm; note that three deaths in the maze procedure arm
occurred just after the 24-month anniversary of their surgery.
TABLE 12 Two-year quality-adjusted survival among patients randomised to the maze procedure arm by subgroup
(details of lesion sets are given in Table 9)
Level Mean SEM 95% CI
Lesion sets performed
Lesion sets I and II 1.522 0.092 1.342 to 1.702
Lesion set III 1.443 0.100 1.247 to 1.639
Lesion sets IV and V 1.451 0.149 1.158 to 1.743
Lesion set VI 1.308 0.063 1.184 to 1.431
Lesion counts
No lesions 1.308 0.155 1.005 to 1.611
0–4 1.494 0.078 1.341 to 1.646
5–9 1.377 0.060 1.260 to 1.494
≥ 10 1.290 0.082 1.130 to 1.450
Energy source usage
Bipolar RF 1.402 0.052 1.301 to 1.503
Cryotherapy 1.420 0.112 1.200 to 1.640
Cautery 1.196 0.091 1.018 to 1.373
Cut and sew 1.351 0.087 1.181 to 1.521
Unipolar RF 1.429 0.175 1.086 to 1.772
Ultrasound 1.422 0.184 1.062 to 1.782
RF, radiofrequency; SEM, standard error of the mean.
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Kaplan–Meier estimates of cumulative probability of death are plotted in Figure 5. This includes all 30
deaths in the maze procedure arm and all 25 deaths in the control arm at the end of the trial; the HR was
1.23 (95% CI 0.73 to 2.10; p = 0.437). Thus, the adjunct maze procedure did not significantly increase
early or late death rates in this trial.
Figure 6 plots the cumulative incidence of death or stroke. During follow-up, 13 strokes were recorded in
10 (5.7%) maze procedure patients and 19 were recorded in 16 (9.1%) control patients; the difference
of –3.4% (95% CI –14.1% to 7.3%) was not statistically significant (Fisher’s exact test, p = 0.3083).
Moreover, there was no significant difference in stroke-free survival between the two trial arms (HR 0.99,
95% CI 0.64 to 1.53; p = 0.949).
Anticoagulant and antiarrhythmic drug use
Table 13 shows that the number of patients requiring anticoagulant drug use was significantly lower in
the maze procedure arm from 6 months after the procedure. Conversely, there were slightly more maze
patients requiring antiarrhythmic drugs throughout follow-up, but the difference was not statistically
significant at traditional levels.
Further cardioversions
There was no difference between the two treatment arms in the need for further cardioversion or permanent
pacemaker implants. Sixty maze procedure patients (34.1%) required 65 cardioversions and 67 control
patients (38.1%) required 72 cardioversions. The cardioversion success rates for these interventions were
the same [48/65 (73.8%) for the maze arm and 54/72 (75.0%) for the control arm]. Fifteen maze procedure
patients (8.6%) and 17 control patients (9.7%) required pacemaker implantation.
Additional results from the electrocardiogram recordings
At baseline, 27 maze procedure patients (15.3%) and 16 control patients (9.1%) had AF or tachycardia on
at least 1 day of the ECG recordings. Corresponding numbers at 12 months were 29 (16.5%) and 26
(14.8%) for the maze procedure patients and control patients, respectively, which fell to 19 (10.8%) and
18 (10.2%), respectively, at 24 months. Junctional rhythm was observed for only one (maze procedure)
patient at baseline, eight maze procedure patients at 12 months and six maze procedure patients and two
control patients at 24 months.
Hospital admissions for haemorrhage
There were three admissions in three patients who had the maze procedure, and two admissions in
two patients who did not have the maze procedure up to 2 years after randomisation.
New York Heart Association results
Figure 7 and Appendix 3, Table 42 summarise the NYHA results for each treatment arm over the 2-year
follow-up period. Among those who had complete data, there was some evidence that more patients in
the maze procedure arm had symptoms of heart failure at 6 months after surgery (52.9% vs 42.7%).
The difference was 10.2% (95% CI –1.4% to 21.5%; p = 0.0995), but the distribution of NYHA classes
in each treatment arm was very similar thereafter.
Short Form questionnaire-36 items
Results for the eight dimensions of the SF-36 are shown in Figure 8 and Appendix 3, Table 43. For all
dimensions, the two treatment arms of the trial had very similar (baseline-adjusted) SF-36 results at
all follow-up points. With the exception of the pain scale, which increased (improved) only slightly, all
dimensions increased substantially for both treatment arms and to a similar extent.
For most ‘physical’ dimensions, the mean SF-36 score increased between baseline and 6 months, but did
not increase substantially thereafter. However, the ‘role limitations due to physical problems’ scale
continued to improve steadily over the 2-year follow-up period, as patients recovered from the procedure
and gained confidence in their ability to carry out usual activities.
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FIGURE 5 Kaplan–Meier estimates of the cumulative incidence of death throughout the trial.
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FIGURE 6 Kaplan–Meier estimates of the cumulative incidence of death or stroke.
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TABLE 13 Anticoagulant and antiarrhythmic drug use
Time point for each
type of drug
Treatment arm (n/N)
Adjusted OR maze
procedure/control 95% CI p-valueMaze procedure Control
Anticoagulants
Discharge 136/167 141/165 0.619 0.268 to 1.431 0.2616
6 weeks 130/160 138/161 0.483 0.206 to 1.131 0.0936
6 months 113/156 129/160 0.309 0.140 to 0.683 0.0037
12 months 94/149 106/149 0.381 0.178 to 0.818 0.0133
24 months 82/134 96/138 0.389 0.179 to 0.845 0.0171
Antiarrhythmias
Discharge 138/167 134/165 1.323 0.623 to 2.806 0.4660
6 weeks 137/160 134/161 1.547 0.704 to 3.399 0.2775
6 months 131/156 127/160 1.603 0.751 to 3.423 0.2225
12 months 117/149 109/149 1.541 0.744 to 3.192 0.2446
24 months 102/134 97/138 1.613 0.778 to 3.344 0.1983
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FIGURE 8 Random coefficient model: mean and 95% CIs for SF-36 scores over time. Random patient effect excluded, baseline score adjusted. (a) SF-36 bodily pain score over
time; (b) SF-36 general health score over time; (c) SF-36 mental health score over time; (d) SF-36 physical function score over time; (e) SF-36 role emotional score over time;
(f) SF-36 role physical score over time; (g) SF-36 social functioning score over time; and (h) SF-36 vitality score over time. (continued )
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FIGURE 8 Random coefficient model: mean and 95% CIs for SF-36 scores over time. Random patient effect excluded, baseline score adjusted. (a) SF-36 bodily pain score over
time; (b) SF-36 general health score over time; (c) SF-36 mental health score over time; (d) SF-36 physical function score over time; (e) SF-36 role emotional score over time;
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FIGURE 8 Random coefficient model: mean and 95% CIs for SF-36 scores over time. Random patient effect excluded, baseline score adjusted. (a) SF-36 bodily pain score over
time; (b) SF-36 general health score over time; (c) SF-36 mental health score over time; (d) SF-36 physical function score over time; (e) SF-36 role emotional score over time;
(f) SF-36 role physical score over time; (g) SF-36 social functioning score over time; and (h) SF-36 vitality score over time. (continued )
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FIGURE 8 Random coefficient model: mean and 95% CIs for SF-36 scores over time. Random patient effect excluded, baseline score adjusted. (a) SF-36 bodily pain score over
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FIGURE 8 Random coefficient model: mean and 95% CIs for SF-36 scores over time. Random patient effect excluded, baseline score adjusted. (a) SF-36 bodily pain score over
time; (b) SF-36 general health score over time; (c) SF-36 mental health score over time; (d) SF-36 physical function score over time; (e) SF-36 role emotional score over time;
(f) SF-36 role physical score over time; (g) SF-36 social functioning score over time; and (h) SF-36 vitality score over time. (continued )
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FIGURE 8 Random coefficient model: mean and 95% CIs for SF-36 scores over time. Random patient effect excluded, baseline score adjusted. (a) SF-36 bodily pain score over
time; (b) SF-36 general health score over time; (c) SF-36 mental health score over time; (d) SF-36 physical function score over time; (e) SF-36 role emotional score over time;
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FIGURE 8 Random coefficient model: mean and 95% CIs for SF-36 scores over time. Random patient effect excluded, baseline score adjusted. (a) SF-36 bodily pain score over
time; (b) SF-36 general health score over time; (c) SF-36 mental health score over time; (d) SF-36 physical function score over time; (e) SF-36 role emotional score over time;
(f) SF-36 role physical score over time; (g) SF-36 social functioning score over time; and (h) SF-36 vitality score over time.
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The physical dimension scales all remained somewhat lower than for the general population, which may
be expected given that the patients all had heart problems. The baseline-adjusted PCS was around 38 or
39 points on average at all postoperative time points for both treatment arms, which was significantly
below the population average of 50 points, but was greater than baseline (Figure 9; see also Appendix 3,
Table 44; p < 0.0001 for all follow-up points and both treatment arms). The improvement from baseline
for the PCS was lower than that for the individual physical scales, as a result of it being a weighted
average over all eight individual dimensions, some of which changed only slightly.
For the three scales that measured social, emotional and mental health aspects of life, a similar pattern
emerged, with the arms improving between baseline and 6 months to a similar extent, but changing only
slightly beyond this point. The mean MCS was very close to the general population average at baseline,
and this increased by 4 points on average at 6 months post randomisation, remaining at that level for
2 years for both arms of the trial. There were no significant differences between the two treatment arms
at any time point.
Finally, patients reported that their general health status, measured using the SF-36 general health scale,
improved in both treatment arms to a similar extent, with no significant differences between the treatment
arms at any follow-up time point.
EuroQol-5 Dimensions, three-level version
The results of the EQ-5D-3L utility score for those patients who completed the EQ-5D-3L are summarised
in Appendix 3, Table 45 and Figure 10. As is common for surgical trials, there was a dip in estimated utility
early after surgery, which was largely related to postoperative limitations in usual activities and self-care,
and symptoms of pain/discomfort (data not shown). However, by 6 weeks after randomisation, the mean
utility had increased in both treatment arms and was slightly higher than at baseline. By 6 months post
randomisation, both treatment arms had a mean utility that was higher than the general population aged
65–74 years. There were no significant differences in baseline-adjusted EQ-5D-3L utility score at any
follow-up time point. A similar pattern was observed for the visual analogue scale (data not presented).
Safety
The safety results were based on 167 completed maze procedures (165 patients randomised to the maze
procedure arm and two patients randomised to the control arm) and 185 non-maze cardiac procedures
(11 patients randomised to the maze procedure arm and 174 patients randomised to the control arm).
AEs are expected in surgical trials as a result of the high-risk nature of procedures. In the Amaze trial, a
total of 560 events (136 patients) were reported after maze procedures and 589 events (157 patients)
were reported after control procedures; an overview is provided in Table 14, with details in Appendix 3,
Table 46. The number of these events classed as SAEs were 330 (100 patients) and 333 (111 patients) in
the maze procedure and control arms, respectively. The proportion of patients having a SAE in the two
treatment arms was very similar (maze procedure 100/167; control 111/185; p = 1.000). Most events were
mild in severity, but 71 maze procedure patients (42.5%) and 84 control patients (45.5%) had at least one
event of moderate severity, and 31 maze procedure patients (18.6%) and 38 control patients (20.5%) had
a severe event. Twenty-three events in 17 patients (10.2%) were possibly related to treatment in the maze
procedure arm, compared with 28 events in 19 patients (10.3%) being possibly related to treatment in
the control arm; one control patient (0.5%) was admitted to hospital for investigation of an atrial flutter,
which was classified as definitely related to treatment. Overall, the safety profiles of these two treatment
arms were similar.
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FIGURE 9 Random coefficients model: mean and 95% CIs for the SF-36 PCS and MCS. Random patient intercept, baseline score adjusted. (a) SF-36 PCS over time; and (b) SF-36
MCS over time. (continued )
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FIGURE 9 Random coefficients model: mean and 95% CIs for the SF-36 PCS and MCS. Random patient intercept, baseline score adjusted. (a) SF-36 PCS over time; and (b) SF-36
MCS over time.
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TABLE 14 Overview of the numbers of patients who reported AEs up to 2 years post randomisation
AE category
Treatment arm, n (%)
Total (n= 352), n (%)Maze procedure (n= 167) Control (n= 185)
Any AEs/SAEs/SUSARs reported 136 (81.4) 157 (84.9) 293 (83.2)
Any AEs reported 103 (61.7) 116 (62.7) 219 (62.2)
Any SAEs reported 100 (59.9) 111 (60.0) 211 (59.9)
Any SUSARs reported 0 (0.0) 0 (0.0) 0 (0.0)
Related events reported
Definitely related – 1 (0.5) 1 (0.3)
Possibly related 17 (10.2) 19 (10.3) 36 (10.2)
Unrelated 133 (79.6) 151 (81.6) 284 (80.7)
Severity
Mild 109 (65.3) 120 (64.9) 229 (65.1)
Moderate 71 (42.5) 84 (45.4) 155 (44.0)
Severe 31 (18.6) 38 (20.5) 69 (19.6)
SUSAR, suspected unexpected serious adverse reaction.
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Chapter 4 The ‘Has Electrical Sinus Translated into
Effective Remodelling?’ substudy
Background
An important issue related to the maze procedure is that restoration of SR may not result in the return of
atrial contractile function. Clinical consensus is that the increased risk of thromboembolic complications in
AF is related to blood stagnation in parts of the left atrium, caused by the loss of contractile function.
In addition, loss of atrial contraction also contributes to exacerbation of congestive heart failure and
atrioventricular asynchrony.65
Published literature on atrial transport following the maze procedure is limited by small sample sizes and
selection bias. In addition, most studies had no matched control patients for comparison. To date, there is
little rigorous evidence that attempting to restore SR by treating AF with an ablation device during cardiac
surgery restores atrial transport.
Objectives
The HESTER substudy aimed to assess whether or not patients in SR at least 1 year after an adjunct maze
procedure had an equivalent active left atrial ejection fraction (ALAEF) to that of control patients who had
undergone cardiac surgery and were in SR both prior to and at least 1 year after surgery.
Methods
Patients and matching
The HESTER substudy was a (1 : 1) matched cohort study: the maze procedure cohort were (trial or
non-trial) patients with AF who underwent the maze procedure as an adjunct to routine cardiac surgery
and who were in SR at least 1 year postoperatively; the control cohort were patients who were in SR both
before and at least 1 year after routine cardiac surgery.
Eligibility criteria were patients aged > 18 years, who were able to give informed consent and attend
investigations, and who had a presence of ECG-confirmed SR at least 1 year after cardiac surgery. Exclusion
criteria were contraindications to cardiac MRI: cardiac pacemakers, surgical clips in the head, electronic
inner-ear implants, ocular metal fragments, electronic stimulators, implanted pumps and severe claustrophobia.
Consecutive eligible participants in the Amaze trial, recruited at Papworth Hospital and Glenfield Hospital,
as well as consecutive non-trial AF patients who received the maze procedure as part of their routine
elective surgery and were in SR at their last hospital visit, were invited to participate in the HESTER
substudy. After consenting, each participant had confirmatory ECG.
A list of potential control patients was compiled from Papworth Hospital databases by an independent
member of the hospital audit team. Once a maze procedure patient had consented, a list of potential
matched control patients was compiled, matched for time since procedure (± 6 months), age (± 5 years),
sex, type of surgery, preoperative LVEF and predicted operative mortality (logistic EuroSCORE).61 Matching
was undertaken by researchers independent of data collection and analysis. Hospital records for potential
control patients were reviewed to confirm SR before surgery and the matching criteria before inviting
patients to take part.
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Data collection
Eligible patients underwent ECG to confirm SR, transthoracic two- and three-dimensional echocardiography
and MRI to evaluate left atrial function.
All echocardiography studies were performed using a Philips IE33 ultrasound machine (Philips UK Ltd,
Guildford, UK) and the British Society of Echocardiography standard minimum data set. Analysis was by
Philips QLab software, version 9.0 (Philips UK Ltd, Guildford, UK), and Xcelera, version 3.2.1.712-2011
(Philips UK Ltd, Guildford, UK), reporting system.
Magnetic resonance imaging studies used a 1.5-T MRI scanner (Siemens Avanto, Erlangen, Germany) and
were evaluated using Argus cardiac software, version B17 (Siemens Healthcare, Erlangen, Germany).
Images were acquired in standard planes, positioned either parallel to (horizontal and vertical long-axis
planes) or perpendicular to the long axis of the heart (short-axis planes), using ECG-triggering steady-state
gradient echo sequences (balanced fast-field echo). Left atrial volumes were measured with Argus
software.
Each investigation was performed and interpreted by a single operator blinded to the patient identity.
Outcomes
The primary outcome was ALAEF, the measurement most directly related to active left atrial contractility.
Maximum left atrial volume (LAVmax), minimum left atrial volume (LAVmin) and pre A-wave left atrial volume
(LAVpreA) were measured by echocardiography. ALAEF was derived as a percentage:
ALAEF = 100 ×
LAVpreA− LAVmin
LAVpreA
. (1)
Each volume was measured using both the two- and four-chamber views. The four-chamber assessment of
ALAEF was our primary end point, with the two-chamber version being a key secondary end point.
Volume measurements and E/A ratio (an ECG marker of left ventricular function) were secondary end
points. Derived secondary end points were active stroke volume (LAVpreA – LAVmin), passive stroke volume
(LAVmax – LAVpreA) and left atrial ejection fraction (LAEF):
LAEF = 100 ×
LAVmax − LAVmin
LAVmax
. (2)
Maximum left atrial volume and LAVmin were also measured using the MRI multiple-slice method and were,
along with the LAEF derived from them, secondary end points.
Sample size
In AF, ALAEF is virtually zero, so that any measurable ALAEF after SR restoration is a marker of at least
partial treatment success. In a previous study of subjects in SR, with a LAVmax of 50–70 ml, but without
atrioventricular or intraventricular conduction abnormalities on a resting 12-lead ECG, the mean ALAEF
(measured in four-chamber view echocardiography) was 43% with a SD of 18.2%.66 Based on this, and
the expert judgement of the investigators, the minimum clinically important difference in ALAEF was set
at 1 SD, or 18.2%. Equivalence would therefore be concluded on estimating a treatment effect (maze
procedure vs. control) with a two-sided 95% CI contained entirely in the interval from –18.2% to 18.2%.
Based on this, 22 patients in each treatment arm would provide 80% power to demonstrate equivalence.
Statistical analyses
For the primary end point, a mixed-effects linear regression model was fitted, including fixed effects for
treatment and matching variables, and random effects for the matched pairs. A variance components
model was assumed for the covariance structure, with residuals at both levels assumed to be independent
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and normally distributed. The estimated treatment coefficient from the model was taken as the mean
difference in ALAEF between maze procedure patients and control patients. Model assumptions were
checked using residual plots.
The same model was fitted to each secondary end point. If the estimated random-effects variance was
zero for any end point, the pairing was included as a fixed effect. No equivalence margins were specified
for the secondary end points.
Analysis was undertaken in SAS version 9.4, using the PROC MIXED procedure to fit mixed-effects models
by the method of restricted maximum likelihood. There were no missing values for the primary end point.
For secondary end points with missing values, complete-case analyses were used. The guidelines from
the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement were
followed.67
Results
Between 24 July 2013 and 8 July 2015, 22 eligible patients were recruited for each cohort and underwent
echocardiography and MRI (Figure 11). All 22 control patients and 15 maze procedure patients were
from Papworth Hospital, and seven maze procedure patients were from Glenfield Hospital. No patients
experienced AEs during these tests.
Summaries of the variables used in matching are presented in Table 15. Matching by sex was exact.
Two pairs differed in left ventricular function (maze procedure arm: LVEF of > 50%, control arm: LVEF of
30–50%; and maze procedure arm: LVEF 30–50%, control arm: LVEF of > 50%). Only two pairs differed
in operation performed: one maze procedure patient who underwent mitral and tricuspid valve surgery
was matched with a control patient who underwent mitral surgery alone; another who underwent CABG
and atrial septal defect repair was matched with a control patient who underwent isolated CABG. For all
but three of the pairs, the length of time since surgery was longer for the maze procedure patient than the
control patient. Nine pairs differed by > 6 months in the length of time since surgery. Maze procedure
patients were, on average, older and 16 were older than their matched control patients, including two age
differences > 5 years. Maze procedure patients tended to have a slightly higher logistic EuroSCORE.61
Summaries of the four-chamber ALAEF assessment are in Table 16. The SD in both cohorts was 8%, but
maze procedure patients had a lower mean ALAEF (18%) than control patients (26%). Figure 12 shows
that the ALAEF of the control patients was higher in all but three pairs. The maximum ALAEF was similar
between treatment arms (41% for control patients and 39% for maze procedure patients), but the
minimum for maze procedure patients (6%) was less than half that of the control patients (13%).
After adjusting for the matched design, the mean difference in ALAEF (four-chamber view) between
maze procedure and control patients was –8.03 (95% CI –12.43 to –3.62; see Figure 13 and Appendix 3,
Table 47). The 95% CI was contained entirely in the interval (–18.2 to 18.2), so our predefined criterion
for equivalence was met. However, the mean ALAEF was significantly lower in maze procedure patients
than in control patients (p = 0.0015).
For the two-chamber measurements, the mean maze–control difference was –3.48 (95% CI –8.45 to 1.49),
supporting the conclusions of the primary outcome analysis.
Excluding one patient in the maze procedure cohort with a high logistic EuroSCORE61 of 16.9% did not
affect the conclusion of equivalence (mean difference –7.90, 95% CI –12.55 to –3.25).
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Secondary outcomes are summarised in Appendix 3, Tables 47–49. Although the summaries for the
four- and two-chamber echocardiography measurements were very similar, they were not consistent with
the MRI summaries.
In regression analysis, the mean E/A ratio was significantly higher and the mean LAEF (four-chamber view
and MRI) was significantly lower for maze procedure patients than those for control patients (Figure 14).
There were no significant differences in the other end points.
Potential study group patients 
(n = 260)
HESTER study group 
(n = 22)
HESTER control group 
(n = 22)
Assessed sequentially until
22 eligible patients were
found, consented and had
SR confirmed by ECG
Assessed sequentially until an
eligible matched control for
each study group patient was
found, consented and had SR
confirmed by ECG
Potential matches 
(n = 430)
     Excluded 
     (n = 200)
• Paroxysmal AF, n = 44
• Still in AF, n = 50
• Junctional rhythm, n = 3
• Maze procedure only, n = 4
• Did not have radiofrequency
   ablation, n = 2
• Ablation 2 years post surgery,
   n = 2
• Permanent pacemaker, n = 35
• Died, n = 48
• Incorrect surgery, n = 6
• Withdrew from Amaze, n = 6
             Did not consent 
      (n = 16)
• Lived too far away, n = 5
• Poor health, n = 11
             Failed screening 
                     (n = 5)
• AF, n = 3
• Atrial flutter, n = 2
           Identified but excluded 
        (n = 163)
• Surgery not matched, n = 29
• Too young, n = 48
• Too old, n = 21
• EuroSCORE too high, n = 25
• Left ventricular function not 
   matched, n = 2
• Sex not matched, n = 2
• In AF, n = 14
• Paroxysmal AF, n = 5
• Permanent pacemaker, n = 5
• Recent cardiac surgery, n = 2
• Died, n = 7
• Taking part in the Amaze
    study, n = 1
• Atrial tachycardia, n = 1
• Unable to contact, n = 1
         Did not consent 
       (n = 8)
• Lived too far away, n = 5
• Poor health, n = 3
           Matched but MRI failed 
         (n = 3)
• Unable to tolerate MRI, n = 2
• MRI data not captured, n = 1
1 : 1
matching
Cardiac surgery with maze procedure Cardiac surgery without maze 
procedure, and believed to be in SR 
before surgery
FIGURE 11 Recruitment and matching for the HESTER substudy.
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TABLE 15 Summary statistics for the variables used in matching maze procedure and control patients in the
HESTER substudy
Variable
Treatment arm
Maze procedure (n= 22) Control (n= 22)
Age at surgery (years), mean (SD) 69 (9) 66 (12)
Years since surgery, mean (SD) 2.7 (1.0) 2.9 (1.1)
Logistic EuroSCORE (%), mean (SD) 4.3 (3.7) 3.7 (2.5)
Left ventricular function, n (%)
Poor (LVEF of < 30%) 1 (5) 1 (5)
Moderate (LVEF of 30–50%) 5 (23) 5 (23)
Good (LVEF of > 50%) 16 (73) 16 (73)
Sex, n (%)
Male 20 (91) 20 (91)
Female 2 (9) 2 (9)
Surgery, n (%)
CABG 5 (23) 6 (27)
MVR 8 (36) 9 (41)
AVR 2 (9) 2 (9)
Combined procedures 6 (29) 4 (24)
ASD repair 1 (5) 1 (5)
ASD, atrial septal defect.
TABLE 16 Mean (SD) of all primary and secondary end points, measured using echocardiography (four-chamber
view), in the HESTER substudy
End point
Treatment arm
Maze procedure (n= 22) Control (n= 22)
ALAEF (%) 18 (8) 26 (8)
LAEF (%) 31 (9) 38 (7)
LAVmin (ml) 59 (20) 45 (14)
LAVpreA (ml) 72 (22) 60 (18)
LAVmax (ml) 86 (25) 72 (19)
Passive stroke volume (ml) 13 (7) 11 (4)
Active stroke volume (ml) 13 (7) 16 (7)
E/A ratio 1.8 (0.8) 0.9 (0.4)
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FIGURE 12 Four-chamber ALAEF measurements for individual patients undergoing the maze procedure and their
matched control patients for the HESTER substudy.
100–10–20 20
ALAEF (%)
– 3.48 (95% CI – 8.45 to 1.49)
– 8.03 (95% CI – 12.43 to – 3.62)
Two-chamber view
Four-chamber view
FIGURE 13 Forest plot showing estimated treatment effects (maze procedure vs. control) and 95% CIs for the
four- and two-chamber measurements of ALAEF in the HESTER substudy. Equivalence limits (at ± 18.2%) are shown
as dashed vertical lines.
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35.96 (95% CI – 1.37 to 73.30)
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– 3.44 (95% CI – 7.79 to 0.90)
0.86 (95% CI – 2.26 to 3.98)
11.30 (95% CI – 7.71 to 30.30)
10.02 (95% CI – 9.40 to 29.44)
14.53 (95% CI – 1.75 to 30.81)
E/A ratio
LAEF (%)
Active stroke volume (ml)
Passive stroke volume (ml)
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LAVmax (ml)a
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Four-chamber view
LAEF (%)
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LAVpreA (ml)a
LAVmax (ml)a
LAVmin (ml)a
Two-chamber view
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LAVmin (ml)a
MRI
Echocardiography
FIGURE 14 Forest plots showing estimated treatment effects (maze procedure vs. control) and 95% CIs for
secondary end points in the HESTER substudy. a, For these variables, the models were fitted with patient pairing as
a fixed effect.
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Chapter 5 Trial results: cost-effectiveness
Data completeness
There were very few item non-responses for resource use during the primary admission (one control patient
and two patients from the maze procedure arm had missing length of stay data). Half the patients who were
referred to a rehabilitation centre (nine maze procedure patients and six control patients) or an acute hospital
(three maze procedure patients) had missing final discharge dates and, therefore, values were imputed.
Excluding patients who died, the proportion of missing resource-use items at each follow-up point ranged
from 6.5% to 13.4% and the proportion lost to follow-up grew from 4% at 6 weeks to 6.5% at 12 months
(Table 17). The proportion of incomplete EQ-5D-3L and SF-36 scores ranged from 0.9% to 10.5% across
time. Patients with poorer initial health status, measured using the EQ-5D-3L, were significantly more likely
to have missing responses.
Resource costs
Table 18 shows the length of stay for each stage of the primary admission, by intervention arm and control
arm. Patients in the maze procedure arm had a longer stay in the ICU and the cardiac ward, and spent a
longer time in an acute hospital, following referral, than those in the control arm. The distribution of
resource use in the maze procedure arm included two outliers: one patient stayed in an ICU post operation
TABLE 17 Availability of resource-use follow-up data
Time point Follow-up resource use
Treatment arm (n)
TotalMaze procedure Control
6 weeks Observations 157 156 313
Dead 6 10 16
Lost to follow-up 8 6 14
Missing 5 4 9
6 months Observations 152 154 306
Deada 14 14 28
Lost to follow-upa 13 9 22
Missing 5 5 10
12 months Observations 147 146 293
Deada 16 16 32
Lost to follow-upa 25 20 45
Missing 1 3 4
24 months Observations 130 134 264
Deada 23 18 41
Missing 23 24 47
a The numbers presented here differ from the CONSORT flow diagram (see Figure 2). These missing numbers are based
on completion of the resource-use CRF during follow-up and cumulative death at each time period.
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for 52.9 days and, following discharge directly to their home, died a few days later; and one patient was in
the cardiac ward for 144 days.
The average total cost of resources in the maze procedure arm was £3839 more than that of the control
arm, and this difference was statistically significant (p = 0.0013). Table 19 shows that the primary
admission had the highest cost (£14,880 in the maze procedure arm; £11,406 in the control arm) and
resulted in a large proportion of the difference in cost between the trial arms (£3442; p = 0.0016). The
primary admission contributed most to the variability in cost, as both arms had many high-cost outliers
(Figure 15). The difference in cost between the trial arms during the primary admission stemmed largely
from additional length of stay in each hospital location (surgery, ICU and cardiac ward, with the exception
of rehabilitation centres), additional costs of surgical equipment to carry out the maze procedure and the
influence of two outliers (see Appendix 2, Tables 25 and 26, for a detailed breakdown of resource use and
total costs). Table 19 shows that, after discounting, the average cost difference was £3841 (95% CI £1514
to £6167) higher per patient for the maze procedure arm than for the control arm (p = 0.0013).
The mean follow-up costs for the maze procedure arm were £460 more than those for the control arm,
mainly because of a difference in readmissions; both treatment arms had large variations around the mean
value (see Table 19). The mean cost of drugs was £63 less for the maze procedure arm than that for the
control arm [the most expensive drugs used in the trial were the calcium channel blockers amlodipine and
diltiazem hydrochloride (Dilzem® SR, Cephalon UK Limited, Castleford, UK), followed by acenocoumarol
(Sinthrome®, Merus Labs Luxco S.a.R.L., Luxembourg City, Luxembourg)]. For more details of costs per
patient, see Appendix 2, Table 23.
Comparison of Tables 24 and 25 (Appendix 2) shows that, as a result of data completeness, there was very
little impact of imputation during primary admission; resource use for both the intervention and control
arms increased very slightly. Further details of the total costs for the two treatment arms are given in
Appendix 2, Table 26.
TABLE 18 Length of stay in theatre, ICU and wards for primary admission
Resource use Treatment arm Number of observations Mean Min. Max.
Theatre time (minutes) Maze procedure 176 261.2 75.0 582.0
Control 176 247.4 100.0 775.0
Cardiac ward (days) Maze procedure 174 8.7 0.0 153.0
Control 176 7.9 0.0 33.0
ICU (days) Maze procedure 175 3.2 0.0 52.9
Control 176 2.4 0.2 36.2
Rehabilitation centre referral (days) Maze procedure 167a 0.3 0.0 19.0
Control 170b 1.0 0.0 84.0
Acute hospital referral (days) Maze procedure 173c 2.4 0.0 144.0
Control 176d 0.4 0.0 45.0
max., maximum; min., minimum.
a Four maze procedure patients were referred.
b Eight control patients were referred.
c Eight maze procedure patients were referred.
d Four control patients were referred.
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Quality of life
Table 20 shows that, in both years, the average QALYs in the maze procedure arm were slightly lower
than in the control arm for both the EQ-5D-3L and the SF-6D, although these differences were not
statistically significant. The difference in mean EQ-5D-3L QALYs per patient over 2 years was –0.044
(95% CI –0.16 to 0.07 QALYs; p = 0.44), which is also less than our a priori estimate of a minimum
clinically important difference. Comparison of Tables 27 and 28 (Appendix 2) shows that imputation had
no impact on these results.
TABLE 19 Mean (SD) of per-patient costs of resource use, with imputation
Health service use
Treatment arm, mean cost (£) per patient (SD)
Difference in cost (£)
(maze procedure vs. control)Maze (n= 176) Control (n= 176)
Primary admission
Theatre use 5225 (1594) 4949 (1863) 276
Ablation device 1212 (408) 14 (133) 1197
Adult critical care 4029 (7600) 3065 (5586) 964
Cardiac ward 3397 (4661) 3064 (2014) 333
Rehabilitation 48 (325) 148 (1082) –100
Acute trust 937 (6105) 165 (1409) 772
Subtotal 14,847 (12,474) 11,404 (7194) 3443
Medication (whole trial period) 618 (1584) 681 (2765) –63
Follow-up
Readmissions 1650 (4192) 1220 (2994) 430
Tests 388 (376) 344 (283) 44
Health-care visits 1179 (1061) 1193 (1052) –14
Subtotal 3217 (5629) 2757 (4329) 460
Grand total 18,681 (13,340) 14,842 (8295) 3841
Maze procedure Control
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FIGURE 15 Comparison of the total primary admission cost with the total trial cost (with imputation).
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Comparing costs and effects
Table 21 shows that the mean cost per patient (with imputation, but without adjustments) was statistically
significantly higher for the maze procedure arm, and that mean incremental QALYs per patient were
slightly lower (although not statistically significantly different) than those in the control arm. Therefore, the
maze procedure arm was dominated by the control arm and, when valuing a QALY at £20,000, the INMB
of the maze procedure arm was negative.
Cost-effectiveness
Table 22 shows the primary cost-effectiveness analysis from a seemingly unrelated regression analysis of
costs and QALYs, adjusted for baseline differences and correlation between costs and QALYs, with
discounting for year 2. The mean difference in the cost of the maze procedure, adjusting for age, sex,
baseline EQ-5D-3L score and paroxysmal AF, was £3533 (95% CI £1321 to £5746) higher than for the
control intervention, and the difference was statistically significant. The mean difference in QALYs between
the maze procedure arm and the control arm, after also controlling for actual procedure used, was –0.022
(95% CI –0.1231 to 0.0791 QALYs), which was not statistically significant. The maze procedure arm was
therefore dominated by the control arm.
TABLE 21 Unadjusted comparison of costs and QALYs per patient, with imputation
Cost-effectiveness parameter
Treatment arm, mean (SD)
Maze procedure (n= 176) Control (n= 176)
Total cost (£) in year 1 17,834 13,225 13,944 7954
Total cost (£) in year 2 (with discounting) 818 2185 868 1414
Total cost (£) over 2 years (present value) 18,653 – 14,812 –
Incremental cost (£) (maze procedure vs. control) 3841 (95% CI 1514 to 6167)
EQ-5D-3L QALYs in year 1 0.7160 0.26 0.7235 0.26
EQ-5D-3L QALYs in year 2 (with discounting) 0.6663 0.30 0.7028 0.29
Total QALYs over 2 years (present value) 1.3823 – 1.4263 –
Incremental EQ-5D-3L QALYs (maze procedure vs. control) –0.04398 (95% CI –0.1558 to 0.0678)
ICER Dominated
INMB (£) at a WTP of £20,000 per QALY –4720
INMB (£) at a WTP of £30,000 per QALY –5160
TABLE 20 Mean (SD) of the QALYs per patient by year of follow-up, with imputation
QALY type Year of QALY
Treatment arm, mean (SD)
Maze procedure (n= 176) Control (n= 176)
EQ-5D-3L QALY year 1 0.7160 (0.2583) 0.7235 (0.2640)
QALY year 2 0.6896 (0.3066) 0.7274 (0.2964)
SF-6D QALY year 1 0.6549 (0.2059) 0.6647 (0.2152)
QALY year 2 0.6418 (0.2486) 0.6699 (0.2374)
TRIAL RESULTS: COST-EFFECTIVENESS
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The plot of the estimated joint distribution of cost and QALY differences (Figure 16) shows that few
estimates fall below the line representing £30,000 per QALY, which is currently considered the upper limit
for cost-effective health interventions by NICE.45 The cost-effectiveness acceptability curve (Figure 17)
shows that, even at a WTP of £70,000 per QALY, the maze procedure has only a 10% probability of being
cost-effective, and Figure 18 shows a continuously declining net monetary benefit of the maze procedure
from around –£3500.
TABLE 22 Coefficients and standard errors from seemingly unrelated regression models for costs and QALYs,
adjusting for baseline covariates (primary cost-effectiveness analysis)
Dependent variable Independent variable Coefficient SEM p-value
EQ-5D-3L QALYs Maze procedure arm –0.0220 0.0516 0.67
Male –0.0836 0.0551 0.13
Age (years) –0.0045 0.0035 0.20
Baseline EQ-5D-3L score 0.9369 0.1209 < 0.01
Paroxysmal AF –0.1053 0.0599 0.08
Actual procedure 0.0006 0.0136 0.96
Constant 1.3544 0.2855 < 0.01
Total cost (£) per patient Maze procedure arm 3533 1129 < 0.01
Male –2131 1205 0.08
Age (years) 255 75 < 0.01
Baseline EQ-5D-3L score –9367 2645 < 0.01
Paroxysmal AF 2693 1300 0.04
Constant –1691 6247 0.79
SEM, standard error of the mean.
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Tables 29 and 30 in Appendix 2 show that none of the sensitivity analyses suggested that the maze
procedure is likely to be cost-effective at £30,000 per QALY at 2 years. The closest the results came to this
was limiting the analysis to patients randomised from April 2011, when the maze procedure had an ICER
of £53,538 at 2 years. However, the INMB was negative and the analysis limiting patients to those
randomised after April 2011 indicated that the probability of the maze procedure being cost-effective at
£30,000 per QALY was < 30% (see the probabilistic sensitivity analyses in Figure 19). The final sensitivity
analysis (see Appendix 2, Table 31) shows that, with imputation and controlling for baseline differences,
the incremental cost per additional conversion from AF to SR was £25,220.
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FIGURE 17 Cost-effectiveness acceptability curve for the maze procedure relative to the control arm.
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FIGURE 19 Probabilistic sensitivity analyses attached to varying deterministic conditions: (a) using the SF-6D; (b) using
primary admission only; (c) using a cost imputation model; (d) excluding ablation device cost; (e) excluding resource-use
outliers; (f) using complete-case analysis; and (g) excluding patients randomised before 1 April 2011. Incremental
cost=maze procedure cost – control cost; and incremental QALY=maze QALY – control QALY.
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Chapter 6 Discussion
Summary of clinical trial results
The objective of the maze procedure as an adjunct to conventional cardiac surgery is to restore SR and
thereby improve contractile function. If atrial function is restored, the procedure may reduce the risk
of death, stroke and, via reduction in anticoagulant medication, the risk of bleeding. Improvement in
patient-reported HRQoL and cost-effectiveness should follow from a reduction in these clinical events.
The Amaze trial has demonstrated a clear and important increase in the clinical primary outcome and
the proportion of cardiac patients who returned to SR at 12 months (OR 2.06, 95% CI 1.20 to 3.54;
p = 0.0091), and that this was maintained and increased at 24 months (OR 3.24, 95% CI 1.76 to 5.96;
p = 0.0001). Moreover, the odds of returning to SR were greater in maze procedure patients, irrespective
of whether patients had paroxysmal or non-paroxysmal AF, for all concomitant cardiac surgery undertaken
and did not differ between surgeons (although planned surgery outcomes varied by surgeon). Although
these subgroups were small and within-subgroup analyses had low statistical power, this finding adds
weight to the causal link between the maze procedure and return to SR. Note that, although the OR for
being in SR increased over time after randomisation, this largely resulted from a greater proportion of
control patients returning to AF, rather than an increase in prevalence of SR in the maze procedure arm.
Post hoc analysis of the primary outcome showed that the OR for return to SR in early trial patients was
lower than for later patients. There may be a number of reasons for this. First, it may have occurred purely
by chance. Second, there was some evidence that patients recruited to the trial were more likely to have
COPD as the trial progressed, which may have decreased overall success rates. Third, it may be related to
greater understanding of the operative technique as the trial progressed, especially the now accepted
need for multiple applications of the energy source to guarantee a transmural lesion, which has evolved
during the period of the trial.68 However, detailed examination of changes in outcomes as the trial
progressed showed that control patients recruited later in the study had lower rates of return to SR than
control patients recruited in the early period. Conversely, there was little difference in return to SR rates
throughout the trial for the maze procedure arm. The surgical factor that also changed through the trial
was the frequency of left atrial appendage excision, which decreased in control patients and increased
in maze procedure patients, with a weakly significant interaction found between operation order and
treatment group (the OR for left atrial appendage excision for maze procedure patients, relative to control
patients, was 1.34 per 50 patients recruited; p = 0.0244). This divergence in excision rates between the
arms appeared to be more common for specific surgeons who recruited more patients in the second half
of the trial. The implication may be that the maze procedure is equally effective at interrupting AF in all
patients, but there is substantial heterogeneity in results for control patients. Assiduous attention to
cointerventions, such as left atrial appendage excision and cardioversion, is also effective, and at least
some of the effect of the maze procedure may be explained by the use of these cointerventions. We stress
that these post hoc exploratory analyses should be interpreted with caution, as there was little power to
detect changes over time, and many patient and operative characteristics are highly correlated.
The maze procedure did not result in an increase in AEs, although 11 procedures were not completed,
mainly because of technical problems or concerns regarding patient safety. There was also evidence that
maze procedure patients were more likely to have their anticoagulant drugs stopped, which may result in
fewer adverse bleeding events in the future.
In this pragmatic trial, there was no mandated mode of delivery of the maze procedure; radiofrequency
ablation, usually bipolar, was the method of choice for a large proportion of the surgeons in the trial.
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The Amaze trial did not identify any clear differences in return to SR rates between methods, but the
numbers of cases in these subgroups were small and these comparisons were not robust.
The lesion set treated was at the discretion of the operating surgeon, and there did not appear to be a
clear relationship between the number or location of treatments and the odds of return to SR, although
the power to detect these interactions was very low. The Amaze trial has confirmed that there appears to
be still no practised consensus as to the optimal lesion set to be used in the adjunct maze procedure; the
lesion set appeared to be more often determined by the individual surgeon and by the operative scenario
than by firm guidelines and an operative plan. Nevertheless, the highest likelihood of SR restoration was
observed after a left atrial ablation procedure that included the mitral isthmus lesion. Beyond that, we
could discern no additional advantage of adding right atrial lesions.
In the HESTER substudy, the 95% CI for the mean difference in ALAEF, between patients in SR following
the maze procedure and matched control patients who were in SR both before and after surgery, was
within predefined clinically equivalent limits, although the ALAEF was statistically significantly lower in
maze procedure patients. This is an important finding, as return to SR with no or minimal recovery of atrial
function may not reduce the risk of thromboembolism. Absence of atrial contractility has been reported in
around one-third of patients who return to SR following ablation (using a variety of surgical and catheter
ablation techniques) and trials examining the return of atrial function have produced conflicting results.65
Some reported the return of haemodynamically important function, but others suggested that the maze
procedure is unlikely to achieve functional recovery, despite restoring SR.69
It is disappointing that we found no significant differences in survival and QoL between the maze procedure
and control arms at 2 years. As all patients in the Amaze trial also had conventional cardiac surgery, marked
improvements were observed in the NYHA status and QoL parameters in both treatment arms from
6 months after surgery, and most of these improvements must be attributable to the conventional cardiac
operation. The fact that we found no additional HRQoL benefit attributable to the maze procedure may be
because of the absence of such benefit, or because such benefit exists, but is small and requires a longer
follow-up period. If the rate of SR restoration falls further in the control arm as time progresses, and if there
is true recovery of atrial contractility in the restored SR group, then it is reasonable to conjecture that
differences in QoL may be seen in future. Cardiac surgery alone is known to produce a marked increase in
QoL within months of the procedure.70 If AF surgery and restoration of SR have a positive impact on QoL,
this may only be seen in the longer term, as patients no longer in AF are less exposed to the risks of stroke,
anticoagulant drug complications, antiarrhythmic complications and progressive heart failure. The finding in
the HESTER substudy of functional and contractile atria is an indication that such a benefit is possible and
may be seen with longer-term follow-up. A long-term health economics model was not funded by the
original grant. However, continued follow-up of clinical events and HRQoL is in progress and will inform
a long-term analysis.
Comparison with existing evidence
Overall, our SR restoration rate after maze procedure was consistent with other RCTs, but lower than in
some published series that represent selected practitioners treating selected patients.9 The rate of SR
restoration in the control arm was much higher than expected, and remained so, despite the substantial
drop at 2 years. This is a sufficient indication for considering cardioversion in AF patients after conventional
cardiac surgery alone, as over one-third of patients can be in SR at 2 years.
The two adverse features of asymptomatic AF are the impact on cardiac function and the risk of
thromboembolism.71 Both are directly related to atrial function. The HESTER substudy provided evidence
that atrial contractile function increases as a result of the maze procedure; therefore, restoring SR with a
maze procedure might provide clinical benefits in the future.
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Return to SR with no or minimal recovery of atrial function may have no benefit to the patient with
respect to the risk of thromboembolism. Left atrial transport function depends on atrial contractility, atrial
synchrony and left ventricular diastolic function. Absence of atrial contractility has been reported in around
one-third of patients who return to SR following ablation (using a variety of surgical and catheter ablation
techniques).65 Buber et al.65 reported that the absence of left atrial contraction was associated with a
significant increase in the risk of thromboembolic stroke after the maze procedure for patients in SR.
Conversely, effective left atrial transport function may be associated with reduced morbidity after
successful ablation of AF.65
Trials examining the return of atrial function have produced conflicting results. Some have reported the
return of haemodynamically meaningful function, but others have suggested that the maze procedure
is unlikely to achieve functional recovery, despite restoring SR.69 In patients without atrial contraction,
anticoagulant drugs significantly reduce stroke rate, but the incidence of major bleeding is increased.72,73
Furthermore, patients with chronic AF have evidence of persistent left atrial dysfunction, even after
restoration of SR by radiofrequency ablation. This suggests that global and regional atrial dysfunction
may be attributable to a combination of injury from the ablation process and pre-existing disease.66,74
Patients want to know whether or not they can safely stop taking anticoagulants after SR is restored by
a maze procedure. This requires long-term follow-up and stroke surveillance to be addressed with any
certainty. However, the HESTER substudy results lend some support to those advocating or already
practising anticoagulant drug withdrawal. The varying rates of left atrial functional recovery after maze
procedure mean that it would be prudent to measure atrial function before considering withdrawal of
anticoagulant drugs.
Summary and implications of cost-effectiveness results
Given the clinical results, it is perhaps not surprising that the per-patient costs over 2 years in the maze
procedure arm were statistically significantly higher than those in the control arm (£3533, 95% CI £1321
to £5746) and that there was a small non-significant reduction in discounted QALYs (–0.022, 95% CI
–0.1231 to 0.0791 QALYs). With higher costs and no improvement in QoL over the 2 years of the trial,
the control arm, representing current practice, dominates the new maze procedure for patients with AF
within a 2-year period.
Both the deterministic and probabilistic sensitivity analyses confirmed this conclusion, showing that, within
a 2-year period, the probability that the maze procedure would be considered cost-effective was < 5%.
Moreover, a variety of alternative and favourable assumptions would not change the overall conclusion
that, compared with current practice in the control arm, the maze procedure is not a cost-effective
intervention up to 2 years. A potential caveat to this was the result from an unplanned post hoc subgroup
analysis that included only the later patients (n = 200), in which the incremental effect was positive and
the ICER fell to £53,500.
To date, results from the wider literature on the cost per QALY of ablation surgery in patients with AF are
somewhat mixed. This first trial-based economic evaluation found that, comparing an adjunct ablation
surgery with cardiac surgery over a 1-year period, an additional cost of €4426 and a mean 0.06 QALY
gain translated to an ICER of €73,359.75 The associated probabilistic sensitivity analysis indicated that,
at a WTP per QALY of €30,000, the probability that the add-on ablation surgery was cost-effective was
around 10%, and, therefore, was not considered cost-effective at 1 year. Our 2-year results are therefore
in line with these findings. Longer-term economic models have shown that, over 5 years, either a classic
‘cut-and-sew’ maze procedure or a high-intensity ultrasound-assisted surgical ablation procedure, in
addition to scheduled CABG or valve surgery, was highly cost-effective compared with drug treatment.76
Cost-effectiveness decreased slightly if the intervention was applied with a percutaneous procedure.
However, economic modelling to inform Canadian decision-makers indicated that the cost-effectiveness
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of AF ablation compared with antiarrhythmic medication was more favourable over longer time horizons 
(e.g. 10 years) and could dominate antiarrhythmic medication given time horizons of 20 years; this
was not the case when considering a 5-year time horizon.77 English decision-makers78 concluded that, 
having reviewed McKenna et al.79 and Rodgers et al.,80 duration of benefit is a key determinant of
cost-effectiveness and, therefore, rejected van Breugel et al.75 as having too short a time period for 
appropriate decision-making. This suggests that costs and effects should be examined over a longer
time period, and preferably for longer than 5 years.
A 2013 systematic review, which included each of these studies, concluded that there was insufficient 
evidence to support catheter ablation as a first-line treatment, and that there was mixed evidence for 
second-line ablation.81 The authors specifically lament the lack of QoL data, especially in the long term, 
and highlight the critical importance of this in determining cost-effectiveness. They reflect on the 
shortcomings of existing economic studies and, without hard evidence on such key outcomes in the 
medium term (1–5 years), successfully counselled the Belgian government not to extrapolate beyond a
5-year term, because of uncertainties. This highlights the importance of the planned long-term follow-up 
of patients from the Amaze trial and the relevance of these future data to extending economic analysis 
into the long term. Interestingly, an industry-sponsored, 5-year economic model published in 2014 
reported that, although catheter ablation and the convergent procedure were argued to be cost-effective 
relative to medical management for non-paroxysmal AF, this was dependent on key assumptions about 
long-term maintenance of SR beyond 2 years and its relationship to future QoL.82
Strengths and weaknesses
The Amaze trial was ground-breaking in being a relatively large, multicentre Phase III trial in a surgical 
setting, in which randomisation was completed during surgery, and patients, investigators and clinical staff 
(with the exception of the surgical team) were blinded to treatment allocation. Details of the randomised 
arm were sealed and released only to the clinical teams in the event of a SAE that required unblinding. 
Complete blinding was achieved for patients and HRQoL assessors, and only 13 patients had their 
treatment allocation open to the clinical teams caring for the patients, thus supporting the integrity of the 
trial methodology. A further strength was the longer follow-up period, which incorporated quality-adjusted 
survival as a co-primary outcome.
Screening logs were completed assiduously only at the co-ordinating centre, and reasons for exclusion 
from the trial were not always transparent, which affected the interpretation of the generalisability of the 
results. However, comparison of baseline characteristics with those reported in annual audit statistics and 
registries suggests that trial patients were slightly older and more likely to be female, and that they had a 
slightly lower average EuroSCORE, but otherwise were broadly representative of NHS-treated cardiac 
surgery patients.62
In common with other cardiac surgical trials, prolongation of hospital stay and readmissions were 
common, and this is reflected in the number of SAEs recorded. There were no differences between the 
maze procedure and non-maze procedure patients in the number of events, their severity or relation to 
treatment, or in the number of patients who had events. Slow recruitment is a widespread problem in 
RCTs in general, and surgical trials in particular, and it is unfortunate that the Amaze trial did not achieve 
the target recruitment level.
In the study design, recruitment and randomisation of 400 patients were expected to be complete in
18 months. Delays in obtaining trust approvals at the recruitment sites ranged from 5 to 16 months, so 
that centre set-up took much longer than anticipated. In addition, a high number of staff changes across 
many sites, including withdrawal of Comprehensive Local Research Network support for the study at 
Papworth Hospital, had a significant impact on the recruitment rate.
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During the trial, it became apparent that most local centres significantly overestimated their surgical activity
and/or the recruitment rate for the Amaze trial. Moreover, there was heightened awareness of the maze
procedure among both patients, as a result of their own personal research, and clinicians, which affected
equipoise of potential recruits and decreased the number of patients approached to participate in the trial.
The age distribution of the population that would be eligible for the trial also changed over time, with the
proportion of elderly patients (aged ≥ 80 years) increasing. These patients were generally supportive of
the research, but often declined to participate because of the need for attendance at follow-up visits
and the presence of comorbidities. This was particularly true for patients living in rural areas, despite the
provision of alternative methods of travel, such as taxis.
Recruitment was carefully monitored by the project management team throughout the trial. At every TSC
meeting, a recruitment recovery plan was presented by the project team and reviewed. Specific measures
taken to improve recruitment were as follows: (1) there was an increase in the number of sites, from
8 to 11; (2) all sites were encouraged to include all consultants who had the required experience of the
maze procedure in recruitment; (3) contracts were revised to encourage ‘competitive recruitment’ across
sites; and (4) extensive trial promotional material was produced to raise the profile and to encourage
‘ownership’ of the trial. Despite these measures, target recruitment was not reached within the funded
time period.
Around 26% of the randomised patients (n = 92) had paroxysmal AF at baseline, and we found that being
in SR during baseline ECG monitoring was strongly related to being in SR at annual follow-ups. Although
all patients had a documented history of AF at baseline and satisfied the inclusion criteria for the trial,
and the number of patients with paroxysmal AF at baseline were equally distributed between the two
treatment arms, this could have diluted the treatment effect to some extent.
The decision by the independent DMEC to recommend that the TSC consider stopping the trial on the
basis of futility meant that unblinded trial summaries were available to TSC members. We cannot rule out
bias as a result of the knowledge that treatment effects were not promising at this time. Individual patients
and the investigators recording primary outcomes remained unaware of group allocation, so we believe
that any bias was minor. However, it is possible that clinicians drifted towards recruitment of patients with
more severe AF, which in turn resulted in a larger treatment effect in the second half of the trial.
There were three follow-up data collection points (6, 12 and 24 months). Having longer gaps over which
patients are asked to recall resource use has been shown to link to under-reporting of frequent events,
severity of illness and those using services very intensively.83 Despite this, neither Johnston et al.83 nor
Ridyard and Hughes84 recommended a specific interval between data collection points, but they did
suggest compromising between respondent burden and collecting data on the incidence of events that
drive resource use. Recent evidence published by Seidl et al.85 reported that, in a 1-year trial evaluating
management of acute MI in patients aged > 65 years, in one German hospital, three data collection points
gave similar results to four data collection points.85 In the Amaze trial, almost 95% of the difference in
follow-up costs between trial arms related to admissions; as these are major and infrequent events,
it is unlikely that their costs have been underestimated. There was lower resource use for primary and
community care resources in the second year than in the first year, and although this could be a function
of the frequency of data collection, it could also be a function of higher expected use of outpatient
services following initial admission. Even so, it is not clear this would affect the incremental cost difference
and, therefore, change the findings.
There was no statistically significant effect for the patient-centred primary outcome, undiscounted QALYs
over 2 years, and the 95% CI for the difference between the treatment arms (maze procedure vs. control)
excluded our prespecified minimum clinically important difference of 0.083 QALYs. More specifically,
based on the 95% CI, we could rule out differences in QALYs of ≥ 0.083 in favour of the maze procedure
arm. A long-term economic model may demonstrate a delayed effect on patient-centred outcomes, but it
was outside the scope of this report.
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The HESTER substudy was small and not randomised, so the results regarding restoration of contractile
function were less robust. Echocardiography measurements of left atrial volumes, despite being well
correlated with MRI measurements, tend to be underestimations; therefore, estimated treatment
effects from MRI measurements were larger and had wider CIs than the corresponding estimates from
echocardiography measurements.86,87 Implications for the analyses of ALAEF, for which we do not have
MRI measurements, are difficult to assess. Our a priori definition of clinical equivalence in the HESTER
substudy was based on the SD (18.2%) of normal ALAEF reported in a published study, along with the
investigators’ clinical judgement.88 However, the SD in our sample was lower (< 8%). This may have
resulted from an underestimation of the population SD in our cohort, but could be a consequence of our
sample being a more homogeneous group of patients, which may limit the generalisability of our results.
There were 49 maze procedures at Papworth Hospital outside the trial; these patients either had severely
symptomatic AF, so that surgeons were not in equipoise for these patients, or the patients themselves or
their surgeon had a strong preference for the treatment, despite a lack of robust evidence. Thus, our
results do not necessarily apply to these patients.
Implications for service
l Ablation can be safely practised in a NHS routine cardiac surgical setting and will increase the number
of patients who return to SR after surgery.
l There is some support for anticoagulant drug withdrawal, but the varying rates of left atrial functional
recovery after a maze procedure suggest that measurement of atrial function before considering
withdrawal of anticoagulant drugs would be prudent.
l The improvement in SR restoration as the study progressed suggests better patient selection and better
maze procedures, including cointerventions (e.g. excision of the left atrial appendage), were performed
in the later stages. This may reflect greater understanding of the lesion set and greater success in
achieving truly transmural lesions. Surgeons performing the procedure may wish to audit their SR
restoration rate and modify their practice if necessary.
Implications for further research
l Continued monitoring of clinical events (deaths, strokes and haemorrhaging), resource use (especially
readmissions) and HRQoL to inform a long-term health economics model is required, and for at least
5 years after surgery.
l Further study of the relative effectiveness of different ablation techniques would clarify the choice
of methodology.
Conclusions
In the Amaze trial, the maze procedure, as an adjunct to routine cardiac surgery, was safe and effective in
increasing the probability of restoration of SR in patients with pre-existing paroxysmal or non-paroxysmal
(persistent, longstanding or chronic) AF. The odds of being in SR approximately doubled at 12 months, and
more than tripled at 24 months, after surgery. There was evidence from a small, non-randomised substudy
that this was associated with improved atrial contractile function that was lower, but within the limits of
clinical equivalence, when compared with patients who were in SR before surgery. The additional cost of
the maze procedure per person over 2 years, relative to routine cardiac surgery, was £3500. In the 2-year
follow-up period, these clinical effects had not resulted in additional improvement in HRQoL; however,
given the known association between AF and subsequent neurological events and the reduced use of
anticoagulants in the maze procedure arm, continued follow-up and analysis is warranted.
DISCUSSION
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Appendix 2 Additional tables from the health
economics analysis
TABLE 23 Summary of unit costs
Primary admission cost Source Consultation time/code
Mean cost (£)
(SD) for 2014/15
Theatre use Papworth Hospital estimate 20.00 (4.00)
Adult critical care NHS Reference Costs 2014
to 201559
Total/weighted average 1274.92 (583.33)
Cardiac ward NHS Reference Costs 2014
to 201559
Code: SD01A 387.96 (77.59)
General ward NHS Reference Costs 2014
to 201559
Code: SD03A 103.01 (20.60)
Rehabilitation PSSRU 2015,58 1.3 158.57 (31.71)
Acute (specialised ward) NHS Reference Costs 2014
to 201559
Code: SD01A 387.96 (77.59)
Follow-up admission
ICU NHS Reference Costs 2014
to 201559
Total/weighted average 1274.92 (583.33)
Cardiac ward NHS Reference Costs 2014
to 201559
Code: SD01A 387.96 (77.59)
General ward NHS Reference Costs 2014
to 201559
Code: SD03A 103.01 (20.60)
Day case NHS Reference Costs 2014
to 201559
Code: DC 720.78 (144.16)
Follow-up tests
Angiography NHS Reference Costs 2014
to 201559
Code: EY43F 260.00 (52.00)
MUGA NHS Reference Costs 2014
to 201559
Code: RN22Z 192.39 (38.48)
Echocardiography NHS Reference Costs 2014
to 201559
Simple echocardiogram 83.94 (16.79)
PET NHS Reference Costs 2014
to 201559
Code: RN07A 524.77 (104.95)
TOE NHS Reference Costs 2014
to 201559
Complex echocardiogram 128.49 (25.70)
Computerised tomography scan NHS Reference Costs 2014
to 201559
Total/weighted average 122.31 (48.86)
Echocardiogram stress NHS Reference Costs 2014
to 201559
Complex echocardiogram 128.49 (25.70)
MRI scan NHS Reference Costs 2014
to 201559
Total/weighted average 146.15 (56.64)
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TABLE 23 Summary of unit costs (continued )
Primary admission cost Source Consultation time/code
Mean cost (£)
(SD) for 2014/15
Exercise test NHS Reference Costs 2014
to 201559
Field exercise testing 287.08 (57.42)
ECG NHS Reference Costs 2014
to 201559
ECG monitoring 52.13 (10.43)
24-hour ECG NHS Reference Costs 2014
to 201559
ECG monitoring 169.26 (33.85)
> 24-hour ECG NHS Reference Costs 2014
to 201559
ECG monitoring 169.26 (33.85)
24-hour blood pressure monitoring Lovibond et al.89 61.47 (12.29)
< 24-hour blood pressure monitoring NICE Cost Statement
201390
38.34 (7.67)
Left heart catheterisation Papworth Hospital estimate 1267.00 (253.40)
Radiography (chest) Auguste et al.91 3.46 (0.69)
Follow-up health-care visits
GP visits PSSRU 2015,58 10.8b Per-patient contact
lasting 17.2 minutes
65.00 (13.00)
GP home visits PSSRU 2015,58 10.8b Per-patient contact
lasting 11.7 minutes
45.00 (9.00)
Nurse visits PSSRU 2015,58 10.6 Per-patient contact
15.5 minutes
14.47 (2.89)
Nurse home visits PSSRU 2015,58 10.4 Per-patient contact
17.2 minutes
19.38 (3.88)
Cardiology clinic NHS Reference Costs 2014
to 201559
Code: WF01A 123.02 (24.60)
AF clinic NHS Reference Costs 2014
to 201559
Code: WF01A
(cardiology clinic)
123.02 (24.60)
Pacemaker NHS Reference Costs 2014
to 201559
Code: EY08E 76.32 (15.26)
Physiotherapy NHS Reference Costs 2014
to 201559
Code: WF01A 14.32 (2.86)
Occupational therapy NHS Reference Costs 2014
to 201559
Code: WF01A 21.41 (4.28)
A&E visit NHS Reference Costs 2014
to 201559
Total/weighted average 140.59 (141.05)
Wound clinic NHS Reference Costs 2014
to 201559
Code: N25AF/AN 54.93 (10.99)
Cardiac rehabilitation NHS Reference Costs 2014
to 201559
Code: VC38Z 97.84 (19.57)
MUGA, multigated acquisition scan; PET, positron emission tomography; PSSRU, Personal Social Services Research Unit;
TOE, transoesophageal echocardiography.
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TABLE 24 Resource use across the two treatment arms, without imputation
Primary admission resource
Unit of
measurement
Resource use per patient in each treatment arm
Maze procedure Control
Observation Mean (SD) Observation Mean (SD)
Theatre Minutes 176 261.24 (79.68) 176 247.48 (93.27)
Critical care (ICU) Days 175 3.17 (5.98) 176 2.40 (4.38)
Cardiac ward Days 174 8.73 (12.08) 176 7.90 (5.19)
Convalescence Days 167 0.29 (2.07) 169 0.96 (6.96)
Transferred to acute trusta Days 173 2.37 (15.86) 176 0.43 (3.63)
Follow-up admission
6 weeks in ICU Days 125 0.07 (0.72) 130 0.04 (0.29)
6 weeks in ward Days 125 2.49 (9.06) 130 1.25 (4.12)
6 weeks in cardiac ward Days 125 1.42 (7.29) 130 0.64 (2.37)
6 weeks as a day case Days 125 0.01 (0.09) 130 0.00 (0.00)
6 months in ICU Days 115 0.01 (0.09) 122 0.02 (0.20)
6 months in ward Days 115 0.59 (3.02) 122 0.89 (5.40)
6 months in cardiac ward Days 115 0.61 (2.75) 122 0.70 (3.16)
6 months as a day case Days 115 0.04 (0.24) 122 0.01 (0.09)
12 months in ICU Days 122 0.07 (0.46) 122 0.00 (0.00)
12 months in ward Days 122 0.02 (0.16) 122 0.11 (0.54)
12 months in cardiac ward Days 122 1.38 (5.42) 122 0.56 (2.18)
12 months as a day case Days 122 0.02 (0.20) 122 0.01 (0.09)
24 months in ICU Days 122 0.02 (0.27) 131 0.00 (0.00)
24 months in ward Days 122 0.63 (5.31) 131 0.44 (2.06)
24 months in cardiac ward Days 122 1.28 (5.07) 131 1.30 (5.96)
24 months as a day case Days 122 0.00 (0.00) 131 0.04 (0.19)
Follow-up tests
Year 1 angiography Number of tests 145 0.03 (0.20) 148 0.01 (0.12)
Year 1 MUGA Number of tests 145 0.04 (0.50) 148 0.00 (0.00)
Year 1 echocardiogram TTE Number of tests 145 0.46 (0.77) 148 0.53 (0.83)
Year 1 PET scan Number of tests 145 0.00 (0.00) 148 0.00 (0.00)
Year 1 echocardiogram TOE Number of tests 145 0.02 (0.14) 148 0.02 (0.14)
Year 1 computerised
tomography
Number of tests 145 0.13 (0.40) 148 0.07 (0.26)
Year 1 echocardiogram stress Number of tests 145 0.00 (0.00) 148 0.00 (0.00)
Year 1 MRI scan Number of tests 145 0.05 (0.25) 148 0.04 (0.20)
Year 1 exercise test Number of tests 145 0.04 (0.23) 148 0.01 (0.08)
Year 1 ECG Number of tests 145 2.42 (2.06) 149 2.16 (2.08)
Year 1 24-hour ECG Number of tests 145 0.16 (0.44) 148 0.13 (0.36)
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TABLE 24 Resource use across the two treatment arms, without imputation (continued )
Primary admission resource
Unit of
measurement
Resource use per patient in each treatment arm
Maze procedure Control
Observation Mean (SD) Observation Mean (SD)
Year 1 > 24-hour ECG Number of tests 145 0.13 (0.46) 148 0.10 (0.38)
Year 1 24-hour blood
pressure monitoring
Number of tests 145 0.02 (0.14) 148 0.02 (0.18)
Year 1 < 24-hour blood
pressure monitoring
Number of tests 145 0.01 (0.12) 148 0.09 (0.69)
Year 1 left heart catheter Number of tests 145 0.00 (0.00) 148 0.00 (0.00)
Year 1 radiography Number of tests 145 1.61 (2.47) 149 1.12 (1.34)
Year 2 angiography Number of tests 146 0.01 (0.12) 150 0.01 (0.12)
Year 2 MUGA Number of tests 146 0.00 (0.00) 150 0.00 (0.00)
Year 2 echocardiogram TTE Number of tests 146 0.21 (0.53) 150 0.18 (0.42)
Year 2 PET scan Number of tests 146 0.00 (0.00) 150 0.00 (0.00)
Year 2 echocardiogram TOE Number of tests 146 0.02 (0.14) 149 0.01 (0.08)
Year 2 computerised
tomography
Number of tests 146 0.05 (0.26) 150 0.09 (0.42)
Year 2 echocardiogram stress Number of tests 146 0.00 (0.00) 150 0.01 (0.08)
Year 2 MRI scan Number of tests 146 0.05 (0.30) 150 0.03 (0.16)
Year 2 exercise test Number of tests 146 0.00 (0.00) 150 0.01 (0.12)
Year 2 ECG Number of tests 146 0.92 (3.67) 150 0.69 (1.13)
Year 2 24-hour ECG Number of tests 146 0.02 (0.14) 150 0.07 (0.28)
Year 2 > 24-hour ECG Number of tests 146 0.03 (0.16) 150 0.04 (0.20)
Year 2 24-hour blood
pressure monitoring
Number of tests 146 0.01 (0.12) 150 0.01 (0.08)
Year 2 < 24-hour blood
pressure monitoring
Number of tests 146 0.01 (0.12) 150 0.03 (0.20)
Year 2 left heart catheter Number of tests 146 0.01 (0.08) 150 0.00 (0.00)
Year 2 radiography Number of tests 146 0.19 (0.67) 149 0.18 (0.57)
Follow-up health-care visits
Year 1 GP visits Number of visits 145 3.77 (4.59) 148 3.66 (4.28)
Year 1 GP home visits Number of visits 145 0.17 (0.72) 148 0.24 (1.23)
Year 1 nurse (general
practice) visits
Number of visits 145 4.21 (8.74) 148 4.17 (8.84)
Year 1 nurse home visits Number of visits 145 1.46 (4.90) 148 0.86 (2.39)
Year 1 cardiovascular clinic Number of visits 145 1.63 (1.34) 148 1.32 (1.20)
Year 1 AF clinic Number of visits 145 0.03 (0.20) 148 0.01 (0.08)
Year 1 pacemaker Number of visits 145 0.10 (0.36) 148 0.21 (0.81)
Year 1 physiotherapy Number of visits 145 0.32 (1.35) 148 0.47 (2.85)
Year 1 occupational therapy Number of visits 145 0.01 (0.08) 148 0.07 (0.41)
Year 1 A&E visit Number of visits 145 0.26 (0.76) 148 0.27 (0.75)
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TABLE 24 Resource use across the two treatment arms, without imputation (continued )
Primary admission resource
Unit of
measurement
Resource use per patient in each treatment arm
Maze procedure Control
Observation Mean (SD) Observation Mean (SD)
Year 1 wound clinic Number of visits 145 0.05 (0.27) 148 0.02 (0.18)
Year 1 cardiac rehabilitation Number of visits 145 3.09 (7.76) 148 3.32 (6.93)
Year 2 GP visits Number of visits 146 1.55 (3.37) 150 1.54 (2.56)
Year 2 GP home visits Number of visits 146 0.01 (0.12) 150 0.09 (0.99)
Year 2 nurse (general
practice) visits
Number of visits 146 2.63 (6.87) 150 2.40 (4.99)
Year 2 nurse home visits Number of visits 146 0.21 (1.51) 150 0.15 (1.35)
Year 2 cardiovascular clinic Number of visits 146 0.54 (0.74) 150 0.59 (0.98)
Year 2 AF clinic Number of visits 146 0.00 (0.00) 150 0.01 (0.16)
Year 2 pacemaker Number of visits 146 0.08 (0.30) 150 0.15 (0.50)
Year 2 physiotherapy Number of visits 146 0.18 (0.99) 150 0.10 (0.82)
Year 2 occupational therapy Number of visits 146 0.03 (0.33) 150 0.04 (0.42)
Year 2 A&E visit Number of visits 146 0.10 (0.40) 150 0.17 (0.61)
Year 2 wound clinic Number of visits 146 0.00 (0.00) 150 0.00 (0.00)
Year 2 cardiac rehabilitation Number of visits 146 0.36 (3.45) 150 0.33 (3.76)
MUGA, multigated acquisition scan; PET, positron emission tomography; TOE, transoesophageal echocardiography;
TTE, transthoracic echocardiography.
a Assumed as transfer to specialised care at an acute trust.
TABLE 25 Resource use across the two treatment arms, with imputation
Primary admission cost Unit of measurement
Resource use per patient in each treatment arm,
mean (SD)
Maze procedure (n= 176) Control (n= 176)
Theatre use Minutes 261.24 (79.68) 247.43 (93.13)
Adult critical care Days 3.16 (5.96) 2.40 (4.38)
Cardiac ward (specialised ward) Days 8.76 (12.01) 7.90 (5.19)
Rehabilitation Days 0.30 (2.05) 0.93 (6.83)
Acute (specialised ward) Days 2.41 (15.74) 0.43 (3.63)
Follow-up admission at week 6
ICU Days 0.05 (0.61) 0.03 (0.25)
General ward Days 1.80 (7.72) 1.03 (3.72)
Cardiac ward Days 1.47 (6.86) 0.50 (2.08)
Day case Days 0.01 (0.08) 0.00 (0.00)
Follow-up admission at 6 months
ICU Days 0.01 (0.08) 0.02 (0.17)
General ward Days 0.39 (2.45) 0.66 (4.52)
Cardiac ward Days 0.40 (2.24) 0.52 (2.67)
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TABLE 25 Resource use across the two treatment arms, with imputation (continued )
Primary admission cost Unit of measurement
Resource use per patient in each treatment arm,
mean (SD)
Maze procedure (n= 176) Control (n= 176)
Day case Days 0.04 (0.23) 0.01 (0.08)
Follow-up admission at 12 months
ICU Days 0.05 (0.38) 0.00 (0.00)
General ward Days 0.02 (0.13) 0.09 (0.48)
Cardiac ward Days 1.02 (4.58) 0.41 (1.85)
Day case Days 0.02 (0.17) 0.01 (0.08)
Follow-up admission at 24 months
ICU Days 0.02 (0.23) 0.00 (0.00)
General ward Days 0.48 (4.43) 0.44 (1.91)
Cardiac ward Days 1.06 (4.38) 1.17 (5.24)
Day case Days 0.00 (0.00) 0.03 (0.17)
Follow-up tests (year 1)
Angiography Number of tests 0.04 (0.22) 0.02 (0.13)
MUGA Number of tests 0.03 (0.45) 0.00 (0.00)
TTE Number of tests 0.49 (0.77) 0.55 (0.80)
PET scan Number of tests 0.00 (0.00) 0.00 (0.00)
TOE Number of tests 0.03 (0.14) 0.03 (0.14)
Computerised tomography Number of tests 0.14 (0.38) 0.08 (0.27)
Echocardiogram stress Number of tests 0.00 (0.00) 0.00 (0.00)
MRI scan Number of tests 0.05 (0.23) 0.05 (0.19)
Exercise test Number of tests 0.04 (0.22) 0.01 (0.08)
ECG Number of tests 2.43 (1.98) 2.34 (2.23)
24-hour ECG Number of tests 0.15 (0.41) 0.13 (0.34)
> 24-hour ECG Number of tests 0.16 (0.48) 0.11 (0.39)
Blood pressure monitoring Number of tests 0.02 (0.13) 0.02 (0.17)
24-hour blood pressure monitoring Number of tests 0.02 (0.12) 0.09 (0.64)
Left heart catheter Number of tests 0.00 (0.00) 0.00 (0.00)
Radiography Number of tests 1.65 (2.38) 1.10 (1.29)
Follow-up tests (year 2)
Angiography Number of tests 0.01 (0.11) 0.01 (0.11)
MUGA Number of tests 0.00 (0.00) 0.00 (0.00)
TTE Number of tests 0.22 (0.51) 0.19 (0.40)
PET scan Number of tests 0.00 (0.00) 0.00 (0.00)
TOE Number of tests 0.02 (0.13) 0.01 (0.08)
Computerised tomography Number of tests 0.07 (0.26) 0.10 (0.41)
Echocardiogram stress Number of tests 0.00 (0.00) 0.01 (0.08)
MRI scan Number of tests 0.05 (0.28) 0.03 (0.18)
Exercise test Number of tests 0.00 (0.00) 0.02 (0.12)
ECG Number of tests 0.87 (3.35) 0.71 (1.10)
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TABLE 25 Resource use across the two treatment arms, with imputation (continued )
Primary admission cost Unit of measurement
Resource use per patient in each treatment arm,
mean (SD)
Maze procedure (n= 176) Control (n= 176)
24-hour ECG Number of tests 0.03 (0.15) 0.06 (0.26)
> 24-hour ECG Number of tests 0.03 (0.16) 0.04 (0.19)
Blood pressure monitoring Number of tests 0.02 (0.12) 0.01 (0.08)
24-hour blood pressure monitoring Number of tests 0.01 (0.11) 0.03 (0.20)
Left heart catheter Number of tests 0.01 (0.08) 0.00 (0.00)
Radiography Number of tests 0.22 (0.68) 0.20 (0.57)
Follow-up health-care visits (year 1)
GP visits Number of visits 3.72 (4.31) 3.81 (4.22)
GP home visits Number of visits 0.18 (0.69) 0.22 (1.13)
Nurse (general practice) visits Number of visits 4.16 (8.33) 4.22 (8.58)
Nurse home visits Number of visits 1.38 (4.55) 0.86 (2.25)
Cardiovascular clinic Number of visits 1.59 (1.30) 1.30 (1.16)
AF clinic Number of visits 0.03 (0.19) 0.01 (0.08)
Pacemaker Number of visits 0.11 (0.34) 0.23 (0.81)
Physiotherapy Number of visits 0.44 (1.44) 0.64 (3.25)
Occupational therapy Number of visits 0.01 (0.08) 0.07 (0.38)
A&E visit Number of visits 0.29 (0.80) 0.29 (0.74)
Wound clinic Number of visits 0.07 (0.30) 0.02 (0.17)
Cardiac rehabilitation Number of visits 3.07 (7.34) 3.23 (6.51)
Follow-up health-care visits (year 2)
GP visits Number of visits 1.65 (3.25) 1.70 (2.67)
GP home visits Number of visits 0.01 (0.11) 0.09 (0.91)
Nurse (general practice) visits Number of visits 2.67 (6.65) 2.53 (4.96)
Nurse home visits Number of visits 0.22 (1.46) 0.14 (1.25)
Cardiovascular clinic Number of visits 0.53 (0.72) 0.61 (0.94)
AF clinic Number of visits 0.00 (0.00) 0.01 (0.15)
Pacemaker Number of visits 0.11 (0.33) 0.17 (0.49)
Physiotherapy Number of visits 0.21 (1.05) 0.13 (0.92)
Occupational therapy Number of visits 0.02 (0.30) 0.05 (0.43)
A&E visit Number of visits 0.13 (0.43) 0.16 (0.57)
Wound clinic Number of visits 0.00 (0.00) 0.00 (0.00)
Cardiac rehabilitation Number of visits 0.36 (3.20) 0.41 (3.87)
MUGA, multigated acquisition scan; PET, positron emission tomography; TOE, transoesophageal echocardiography;
TTE, transthoracic echocardiography.
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TABLE 26 Total cost across two arms, with imputation
Primary admission cost
Resource use (£) per patient in each treatment arm,
mean (SD)
Maze procedure (n= 176) Control (n= 176)
Theatre use 5224.89 (1593.66) 4948.52 (1862.51)
Ablation device 1211.65 (408.33) 14.20 (132.87)
Adult critical care 4028.75 (7600.08) 3064.51 (5585.89)
Cardiac ward 3396.88 (4661.36) 3064.03 (2013.71)
Rehabilitation 47.75 (324.98) 147.76 (1082.35)
Acute (specialised ward) 936.84 (6105.06) 165.33 (1408.64)
Subtotal 14,846.76 (12,473.61) 11,404.35 (7193.49)
Readmissions at 6 weeks
ICU 65.19 (774.24) 36.22 (317.57)
General ward 151.58 (706.84) 51.21 (213.78)
Cardiac ward 697.67 (2994.27) 398.99 (1444.75)
Day case 4.10 (54.33) 0.00 (0.00)
Readmissions at 6 months
ICU 7.24 (96.10) 21.73 (214.40)
General ward 40.97 (230.75) 53.55 (274.82)
Cardiac ward 149.89 (951.09) 254.60 (1753.63)
Day case 28.67 (165.46) 4.10 (54.33)
Readmissions at 12 months
ICU 61.57 (489.90) 0.00 (0.00)
General ward 105.35 (471.71) 42.72 (190.13)
Cardiac ward 7.72 (52.30) 35.27 (185.59)
Day case 12.29 (121.21) 4.10 (54.33)
Readmissions at 24 months
ICU 21.73 (288.30) 0.00 (0.00)
General ward 109.45 (451.38) 120.86 (539.50)
Cardiac ward 186.27 (1720.26) 171.94 (741.60)
Day case 0.00 (0.00) 24.57 (125.38)
Subtotal 1649.69 (4192.49) 1219.85 (2994.21)
Follow-up tests (year 1)
Angiography 9.60 (57.33) 5.17 (35.05)
MUGA 6.56 (87.01) 0.00 (0.00)
TTE 40.78 (64.93) 46.26 (67.46)
PET scan 0.00 (0.00) 0.00 (0.00)
TOE 3.29 (18.52) 3.29 (18.52)
Computerised tomography 17.03 (47.00) 10.08 (32.76)
Echocardiogram stress 0.00 (0.00) 0.00 (0.00)
MRI scan 7.47 (34.12) 6.64 (28.46)
Exercise test 11.42 (64.09) 1.63 (21.64)
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TABLE 26 Total cost across two arms, with imputation (continued )
Primary admission cost
Resource use (£) per patient in each treatment arm,
mean (SD)
Maze procedure (n= 176) Control (n= 176)
ECG 126.63 (103.36) 122.18 (116.13)
24-hour ECG 25.00 (69.09) 21.64 (57.75)
> 24-hour ECG 26.93 (80.46) 18.75 (65.98)
Blood pressure monitoring 1.05 (7.98) 1.05 (10.34)
24-hour blood pressure monitoring 0.65 (4.54) 3.38 (24.49)
Left heart catheter 0.00 (0.00) 0.00 (0.00)
Radiography 5.71 (8.24) 3.79 (4.45)
Follow-up tests (year 2)
Angiography 3.69 (29.25) 2.95 (27.64)
MUGA 0.00 (0.00) 0.00 (0.00)
TTE 18.12 (42.47) 15.74 (33.76)
PET scan 0.00 (0.00) 0.00 (0.00)
TOE 2.56 (17.32) 1.10 (10.80)
Computerised tomography 7.99 (32.03) 12.51 (50.35)
Echocardiogram stress 0.00 (0.00) 0.73 (9.69)
MRI scan 7.89 (40.95) 4.98 (26.60)
Exercise test 0.00 (0.00) 4.89 (33.96)
ECG 45.32 (174.84) 37.17 (57.48)
24-hour ECG 5.29 (25.84) 10.58 (43.98)
> 24-hour ECG 5.29 (27.38) 7.21 (32.45)
Blood pressure monitoring 1.22 (7.61) 0.35 (4.63)
24-hour blood pressure monitoring 0.54 (4.31) 1.20 (7.71)
Left heart catheter 7.20 (95.50) 0.00 (0.00)
Radiography 0.75 (2.36) 0.69 (1.96)
Subtotal 387.97 (375.85) 343.96 (283.09)
Follow-up health-care visits (year 1)
GP visits 241.72 (280.11) 247.63 (274.01)
GP home visits 8.05 (31.01) 9.72 (50.95)
Nurse (general practice) visits 60.17 (120.49) 61.11 (124.06)
Nurse home visits 26.75 (88.09) 16.68 (43.53)
Cardiology clinic 195.36 (160.23) 160.42 (142.71)
AF clinic 3.84 (23.85) 0.70 (9.27)
Pacemaker 8.02 (26.32) 17.78 (61.72)
Physiotherapy 7.10 (23.29) 10.41 (52.43)
Occupational therapy 0.14 (1.40) 1.23 (6.31)
A&E visit 41.14 (113.06) 41.14 (104.50)
Wound clinic 3.90 (16.28) 1.09 (9.45)
Cardiac rehabilitation 300.19 (718.22) 315.76 (637.43)
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TABLE 26 Total cost across two arms, with imputation (continued )
Primary admission cost
Resource use (£) per patient in each treatment arm,
mean (SD)
Maze procedure (n= 176) Control (n= 176)
Follow-up health-care visits (year 2)
GP visits 107.29 (211.47) 110.61 (173.24)
GP home visits 0.64 (5.06) 3.96 (41.02)
Nurse (general practice) visits 38.59 (96.18) 36.58 (71.71)
Nurse home visits 4.24 (28.20) 2.64 (24.17)
Cardiology clinic 65.35 (88.02) 75.14 (115.44)
AF clinic 0.00 (0.00) 1.40 (18.55)
Pacemaker 8.02 (25.02) 12.79 (37.30)
Physiotherapy 3.39 (16.89) 2.02 (14.80)
Occupational therapy 0.38 (5.03) 0.81 (7.11)
A&E visit 18.77 (60.69) 23.17 (80.04)
Wound clinic 0.00 (0.00) 0.00 (0.00)
Cardiac rehabilitation 35.58 (313.15) 40.03 (378.61)
Subtotal 1178.66 (1060.51) 1192.79 (1052.40)
Medication
Year 1 476.94 (1203.98) 510.06 (2092.35)
Year 2 141.20 (456.15) 171.29 (727.75)
Subtotal 618.14 (1583.61) 681.35 (2764.66)
Total 18,681.21 (13,339.82) 14,842.30 (8295.33)
MUGA, multigated acquisition scan; PET, positron emission tomography; TOE, transoesophageal echocardiography;
TTE, transthoracic echocardiography.
TABLE 27 Summaries of utility scores by treatment arm, with imputation
Time point of utility score
Utility score by treatment arm, mean score (SD)
Maze procedure (n= 176) Control (n= 176)
EQ-5D-3L score
Baseline 0.7417 (0.22) 0.7544 (0.21)
Discharge 0.5927 (0.29) 0.5943 (0.28)
6-week follow-up 0.7187 (0.27) 0.7246 (0.27)
6-month follow-up 0.7312 (0.29) 0.7350 (0.31)
12-month follow-up 0.7167 (0.31) 0.7397 (0.30)
24-month follow-up 0.6719 (0.34) 0.7163 (0.32)
SF-6D score
Baseline 0.6599 (0.11) 0.6651 (0.11)
6-month follow-up 0.6703 (0.23) 0.6853 (0.23)
12-month follow-up 0.6565 (0.24) 0.6723 (0.24)
24-month follow-up 0.6350 (0.27) 0.6685 (0.25)
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TABLE 28 Summaries of utility scores by treatment arm, without imputation
Time point of utility score
Treatment arm
Maze procedure Control
Observations Mean score (SD) Observations Mean score (SD)
EQ-5D-3L score
Baseline 174 0.7417 (0.22) 175 0.7544 (0.21)
Discharge 161 0.6091 (0.28) 165 0.6034 (0.28)
6-week follow-up 164 0.7378 (0.25) 169 0.7339 (0.26)
6-month follow-up 169 0.7311 (0.30) 174 0.7323 (0.31)
12-month follow-up 165 0.7142 (0.32) 167 0.7367 (0.31)
24-month follow-up 158 0.6680 (0.35) 161 0.7098 (0.34)
SF-6D score
Baseline 172 0.6623 (0.11) 174 0.6644 (0.11)
6-month follow-up 168 0.6694 (0.23) 171 0.6846 (0.24)
12-month follow-up 166 0.6557 (0.24) 166 0.6678 (0.25)
24-month follow-up 158 0.6291 (0.28) 157 0.6597 (0.26)
TABLE 29 Deterministic sensitivity analysis (using the difference between maze procedure and control, adjusted for
baseline)
Scenario Observations
Difference (maze procedure
vs. control), mean (SD)
ICER (£)
INMB (£) at a WTP of
Incremental
cost (£) over
24 months
Incremental
QALYs over
24 months
£20,000
per QALY
£30,000
per QALY
Using EQ-5D-3L QALYs
(base case)
352 3533 (1129) –0.0220 (0.0516) Dominated –3974 –4194
Using SF-6D QALYs 352 3533 (1129) –0.0197 (0.0433) Dominated –3928 –4125
Including costs and
QALYs data only up to
discharge
352 3140 (1044) 0.0014 (0.0018) 2,234,462 –3112 –3098
Excluding outliers from
the analysis
350 2856 (1013) –0.0108 (0.0512) Dominated –3073 –3181
Alternate imputation
model (cost imputation)
352 4103 (1180) –0.0214 (0.0520) Dominated –4530 –4744
Excluding device cost 352 2336 (1128) –0.0220 (0.0516) Dominated –2777 –2997
Complete-case analysis 234 2210 (1108) 0.0264 (0.0571) 83,625 –1682 –1417
Randomised after April
2011
200 3364 (1574) 0.0628 (0.0693) 53,538 –2107 –1479
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TABLE 30 Probabilistic sensitivity analysis (using the difference between maze procedure and control, adjusted for
baseline)
Scenario Observations
Difference (maze procedure
vs. control), mean (SD)
ICER (£)
INMB (£) at a WTP of
Incremental
cost (£) over
24 months
Incremental
QALYs over
24 months
£20,000
per QALY
£30,000
per QALY
Using EQ-5D-3L QALYs 1000 3656 (1259) –0.0205 (0.0545) Dominated –4066 –4271
Using SF-6D QALYs 1000 3779 (1280) –0.0204 (0.0443) Dominated –4187 –4391
Including costs and
QALYs data only up to
discharge
1000 3003 (1125) 0.0017 (0.0020) 1,745,221 –2969 –2952
Excluding outliers from
the analysis
1000 2936 (1123) –0.0125 (0.0511) Dominated –3186 –3312
Alternate imputation
model
1000 3794 (1103) –0.0144 (0.0515) Dominated –4082 –4226
Excluding additional
device cost for maze
procedure
1000 2580 (1278) –0.0239 (0.0536) Dominated –3058 –3297
Complete case analysis 1000 2256 (1281) 0.0277 (0.0574) 81,516 –1702 –1426
Randomised after April
2011
1000 3942 (1868) 0.0551 (0.0737) 71,505 –2840 –2288
TABLE 31 Coefficients and standard errors from seemingly unrelated regression models for costs and conversions
from AF to SR, adjusting for baseline covariates (secondary cost-effectiveness analysis)
Dependent variable Independent variable Coefficient SEM p-value
Conversion of AF to SR Maze procedure 0.14 0.04 3.37
Male –0.05 0.04 –1.12
Age 0.008 0.002 0.03
Baseline EQ-5D-3L score 0.23 0.1 2.3
Paroxysmal AF 0.05 0.04 1.1
Actual procedure –0.005 0.01 –0.48
Constant –0.25 0.23 –1.07
Total cost (£) per patient Maze procedure 3533 1129 0.00
Male –2131 1205 0.08
Age 255 75 0.00
Baseline EQ-5D-3L score –9367 2645 0.00
Paroxysmal AF 2693 1300 0.04
Constant –1691 6247 0.79
SEM, standard error of the mean.
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Appendix 3 Additional tables
TABLE 32 Reasons for exclusion from the trial at the screening at Papworth Hospital (n = 366)
Reason for exclusion Frequency
Patient decision (n= 107)
Too much to think about 27
Could not commit to follow-up or too far to travel 18
Patient did not want/was unsure about surgery, or was treated medically 12
Age concerns 4
GP or family concerned about trial participation 3
Patient did not want a 4-day ECG 3
Patient did not want the maze procedure 1
Uncomfortable about blinding of trial allocation 1
No reason given 38
Consultant decision (n= 115)
Maze procedure carried out outside the trial 49
Minimally invasive or other procedure required 11
Withdrawn from surgery 13
Too frail/sick/comorbidities 9
Procedure was too high risk/complicated 9
Maze procedure was not desirable because of small left atrium and only paroxysmal AF 1
Not suitable – reason not specified 23
Patient failed eligibility or ethics criteria (n= 49)
Patient already in another trial 19
Patient was an in-house urgent patient prior to change in eligibility criteria 6
Patient in SR 5
Patient had previous cardiac surgery 3
Patient unsuitable – reason not recorded 16
Patient died (n= 8)
Other (n= 87)
Not enough time to consider the trial 25
Unable to contact patient 13
Patient information sheet not given to the patient 6
Language barrier 1
Other administrative reasons – not recorded 42
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TABLE 33 Comorbidities at baseline
Comorbidity
Treatment arm, n (%)
Total (n= 352), n (%)Maze procedure (n= 176) Control (n= 176)
COPD
Yes 14 (8.0) 20 (11.4) 34 (9.7)
No 162 (92.0) 155 (88.1) 317 (90.1)
Missing/not known – 1 (0.6) 1 (0.3)
Pulmonary hypertension
Yes 25 (14.2) 28 (15.9) 53 (15.1)
No 151 (85.8) 147 (83.5) 298 (84.7)
Missing/not known – 1 (0.6) 1 (0.3)
Extracardiac ateriopathy
Yes 9 (5.1) 6 (3.4) 15 (4.3)
No 167 (94.9) 169 (96.0) 336 (95.5)
Missing/not known – 1 (0.6) 1 (0.3)
Neurological dysfunction
Yes 5 (2.8) 5 (2.8) 10 (2.8)
No 171 (97.2) 170 (96.6) 341 (96.9)
Missing/not known – 1 (0.6) 1 (0.3)
Serum creatinine level of > 200 µmol/l
Yes 2 (1.1) – 2 (0.6)
No 174 (98.9) 176 (100.0) 350 (99.4)
Rheumatic fever
Yes 7 (4.0) 6 (3.4) 13 (3.7)
Cardiomyopathy
Yes 2 (1.1) 4 (2.3) 6 (1.7)
Marfan syndrome
Yes 1 (0.6) – 1 (0.3)
Transient ischaemic attack
Yes 19 (10.8) 12 (6.8) 31 (8.8)
Cerebrovascular accident
Yes 11 (6.3) 11 (6.3) 22 (6.3)
Other clinical history
Yes 152 (86.4) 146 (83.0) 298 (84.7)
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TABLE 34 Major surgical complications
Complication
Treatment arm, n (%)
Total (n= 352), n (%)Maze procedure (n= 176) Control (n= 176)
No complicationsa 34 (19.3) 38 (21.6) 72 (20.5)
AF/arrhythmia 69 (39.2) 80 (45.5) 149 (42.3)
Need for a permanent pacemaker 6 (3.4) 5 (2.8) 11 (3.1)
Bleeding/tamponade 22 (12.5) 17 (9.7) 42 (11.1)
Aortic dissection – 1 (0.6) 1 (0.3)
Cardiac arrest 2 (1.1) – 2 (0.6)
Cardiogenic shock 1 (0.6) 1 (0.6) 2 (0.6)
Pericardial effusion 2 (1.1) – 2 (0.6)
Other cardiac event 4 (2.3) 6 (3.4) 10 (2.8)
Wound infection 3 (1.7) 4 (2.3) 7 (2.0)
Infection/sepsis 1 (0.6) 4 (2.3) 5 (1.4)
Hypotension 5 (2.8) 1 (0.6) 6 (1.7)
Respiratory/respiratory infection 19 (10.8) 21 (11.9) 40 (11.4)
Pleural effusion 14 (8.0) 25 (14.2) 39 (11.1)
Pulmonary embolism – 1 (0.6) 1 (0.3)
Pneumothorax – 2 (1.1) 2 (0.6)
Renal failure/dysfunction 13 (7.4) 10 (5.7) 23 (6.5)
Neurological 3 (1.7) 6 (3.4) 9 (2.6)
Delirium 5 (2.8) 1 (0.6) 6 (1.7)
Non-cardiac bleeding complication 1 (0.6) – 1 (0.3)
Gastrointestinal complication 4 (2.3) 4 (2.3) 8 (2.3)
Metabolic complication 2 (1.1) 4 (2.3) 6 (1.7)
Peripheral oedema – 1 (0.6) 1 (0.3)
Wound complication 1 (0.6) 1 (0.6) 2 (0.6)
Other complication 5 (2.8) 2 (1.1) 7 (2.0)
Perioperative death – 1 (0.6) 1 (0.3)
Returned to theatre 20 (11.4) 18 (10.2) 38 (10.8)
Reason for return to theatre
Bleeding 4 (2.3) 10 (5.7) 14 (4.0)
Tamponade 4 (2.3) 1 (0.6) 5 (1.4)
Gastrointestinal complication 2 (1.1) 2 (1.1) 4 (1.1)
Respiratory complication 2 (1.1) 1 (0.6) 3 (0.9)
Cardiac arrest 2 (1.1) – 2 (0.6)
Reoperation – 1 (0.6) 1 (0.3)
Permanent pacemaker 1 (0.6) – 1 (0.3)
Cardiac reason – 1 (0.6) 1 (0.3)
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TABLE 34 Major surgical complications (continued )
Complication
Treatment arm, n (%)
Total (n= 352), n (%)Maze procedure (n= 176) Control (n= 176)
Arrhythmia 1 (0.6) – 1 (0.3)
Bleeding (non-cardiac) 1 (0.6) – 1 (0.3)
Hypotension 1 (0.6) – 1 (0.3)
Pericardial effusion – 1 (0.6) 1 (0.3)
Respiratory complication/infection – 1 (0.6) 1 (0.3)
Wound 1 (0.6) – 1 (0.3)
Cardiogenic shock – 1 (0.6) 1 (0.3)
Pleural effusion 1 (0.6) – 1 (0.3)
Missing/not known 2 (1.1) – 2 (0.6)
a No complications: patient did not experience any perioperative complications.
TABLE 35 Number of patients who had transfusions
Type of transfusion
Treatment arm, n (%)
Total (n= 352), n (%)Maze procedure (n= 176) Control (n= 176)
Total red blood cell transfusion (units)
Not known 4 (2.3) 1 (0.6) 5 (1.4)
0 98 (55.7) 106 (60.2) 204 (58.0)
≥ 1 74 (42.0) 69 (39.2) 143 (40.6)
Total platelets transfusion (units)
Not known 5 (2.8) 3 (1.7) 8 (2.3)
0 128 (72.7) 141 (80.1) 269 (76.4)
≥ 1 43 (24.4) 32 (18.2) 75 (21.3)
Total fresh-frozen plasma transfusion (units)
Not known 4 (2.3) 3 (1.7) 7 (2.0)
0 136 (77.3) 139 (79.0) 275 (78.1)
≥ 1 36 (20.5) 34 (19.3) 70 (19.9)
Total cryoprecipitate transfusion (units)
Not known 7 (4.0) 6 (3.4) 13 (3.7)
0 157 (89.2) 162 (92.0) 319 (90.6)
≥ 1 12 (6.8) 8 (4.5) 20 (5.7)
Total human albumin transfusion (units)
Not known 5 (2.8) 4 (2.3) 9 (2.6)
0 165 (93.8) 163 (92.6) 328 (93.2)
≥ 1 6 (3.4) 9 (5.1) 15 (4.3)
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TABLE 36 Results of the mixed-model-adjusted analysis for the primary outcome of return to SR at 12 months
Effect OR of SR at 12 months (95% CI) p> |t|
Intercept 0.69 (0.34 to 1.40) 0.3078
Randomised to the maze procedure arm 2.06 (1.20 to 3.54) 0.0091
In SR at baseline 6.52 (2.83 to 14.98) < 0.0001
Procedure: CABG vs. MVR 0.84 (0.37 to 1.93) 0.6836
Procedure: AVR vs. MVR 0.42 (0.18 to 0.99) 0.0479
Procedure: CABG and MVR vs. MVR 0.64 (0.21 to 1.93) 0.4288
Procedure: CABG and AVR vs. MVR 0.52 (0.18 to 1.54) 0.2373
Procedure: all others (including none) vs. MVR 0.75 (0.35 to 1.61) 0.4642
TABLE 37 Results of the baseline-adjusted subgroup analyses of SR at 12 months, comparing the maze procedure
arm with the control arm
Level
Treatment arm, in SR/total Adjusted OR (maze
procedure/control)
(95% CI) p> |t|Maze procedure Control
Paroxysmal AF 32/38 30/42 2.286 (0.679 to 7.693) 0.1815
Non-paroxysmal AF 55/103 38/103 2.036 (1.117 to 3.710) 0.0204
CABG 18/30 15/29 1.625 (0.545 to 4.847) 0.3835
MVR 26/34 24/43 3.375 (1.141 to 9.980) 0.0279
AVR 12/27 7/16 1.511 (0.391 to 5.836) 0.5485
CABG and MVR 9/12 2/10 7.159 (0.907 to 56.496) 0.0618
CABG and AVR 5/10 5/14 1.810 (0.275 to 11.921) 0.5355
All others, including none 17/28 15/33 1.437 (0.497 to 4.154) 0.5032
TABLE 38 Results of the baseline-adjusted mixed model for the effect of the maze procedure on 2-year
quality-adjusted survival
Effect Estimate (95% CI) p> |t|
Intercept 0.775 (0.550 to 1.000) < 0.0001
Baseline EQ-5D-3L utility score 0.962 (0.715 to 1.208) < 0.0001
Randomised to the maze procedure arm –0.025 (–0.129 to 0.078) 0.6319
Surgical procedure: CABG –0.081 (–0.238 to 0.075) 0.3087
Surgical procedure: AVR –0.103 (–0.271 to 0.065) 0.2280
Surgical procedure: CABG and MVR –0.043 (–0.256 to 0.170) 0.6925
Surgical procedure: CABG and AVR –0.282 (–0.471 to –0.092) 0.0037
Surgical procedure: all others, including none 0.010 (–0.142 to 0.161) 0.8986
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TABLE 39 Results of the subgroup analysis comparing the maze procedure arm with the control arm for 2-year
quality-adjusted survival
Level
Treatment arm, mean (SEM) Difference (maze
procedure vs. control)
(95% CI) p-valueMaze procedure Control
Paroxysmal AF 1.430 (0.076) 1.511 (0.075) –0.081 (–0.283 to 0.122) 0.4356
Non-paroxysmal AF 1.375 (0.045) 1.379 (0.045) –0.004 (–0.125 to 0.116) 0.9417
CABG 1.403 (0.083) 1.397 (0.085) 0.006 (–0.228 to 0.239) 0.9626
MVR 1.426 (0.078) 1.530 (0.071) –0.104 (–0.310 to 0.103) 0.3265
AVR 1.451 (0.088) 1.272 (0.104) 0.179 (–0.086 to 0.444) 0.1865
CABG and MVR 1.525 (0.131) 1.345 (0.137) 0.179 (–0.192 to 0.550) 0.3438
CABG and AVR 1.068 (0.122) 1.303 (0.108) –0.235 (–0.555 to 0.084) 0.1491
All others, including none 1.452 (0.079) 1.533 (0.080) –0.080 (–0.302 to 0.141) 0.4779
SEM, standard error of the mean.
TABLE 40 Baseline-adjusted mixed model for the effect of the maze procedure on return to SR at 24 months
Effect
OR of SR at 24 months
(95% CI) p> |t|
Intercept (odds of SR at 24 months for baseline AF, MVR operation and
standard care)
0.38 (0.17 to 0.83) 0.0169
In SR at baseline 11.53 (4.48 to 29.70) < 0.0001
Randomised to the maze procedure arm 3.24 (1.76 to 5.96) 0.0002
Procedure: AVR vs. MVR 0.48 (0.18 to 1.29) 0.1435
Procedure: all others (including none) vs. MVR 0.53 (0.22 to 1.31) 0.1695
Procedure: CABG vs. MVR 0.70 (0.28 to 1.76) 0.4499
Procedure: CABG and AVR vs. MVR 0.56 (0.16 to 1.88) 0.3426
Procedure: CABG and MVR vs. MVR 0.80 (0.24 to 2.63) 0.7144
TABLE 41 Cause of death listed by treatment arm
Cause of death by treatment arm Months from randomisation to death
Maze procedure
Haemorrhage 0.00
Pancreatitis 0.13
Unknown 0.16
Multisystem organ failure 0.59
Unknown 0.82
Subdural haematoma 1.28
Infective endocarditis 2.14
Sepsis 2.17
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TABLE 41 Cause of death listed by treatment arm (continued )
Cause of death by treatment arm Months from randomisation to death
Cardiac and renal failure 2.46
Bladder cancer 2.50
Cardiac failure and respiratory failure 3.29
Cardiac failure 3.48
Pneumonia and stroke 5.03
Pneumonia 5.75
Sepsis 7.26
Cardiac failure 10.51
Unknown 15.44
Multiorgan failure 15.64
Aspiration pneumonia 19.35
Pneumonia 21.75
Need more information on this, as it is not a cause of death 24.01
Cerebral haemorrhage 24.05
Cardiac failure 24.24
Stroke and cancer 35.94
Unknown 45.27
Unknown 45.83
Haematological cancer 50.66
Pulmonary embolus 54.50
MI 62.88
Unknown 64.62
Control
MI 0.03
Bowel ischaemia 0.07
Pneumonia 0.10
Cardiac failure 0.13
Air embolus 0.16
Bowel perforation 0.16
Multiorgan failure 0.82
Multiorgan failure 1.05
Gastrointestinal haemorrhage 1.12
Bowel ischaemia 1.28
Cardiac failure 1.77
Sepsis 1.77
Cardiac failure 2.37
Sudden cardiac death 2.79
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TABLE 41 Cause of death listed by treatment arm (continued )
Cause of death by treatment arm Months from randomisation to death
Haemorrhage 6.73
Haematological cancer 7.88
MI 21.78
Pneumonia 23.59
Unknown 40.21
Prostate cancer 46.85
Cardiac failure 46.91
Unknown 51.64
Cardiac failure 54.04
Cardiac failure 59.23
Endometrial cancer 63.44
TABLE 42 Summary of NYHA classifications at follow-up
Classification at each time point
Treatment arm, n (%)
Total (n= 352), n (%)Maze procedure (n= 176) Control (n= 176)
6 months
I 66 (37.5) 86 (48.9) 152 (43.2)
II 53 (30.1) 49 (27.8) 102 (29.0)
III 19 (10.8) 15 (8.5) 34 (9.7)
IV 2 (1.1) – 2 (0.6)
Missing/not known 36 (20.4) 26 (14.8) 62 (17.6)
12 months
I 73 (41.5) 71 (40.3) 144 (40.9)
II 50 (28.4) 58 (33.0) 108 (30.7)
III 20 (11.4) 15 (8.5) 35 (9.9)
IV 1 (0.6) – 1 (0.3)
Missing/not known 32 (18.1) 32 (18.2) 64 (18.2)
24 months
I 68 (38.6) 64 (36.4) 132 (37.5)
II 41 (23.3) 56 (31.8) 97 (27.6)
III 19 (10.8) 16 (9.1) 35 (9.9)
IV 3 (1.7) 2 (1.1) 5 (1.4)
Missing/not known 45 (25.6) 38 (21.6) 83 (23.6)
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TABLE 43 Summary of differences in baseline-adjusted SF-36 scores (maze procedure vs. control) at follow-up
SF-36 item score at each time point Estimate (95% CI) p> |t|
Bodily pain
6 months –1.010 (–5.539 to 3.520) 0.6619
12 months –0.353 (–3.585 to 2.878) 0.8302
24 months 0.959 (–4.352 to 6.271) 0.7231
General health
6 months –0.292 (–3.860 to 3.275) 0.8723
12 months –0.769 (–3.314 to 1.775) 0.5531
24 months –1.723 (–5.907 to 2.461) 0.4191
Mental health
6 months –0.183 (–3.022 to 2.655) 0.8991
12 months –0.374 (–2.399 to 1.651) 0.7171
24 months –0.755 (–4.082 to 2.572) 0.6561
Physical functioning
6 months –0.619 (–4.963 to 3.725) 0.7798
12 months –0.825 (–3.923 to 2.274) 0.6015
24 months –1.236 (–6.331 to 3.858) 0.6340
Role emotional
6 months –4.050 (–10.837 to 2.736) 0.2418
12 months –3.013 (–7.860 to 1.834) 0.2228
24 months –0.939 (–8.899 to 7.021) 0.8170
Role physical
6 months –3.761 (–11.461 to 3.939) 0.3380
12 months –2.776 (–8.271 to 2.720) 0.3218
24 months –0.806 (–9.837 to 8.224) 0.8609
Social functioning
6 months –0.921 (–5.504 to 3.662) 0.6934
12 months –0.625 (–3.894 to 2.644) 0.7074
24 months –0.034 (–5.409 to 5.341) 0.9901
Vitality
6 months 2.641 (–1.051 to 6.333) 0.1606
12 months 1.534 (–1.100 to 4.168) 0.2533
24 months –0.680 (–5.006 to 3.646) 0.7578
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TABLE 44 Summary of SF-36 component summary scores at baseline and follow-up
SF-36 item at each time point
Treatment arm
Total (n= 352)Maze procedure (n= 176) Control (n= 176)
PCS (UK norm: 50, SD 10)
Baseline
Mean score (SD) 30.18 (13.17) 31.00 (13.56) 30.59 (13.36)
Missing 3 2 5
6 months
Mean score (SD) 38.25 (13.95) 39.23 (13.86) 38.75 (13.89)
Missing 21 17 38
12 months
Mean score (SD) 38.55 (14.33) 39.99 (13.18) 39.27 (13.76)
Missing 26 25 51
24 months
Mean score (SD) 38.28 (14.66) 39.54 (12.88) 38.92 (13.78)
Missing 41 37 78
MCS (UK norm: 50, SD 10)
Baseline
Mean score (SD) 50.81 (9.92) 49.58 (10.69) 50.19 (10.32)
Missing 3 2 5
6 months
Mean score (SD) 54.37 (9.47) 54.06 (9.42) 54.21 (9.43)
Missing 21 17 38
12 months
Mean score (SD) 54.09 (9.64) 54.33 (8.83) 54.21 (9.23)
Missing 26 25 51
24 months
Mean score (SD) 54.68 (9.14) 54.44 (9.12) 54.56 (9.11)
Missing 41 37 78
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TABLE 45 Summary of EQ-5D-3L utility scores in surviving patients at follow-up
EQ-5D-3L utility at each time point
Treatment arm
Total (n= 352)Maze procedure (n= 176) Control (n= 176)
Baseline
Mean score (SD) 0.74 (0.22) 0.75 (0.21) 0.75 (0.22)
Missing 2 1 3
Discharge
Mean score (SD) 0.63 (0.27) 0.64 (0.24) 0.63 (0.25)
Missing/died 20 20 40
6 weeks
Mean score (SD) 0.77 (0.21) 0.78 (0.19) 0.77 (0.20)
Missing/died 18 17 35
6 months
Mean score (SD) 0.80 (0.21) 0.80 (0.23) 0.80 (0.22)
Missing/died 21 16 37
12 months
Mean score (SD) 0.79 (0.22) 0.81 (0.20) 0.80 (0.21)
Missing/died 27 25 52
24 months
Mean score (SD) 0.78 (0.22) 0.80 (0.24) 0.79 (0.23)
Missing/died 41 33 74
TABLE 46 Summary of AEs by treatment received
AE
Treatment arm, n (%)
Total, n (%)Maze procedure Control
Total reported: events (patients) 560 (136) 589 (157) 1149 (293)
Cardiac complications 151 (86) 194 (108) 345 (194)
Arrhythmia 78 (58) 108 (80) 186 (138)
Bleeding 21 (14) 23 (16) 44 (30)
Cardiac failure 12 (6) 26 (20) 38 (26)
Cardiac arrest 1 (1) 6 (6) 7 (7)
MI 2 (2) 1 (1) 3 (3)
Other cardiac event 37 (31) 30 (19) 67 (50)
Respiratory complication 77 (51) 70 (47) 147 (98)
Infection 72 (49) 63 (49) 135 (98)
Prolonged hospitalisation 60 (48) 53 (39) 113 (87)
Neurological complication 25 (20) 22 (20) 47 (40)
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TABLE 46 Summary of AEs by treatment received (continued )
AE
Treatment arm, n (%)
Total, n (%)Maze procedure Control
Death 16 (16) 19 (19) 35 (35)
Renal failure 8 (5) 8 (6) 16 (11)
Thromboembolic event 3 (3) 5 (5) 8 (8)
Vascular complication 2 (2) 6 (5) 8 (7)
Multiple organ failure 2 (2) 3 (3) 5 (5)
Inflammation 3 (2) – 3 (2)
Other non-cardiac event 141 (70) 146 (86) 287 (156)
TABLE 47 Estimated effect sizes (maze procedure vs. control) and 95% CIs from each of the secondary analyses in
the HESTER substudy
Effect Estimated effect size (95% CI) p-value
Four-chamber echocardiography (primary analysis)
ALAEF (%) –8.03 (–12.43 to –3.62) 0.0015
LAVmin (ml)
a 14.53 (–1.75 to 30.81) 0.0765
LAVmax (ml)
a 10.02 (–9.40 to 29.44) 0.2889
LAVpreA (ml)
a 11.30 (–7.71 to 30.30) 0.2244
Passive stroke volume (ml) 0.86 (–2.26 to 3.98) 0.5651
Active stroke volume (ml) –3.44 (–7.79 to 0.90) 0.1120
LAEF (%) –6.90 (–11.98 to –1.82) 0.0111
E/A ratioa 0.89 (0.16 to 1.62) 0.0205
Two-chamber echocardiography
ALAEF (%) –3.48 (–8.45 to 1.49) 0.1545
LAVmin (ml)
a 9.95 (–0.48 to 20.37) 0.0600
LAVmax (ml)
a 9.45 (–7.04 to 25.93) 0.2393
LAVpreA (ml)
a 6.92 (–9.28 to 23.13) 0.3728
Passive stroke volume (ml) 1.49 (–2.32 to 5.30) 0.4138
Active stroke volume (ml)a –1.54 (–9.09 to 6.02) 0.6671
LAEF (%) –3.36 (–7.86 to 1.13) 0.1310
Multiple-slice MRI
LAVmin (ml)
a 39.71 (9.05 to 70.37) 0.0146
LAVmax (ml)
a 35.96 (–1.37 to 73.30) 0.0579
LAEF (%)a –13.46 (–19.87 to –7.06) 0.0004
a Analyses performed with pairing as a fixed effect.
All volumes are in ml.
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TABLE 48 Mean (SD) of all primary and secondary end points measured using echocardiography (two-chamber
view) in the HESTER substudy
End point
Treatment arm, mean (SD)
Maze procedure (n= 22) Control (n= 22)
ALAEF (%)a 19 (8) 24 (8)
LAEF (%)b 30 (8) 35 (8)
LAVmin (ml)
b 63 (15) 51 (12)
LAVpreA (ml)
a 77 (17) 68 (17)
LAVmax (ml)
b 90 (19) 79 (17)
Passive stroke volume (ml)a 13 (7) 11 (4)
Active stroke volume (ml)a 15 (6) 17 (8)
a Two control patients missing.
b One control patient missing.
TABLE 49 Mean (SD) of all primary and secondary end points measured using MRI in the HESTER substudy
End point
Treatment arm, mean (SD)
Maze procedure (n= 22) Control (n= 22)
LAEF (%) 24 (7) 37 (6)
LAVmax (ml) 120 (36) 88 (31)
LAVmin (ml) 91 (32) 55.23 (19)
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